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Allylic alcohol transposition lacks a thermodynamic driving force and usually displays stereo-
infidelity and poor regioselectivity. However, regio- and stereoselectivity can be achived by 
coupling allylic alcohol transposition to a subsequent step that is kinetically and 
thermodynamically favorable. Based on this rationale, the allylic alcohol transposition and 
capture sequence was delevoped and applied successfully in heterocycle synthesis. Regio- and 
stereoselectivity were achieved when a pre-existing stereogenic center in the substrates could 
induce significant thermodynamic difference between diastereomeric products and when the 
individual steps toward these diastereomeric products were reversible. 
Epoxides were later used as ennantioenriched electrophiles in this transposition/trapping 
sequence for stereoselective synthesis of heterocycles. The mechanism for this transformation 
was elucidated and a cascade approach using epoxides as trapping agents in the transposition of 
allylic alcohols was developed and applied in the stereoselective formation of polycyclic ethers. 
Finally, an improved sequence using “traceless trapping agents” was developed. This 
new method did not leave any vestige in the resulting product and offered much more freedom 
for the application of allylic alcohol transposition in heterocycle synthesis. Understanding the 
relative rates of the steps in this new sequence led to the design of reactions that created multiple 
stereogenic centers with good to excellent levels of control. 
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1.0  INTRODUCTION 
The direct metal-catalyzed [1,3]-transposition of allylic alcohols or allylic silyl ethers is a 
powerful atom- and step-economical transformation (Scheme 1.1). This method allows facile 
preparation of a less accessible isomer from a more readily available precursor in a single 
operation and obviates the need for substrate derivatization. As a result, it could potentially serve 
as a powerful tool in multistep synthesis of complex molecules. However, the development of 
synthetically useful methods that allow for a high level of regio- and stereoselectivity control 
have emerged only recently and their applications in organic synthesis are very limited even 
though [1,3]-transposition of allylic alcohols has been known since late 1960s.1 The major 
reason for such a dilemma is the intrinsic low regio- and stereoselectivity of this method. Several 
groups have dedicated themselves to solving this problem yet a general solution is still lacking. 
In accord with our continued interest in the synthesis of heterocycles, we sought to develop a 
new protocol that uses the intrinsic low regio- and stereoselectivity to our advantage for the 
stereoselective syntheses of cyclic ethers. 
 
R1
OR
R2 R1 R2
ORLnM=O
R = H, SiR3
1-1 1-2  
Scheme 1.1 [1,3]-transposition of allylic alcohols or allylic silyl ethers catalyzed by metal-oxo complexes 
 2 
1.1 ALLYLIC ALCOHOL ISOMERIZATION 
Allylic alcohols and their derivatives are useful chemical moieties because of their important 
roles in a variety of synthetic transformations such as Claisen and Cope rearrangements, directed 
epoxidations,2 cyclopropanations,3 carbonyl formations,4 etc. Even though there are numerous 
synthetic strategies to prepare allylic alcohols, the [1,3]-isomerization offers unique opportunities 
to access regioisomers that are difficult to access directly through conventional strategies. 
1.1.1 Allyl ester isomerization 
The rearrangement of allylic esters, or the [1, 3]-dioxa-Cope rearrangement, is the first example 
of allylic alcohol isomerization and was first reported in the late 1960s, when Lewis and co-
workers observed this transformations in the gas phase.5 However, this transformation was not 
widely used at that time due to a lack of regioselectivity. When subjecting an allylic ester to the 
reaction conditions, a mixture of isomers was obtained in which the product distribution was 
determined by the thermodynamic stabilities of the two allylic isomers. In the mid 1970s, 
Brønsted acid catalyzed isomerizations of tertiary alcohols into the corresponding primary allylic 
esters were achieved selectively through an ionization-recombination process,6 however the 
harsh reaction conditions limited their synthetic applications. Milder reaction conditions needed 
to be developed for this transformation in order to make it synthetically useful.  
The quest for milder reaction conditions led to studies of catalytic version of these 
transformations in late 1970s.  Late transition metal catalysts such as mercury(II)7 and 
palladium(II)8 were reported by Overman and co-workers to effect rearrangements of allylic 
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acetates and carbamates with moderate to high levels of selectivity, and when enantioenriched 
allylic acetates were used, high levels of chirality transfer could be obtained. Overman also 
postulated that this metal catalyzed isomerization of allylic acetates proceeded via a “cyclization-
induced” process (Scheme 1.2), in which the electrophilic metal binds to the alkene and activates 
it toward nucleophilic attack by the pendant carbonyl oxygen. The resulting cyclic 
organometallic intermediate breaks down to yield the isomerized product. Late transition metal 
catalysts have been proven to be effective for promoting allylic acetate isomerizations and have 
been applied in the synthesis of several natural products.9 
R R'
O O
Me
O O
R R'
M
Me
R R'
O O
Me
1-3 1-4I
MLn MLn
 
Scheme 1.2 Mechanism of “cyclization-induced” rearrangement 
1.1.2 Allylic alcohol isomerization catalyzed by metal-oxo complexes 
Despite the promising aspects of the allylic acetate isomerizations, the direct isomerization of 
allylic alcohols is a more attractive alternative since the two redundant steps of acylation and 
deacylation can be avoided. As shown in Scheme 1.3, it is proposed that the binding of a metal-
oxo complex to the allylic alcohol can form a metalloester, which will subsequently undergo a 
[3,3]-rearrangement through a cyclic transition state (II) to yield the transposed allylic alcohol. 
This process is similar to the thermal rearrangement of allylic acetates catalyzed by late 
 4 
transition metals, but the metal-oxo complex catalyzed isomerization does not require two 
additional steps of acylation and deacylation and is completely atom-economic.  
R
OH
R
O O
Me
R
O
Me
O
R
OH
R
OMO
PdII or HgII
LnM=O
Ln
1-5
1-6 1-7
1-8
II  
Scheme 1.3 Metal-oxo complex vs late transition metal-catalyzed isomerization 
 
Metal-catalyzed allylic [1,3]-transposition was initially discovered by Chabardes using a 
vanadium-oxo complex in the late 1960s.1 The catalysts suitable for this isomerization were later 
extended to several other high oxidation state transition metal-oxo complexes of vanadium,1, 10-14 
tungsten,15 molybdenum,16-18 and rhenium.19-26 These early catalysts have several limitations 
such as the requirement of high reaction temperature for optimal catalytic activities, limited 
stability, poor functional group compatibility, etc. Vanadium- and tungsten-based catalysts such 
as VO(OR)31, 10-12 and WO(OSiEt3)3•Py15 show high catalytic efficiency only at temperatures 
between 140-200 ºC, even though a low catalyst loading (0.05-2 wt%) is sufficient to effect a 
fast equilibrium. Activation of metal-oxo complexes with TMSOOTMS obviates the need for 
high temperature so that the reaction could be performed at room temperature.13-14 However, 
activation of VO(acac)2 with TMSOOTMS yielded an ill-defined catalyst system that resulted in 
selective isomerization of primary allylic alcohols to the corresponding tertiary ones with 
noticeable side reactions13 while the combination of MoO2(acac)2 and TMSOOTMS was shown 
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to be less effective.14 Mo-based catalysts such as MoO2(Ot-Bu)216 and 
MoCl2(O)(O2)(OPMePh2)218 were reported to be more effective. However, due to the high 
oxidation state of molybdenum in these complexes, slow oxidation of the alcohol substrate 
becomes a problem and ultimately reduces the catalyst lifetime.23 In comparison with the weak 
oxidizing capability of Mo- and W-based oxo-complexes, the strong oxidizing power of 
oxochromium(VI) complexes makes them unsuitable for the [1,3]-transposition of primary and 
secondary allylic alcohols although they have been used for oxidative [1,3]-transposition of 
tertiary allylic alcohols to α,β-unsaturated carbonyl compounds.26-29 Another problem arising 
from the high oxidation states of metal-oxo complexes is the inherent Lewis acidity, which 
becomes more evident as the number of oxo ligands increases. As a consequence, side reactions 
such as dehydration, condensation, and racemization become significant and compete with the 
desired [1,3]-transposition.  
Ph
OH
Ph
OH
Ph Ph+
1-9
1-10
40% (56% starting materials)
1-11
66%
1-12
17%
5 min
18 hr
a)
b)
OH
Ph
HO
Ph
Ph
OH
+
5 min
1-13 1-14
41% (cis:trans=1:2.5)
1-15
49% (cis:trans=1:3.5)  
Scheme 1.4 Examples of isomerizations catalyzed by Bu4NReO4/pTsOH•H2O 
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More efficient and mild catalytic systems were developed subsequently for allylic [1,3]-
transposition using oxorhenium complexes. It was initially discovered that 
Bu4NReO4/pTsOH•H2O19-20 catalyst system was superior compared to metal oxo-complexes in 
previous reports. However, the reaction selectivity was low and side reactions such as 
condensation and dehydration were still significant as a result of the Brønsted acidity of this 
catalyst system (Scheme 1.4). MeReO321-23 was developed later as a more efficient and milder 
catalyst and has been applied for the equilibration between secondary and primary allylic 
alcohols in industry. However, water was found to inhibit the catalytic ability by reacting with 
MeReO3 to form the inactive species MeRe(O)2(OH)2.22 Triphenylsilyl perrhenate, 
Ph3SiOReO3,30 has been identified as the most efficient and practically applicable catalyst for the 
[1,3]-transposition of allylic alcohols and allylic silyl ethers after investigations and mechanistic 
studies. Compared to previously known oxorhenium-based catalysts, Ph3SiOReO3 possesses a 
high catalytic activity at or below room temperature with negligible side reactions such as 
condensation, dehydration, oxidation, etc. As a result, this new catalyst has gradually evolved as 
the catalyst of choice for the [1,3]-transposition of allylic alcohols and allylic silyl ethers and has 
been applied extensively thereafter. The substrate scope of the reaction, the degree of chirality 
transfer, and the reaction selectivity have been established through subsequent investigations.31-32 
Despite the improved catalytic efficiency of oxorhenium complexes, they can not tolerate 
basic functional groups such as amines. Imido complexes33 are formed when oxorhenium 
complexes are reacted with amines. Although some imido complexes are still active, their 
catalytic efficiencies are significantly reduced, and therefore amines are widely used to quench 
oxorhenium catalysts. Hall and co-workers showed that boronic acid catalysis (BAC) could be 
applied to allylic alcohol isomerization. BAC not only tolerates both acid and base sensitive 
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functional groups, but also yields higher E/Z selectivity, especially when trisubstituted alkenes 
are formed from isomerization of tertiary allylic alcohols.34 However, the application of this 
method is limited and oxorhenium complexes are still the catalysts of choice for [1,3]-
transposition of allylic alcohols and allylic silyl ethers. 
1.2 MECHANISM OF METAL-CATALYZED [1,3]-TRANSPOSITIONS OF 
ALLYLIC ALCOHOLS 
[1,3]-transpositions of allylic alcohols catalyzed by metal-oxo complexes have been studied by 
several groups. In a general mechanism, formation of a metallo-ester is followed by [3,3]-
sigmatropic rearrangement via a cyclic transition state (II in Scheme 1.3). This mechanism is 
useful in explaining the high E/Z selectivity of disubstituted alkenes, however, it does not 
provide reasonable explanation for several side reactions (observed in different extents) such as 
racemization, dehydration, condensation, etc. The real mechanism is much more complicated 
than initially proposed and can divert significantly from a concerted pathway, depending on the 
catalysts, substrates, and reaction conditions. 
1.2.1 Mechanism of allylic isomerization catalyzed by oxovanadium complexes 
In his seminal work, Chabardes proposed the first mechanism of metal-catalyzed [1,3]-
transposition of allylic alcohols by oxovanadium complexes.10 As shown in Scheme 1.5, the 
substrate alcohol 1-16 reacts with the catalyst by replacing one of its alkoxy ligands to generate 
vanadate ester 1-17.  A subsequent isomerization of 1-17 via [3,3]-sigmatropic rearrangement 
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(intermediate 1-18) delivers the transposed vanadate ester 1-19. This intermediate will release 
product 1-20 and regenerate vanadate ester 1-17 for another catalytic cycle by ligand exchange 
with substrate 1-16. In this mechanism, each individual step is reversible and the reaction 
product is a thermodynamic mixture of isomeric alcohols. This mechanism was initially 
proposed and supported by experiments.25, 26 A few years later, Dedieu and co-workers 
conducted DFT calculations, in which they revealed the details of charge distribution in the 
transition state and its effects on the reaction selectivities.35 
1.2.2 Mechanism of Ph3SiOReO3-catalyzed [1,3]-allylic alcohol transposition by Osborn 
Osborn and coworkers25, 32 conducted kinetic studies on Ph3SiOReO3-catalyzed [1,3]-allylic 
alcohol transposition and found that the formation of cis isomer product (Z)-1-22 was extremely 
slow compared to the formation of trans isomer product (E)-1-22. This difference arises from the 
disparity in the transition states for the formation of each isomer. Isomerization of hex-1-en-3-ol 
1-21 to (E)-hex-2-en-1-ol (E)-1-22 has ∆H≠ = 13.3 ± 0.3 kcal mol-1 and ∆S≠ = -14.8 ± 1.0 e.u. 
The large negative activation entropy suggested a highly ordered polarized transition state 1-24 
via a [1,3]-sigmatropic pathway. In this pathway, a partially negatively perrhenate group 
migrates intramolecularly across a partially positively charged allyl moiety. However, the 
formation of (Z)-1-22 has activation enthalpy of 20.9± 0.3 kcal mol-1 and activation entropy of 
3.1 ± 1.0 e.u. The positive activation entropy indicates a more disordered transition state, namely 
an ionization-recombination pathway with the solvent-separated allylic cation and perrhenate 
anion. This difference was also supported by the solvent study by the same group: polar solvents 
favor the more disordered ionic pathway and increase the formation of the cis isomer.25 
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Scheme 1.5 Mechanism of the [1,3]-transposition of allylic alcohols proposed by Chabardes 
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Scheme 1.6 Mechanism of  [1,3]-allylic alcohol transposition proposed by Osborn 
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Osborn explained the observed selectivity for (E)-1-22 25, 32 based on the trans-diaxial 
interaction between an oxo ligand and the alkyl substituent on the migrating allyl group in the 
transition state, which will be greater for the cis isomer and lead to an increase in charge 
separation. However, whether an oxo ligand is large enough to have this steric effect is still in 
debate.32, 35 Nonetheless, this trans-diaxial interaction can explain why allylic alcohols 
containing Z-alkenes also yield the corresponding E-products after isomerization. In the case of 
1-26, the transition structure leading to the E-isomer has no diaxial interactions while that 
leading to the Z-isomer isomer has one noticeable diaxial interaction (Scheme 1.7a). In the case 
of 1-31 the transition structure leading to the E-isomer has one diaxial interaction while that 
leading to the Z-isomer has one R, R interaction alongside two other diaxial R, O interactions. 
R R'
OH
Re
O
O
H
H
R'
R
O
O
Re
O
O
R'
H
H
R
O
O
O
ReO
H
R
R'
H
O
O
O
ReO
R'
R
H
H
O
O
R R'
OH
R
R'
OH
R R'
OH
R
R'
OH
(Major)
(Minor)
(Major)
(Minor)
R
OH R'
a)
b)
1-26
1-27 1-28
1-29 1-30
1-31
1-32 1-33
1-34 1-35
Ph3SiOReO3
Ph3SiOReO3
Ph3SiOReO3
Ph3SiOReO3
 
Scheme 1.7 Consequence of E/Z isomerization on selectivity 
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1.2.3 Mechanism of Ph3SiOReO3-catalyzed [1,3]-transposition proposed by Grubbs 
Grubbs and coworkers suggested a more detailed mechanism based on thorough studies of the 
reaction and limitations of the [1,3]-transposition of allylic alcohols. As shown in Scheme 1.8, 
this mechanism is similar to the one proposed by Osborn, in which the isomerization proceeds 
through an asynchronous [3,3]-sigmatropic rearrangement via a polarized chair-like transition 
state 1-39.  In this transition state, the C-O bond is highly polarized so that an ion pair 
intermediate 1-41 emerges and competes with the sigmatropic rearrangement. The existence of 
this ion pair intermediate is the reason for the undesirable side reactions such as elimination (1-
42), condensation (1-43), and racemization of enantiomerically enriched substrates. 
R1 R3
OReO3
R2
R1 R3
OH
R2
O
ReO
R3
R2
R1
O
O
R2
R1
R3
OReO3
Ph3SiOReO3
Ph3SiOR
R2
R1
R3
OH
R1 R3
OH
R2
R2
R1
R3
O3ReO R
R1
R3
R1
O
R2 R
3
R3 R1
R2
δ−
δ+
1-36
1-37
1-38
1-36
1-39
1-40
1-41 1-421-43  
Scheme 1.8 Mechanism of allylic [1,3]-transposition proposed by Grubbs and coworkers 
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Similar to the mechanistic rationale suggested by Osborn, Grubbs and coworkers 
explained the selective formation of E-isomers from both (E)- and (Z)-allylic alcohols by the 
increased diaxial interactions in the transition state that led to the (Z)-configured product. Due to 
the high polarization of the transition state 1-39, the electronic effects of substituents have a 
strong influence on the properties of the transition state and, as a result, the reaction outcome. 
Accordingly, more substituted alkenes or alkenes with electron donating substituents are capable 
of stabilizing a positive charge on the allylic moiety and favor the ionic pathway 1-41. Although 
the reaction rate is fast in this case, the reaction selectivity is jeopardized due to several possible 
side reactions of the allyl cation. As a result, low reaction temperatures of –78 ºC to –50 ºC are 
required to suppress the formation of ion pairs. On the other hand, reactions of electron-poor 
allylic alcohols can be performed at room temperature even though the reaction rate is reduced 
compared to electron rich substrates. The degree of chirality transfer is also affected by the 
electronic nature of the substrates: higher electron-withdrawing capacity of the substituents 
results in higher degree of chirality transfer, and vice versa. 
1.3 APPLICATION OF ALLYLIC ALCOHOL ISOMERIZATION 
The most important application of allylic alcohol isomerization is to access regioisomers or 
diastereomers that are not easy to obtain by traditional methods such as the addition of 
nucleophiles to aldehydes,36 kinetic resolution of racemic secondary alcohols,37 stereoselective 
reduction of α,β-unsaturated ketones,38 etc. However, poor stereoselectivity and a lack of 
regioselectivity greatly hamper its application in more complex settings. As a result, the 
application of allylic alcohol isomerization in complex molecule synthesis has been very limited, 
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with the first example reported in 2000,39 more than three decades after its discovery. Ever since 
then, several groups have dedicated themselves toward improving both regio- and 
stereoselectivity of this method. As a result, allylic alcohol isomerization has been applied in the 
total synthesis of various complex molecules such as amphidinolide B1,40 cladiell-11-ene-3,6,7-
triol,41 leucascandrolide A,42 6′-hydroxylarenarol,43 (–)-apratoxin A,44 (–)-dactylolide,45 
laulimalide,46 (–)-amphidinolide V.47 
 
Ph
Me
OH Ph OH
Me
n-C3H7
OH
n-C3H7
OH
10 mol% O3ReONRu4
20 mol% TsOH
CH2Cl2, 23 ºC, 24h
10 mol% O3ReONRu4
MeCN, 0 ºC, 10min
1-43
60 %
1-44
40 %
1-45
70 %
1-46
30 %  
Scheme 1.9 Oxorhenium complex catalyzed allylic alcohol isomerization 
1.3.1 Enhanced selectivity by extended conjugation 
Rhenium oxo-complex catalyzed allylic alcohol isomerization is known for its poor 
regioselectivity. As shown in Scheme 1.9, a mixture of the starting material and the isomerized 
product is usually obtained with the ratio depending on the relative thermodynamic stability of 
each regioisomer. In order to obtain enhanced regioselectivity, significant differences between 
the thermodynamic stabilities of the isomers should be created during the design of the reaction 
substrate.  Grubbs and coworkers were able to achieve a high level of reaction selectivity by 
introducing extended conjugation.31, 32 As shown in Table 1.1, these products have extended 
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conjugation so that they are more thermodynamically stable than the corresponding starting 
substrates. High levels of selectivity were obtained for all substrates tested although the yield for 
electron rich systems (entry 5, 6, 11) are low due to the formation of byproducts resulting from 
increased stability of allyl cations. When enantioenriched substrates (not shown) are used, high 
levels of chirality transfer were observed for electron deficient systems while various degrees of 
racemization were observed for electron rich systems.32 
 
Table 1.1 Isomerization of aryl secondary allylic alcohols 
R3
R2 OH
R1
R3
R2 OH
R1
2 mol% O3ReOSiPh3
0.2 M in Et2O
Entry (E /Z)a ratio R1 R2 R3 Temp
(ºC)
Time
(min)
Yield
(%)b
1 10:1 n-hex H H -50 30 98
2 10:1 n-hex NO2 H 23 30 98
3 <1:20 n-hex H NO2 0 30 94
4c >20:1 n-hex H CF3 -50 60 98
5d 10:1 n-hex OMe H -78 120 68
6d >20:1 n-hex H OMe -78 120 79
7 12:1e c-C6H11 H H -50 30 95
8 1:12e c-C6H11 H -50 30 93
9 H HH 0 30 98
10 H NO2 H 23 30 98
11 H OMe H -50 30 65
H
a) Determined by 1H NMR; b) E /Z>20:1 as determined by 1H NMR, c) use 3 mol% of
 catalyst; d) use 4 mol% of catalyst; e) Determined by GC; f) Reaction done in CH2Cl2.
1-47 1-48
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1.3.2 Enhanced selectivity by consecutive transposition and silylation 
Another way to improve the regioselectivity is to couple the isomerization to a subsequent step 
that shows different reactivity toward the equilibrating isomers. By taking one isomer out of the 
equilibrating system, one can push the reaction to yield the desired product. For example, 
inspired by Osborn’s observation that isomerization of allyl silyl ethers was slow relative to that 
of allylic alcohols25 Grubbs and co-workers designed a unique silylation and desilylation 
sequence that selectively removed the primary alcohol from the equilibrating mixture by taking 
advantage of the fact that the silylation of primary alcohol (1-50) is much faster than that of 
tertiary alcohol (1-49). As shown in Scheme 1.10, after desilylation the primary allylic alcohol 
was obtained as major product with good selectivity.32 However, selective isomerization of 
secondary allyl alcohol to primary allyl alcohol is ineffective using this method. This strategy 
was later applied successfully in the total synthesis of 6′-hydroxylarenarol43 and (–)-apratoxin 
A.44 
 
R
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Me R
Me OHO3ReOSiPh3
BSA
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BSA
Fast
R
OTMS
Me R
Me OTMS
R
OH
Me R
Me OH
1-49 1-50
1-49
(minor)
1-50
(major)
1-51 1-52
desilylation desilylation
 
Scheme 1.10 Enhancing regioselectivity by selective silylation (BSA: N,O-Bis(trimethylsilyl)acetamide) 
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1.3.3 Enhanced selectivity by trapping with boronates 
Lee and co-workers48 were able to shift the equilibrium toward the desired direction by 
introducing an electrophilic boronate group within the molecule that can trap the isomerized 
hydroxyl group. The corresponding substrates are difficult to prepare, but the corresponding 
silylated substrates are much easier to prepare with an Alder-ene reaction (Scheme 1.11, step a). 
Isomerization of 1-55 and subsequent intramolecular trapping of the transposed allyl silyl ether 
moiety forms cyclic boronate 1-56 that serves as important intermediates for Suzuki coupling 
reactions (step c). This strategy offers an easy access to an important class of structures and has 
been applied successfully in the total synthesis of (–)-dactylolide.45 
 
R
OTBS
PinB
R
TBSO PinB
O B
R
OH
OH
R
CO2Et CO2EtI
Pd(PPh3)4
TlOEt
a) 5 mo% [RuCp(CH3CN)3]PF6
acetone, 25 ºC+
b) 2.5 mol% Re2O7
CH2Cl2 or Et2O
25 ºC
R = C5H11 (76%)
R = CH2OBn (88%)
R = CH2CH2Ph (73%)
R = Ph (78%)
1-53
1-54
1-55
1-561-58
1-57c)
 
Scheme 1.11 Allylic transposition of silyl ethers and subsequent Suzuki coupling of cyclic vinyl boronic acid 
 17 
Ph2
SiO
O
Ph2
SiRe2O7 (5 mol%)
Et2O, r.t.
10 min
Ph2
SiOR
O
Ph2
Si
R
Re2O7 (5 mol%)
Et2O, r.t.
OBn
OBn
Ph2
SiOR
O
Ph2
Si
R
Re2O7 (5 mol%)
Et2O, r.t.
OMe
OMe
1-53 1-54 (76)
1-55, R = H 3 h 1-56 (49%)
1-57, R = C5H11
>95% ee
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Scheme 1.12 Ring-contractive allylic transposition of cyclic silyl ethers 
1.3.4 Enhanced selectivity by ring contraction 
Lee and coworkers developed another approach for selective [1,3]-transposition of allyl silyl 
ethers by relieving ring strain of medium-sized rings.49 In this protocol, eight membered ring 
siloxadienes undergo ring contractions to form the corresponding six-membered siloxenes 
bearing an endocyclic double bond and an exocyclic alkenyl substituent. This ring contraction 
also generates a trans-double bond from the internal cis-alkene, providing an additional driving 
force for the transformation. As shown in Scheme 1.12, in the presence of 5 mol% Re2O7, 
various silacyclodienes (1-53, 1-57, 1-61) undergo effective ring contractions to afford 1-54, 1-
58, 1-62 respectively in good to high yields with trans-configuration of the exocyclic double 
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bonds. However, the rearrangement of substrate 1-55 derived from a primary allyl alcohol 
afforded product 1-56 with reduced efficiency and the rearrangement of enantioenriched 
substrate 1-61 afforded 1-62 with some degree of enantiomeric excess erosion.  This method was 
later applied successfully in the total synthesis of (–)-amphidinolide V.47 
 
OH OH OH OH
OH OH
O O
Ph
O O
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OH OH
Re2O7 (2.5 mol%)
CH2Cl2, rt, 2 or 20 h
60% conversion 
dr = 3:2
1-63 1-64
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1-65 1-66
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Scheme 1.13 Regio- and stereocontrol of allylic alcohol isomerization by benzylidene acetal formation 
 
1.3.5 Enhanced selectivity via reversible trapping by benzylidene acetal 
Zakarian and coworkers developed the ketalization-based trapping strategy for the transposed 
hydroxyl group to achieve high product selectivity for the synthesis of the most 
thermodynamically stable 1,3-diol benzylidene acetals.  As shown in Scheme 1.13a, a traditional 
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isomerization of 1-63 gives a diastereomeric mixture of 1-64 in equilibration with the starting 
material. However, the mixture 1-64 possesses a 1,3-diol moiety and can be trapped by 
ketalization to form another mixture 1-66. This mixture of acetals will then slowly equilibrate to 
selectively yield diastereomer 1-67, which has the highest thermodynamic stability (scheme 
1.13b). Subsequent hydrolysis of 1-67 gives syn-1,3-diol 1-68, an  important moiety in organic 
chemistry. 
1.3.6 Enhanced selectivity by dynamic kinetic resolution (DKR) 
Akai and coworkers developed an elegant DKR (dynamic kinetic resolution) approach51, 52 in 
which a free or polymer-bound vanadium-oxo complex was used to catalyze the rapid and 
continuous racemization of the alcohols as well as the allylic transposition of the hydroxyl 
groups, while the lipase was used to effect the chemo- and enantioselective esterification of 
allylic alcohols. As shown in scheme 1.14, regardless of which equilibrating isomer is used, the 
same final product will be obtained with high yield and enatiopurity. This approach is impressive 
since it provides great flexibility to substrate synthesis, as one can simply choose to start with the 
isomer that is easiest to synthesize. 
R1
R2
R3
R2
OH
R1 R
3
OH
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R3
OAcyl
or
1-69
1-70
O=V(OSiPh3)3
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O
V
O
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O
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up to >99% ee
1-71
 
Scheme 1.14 Synthesis of optically active allyl esters via Lipase-Vanadium combo catalysis 
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2.0  STEREOSELECTIVE HETEROCYCLE SYNTHESIS THROUGH A 
REVERSIBLE ALLYLIC ALCOHOL TRANSPOSITION AND NUCLEOPHILIC 
ADDITION SEQUENCE 
Our interest in allylic alcohol isomerization arose from our studies in the total synthesis of 
leucascandrolide A,42 where allylic alcohol 2-1a or 2-1b was subjected to Re2O7 to effect the 
reversible conversion to 2-2 followed by the thermodynamically driven formation of macrolactol 
2-3 (See Scheme 2.1). The same final product was obtained regardless of which starting isomer 
was used, indicating that dynamic thermodynamic stereocontrol can be achieved under these 
reversible conditions due to the lack of stereochemical fidelity in the transposition process. The 
stereochemical infidelity, often viewed as undesirable, was used in this case to our benefit to 
obviate the need for an additional step of preparing a stereochemically defined allylic alcohol, 
which could be labor and material intensive considering the complexity of 2-2. 
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Scheme 2.1 Allylic alcohol transposition and capture in the total synthesis of leucascandrolide A 
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2.1 RESEARCH OBJECTIVES AND SUBSTRATE DESIGN 
Our previous synthesis of leucascandrolide A indicated that a mixture of diastereomers 
could be equilibrated to a single product with proper substrate design, which highlighted the 
possibility of applying non-stereoselective allylic alcohol transposition to stereoselective 
syntheses of complex molecules through thermodynamic equilibration. This strategy, if proved 
viable, will provide great freedom and flexibility to substrate preparation and minimize the need 
for reagent-controlled asymmetric transformations during synthetic endeavors. We begin to 
explore this strategy by studying its applicability in the preparation of some simpler structures 
such as small heterocycles.  
 
R E
+
OH Re2O7
R'
R E
+
OH Re2O7a)
b) R E
+
R'
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+
OH
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O E
O E
R
R'
R
2-4 2-5 2-6
2-7 2-8 2-9  
Scheme 2.2 Proposed transposition and trapping sequence catalyzed by Re2O7 
 
We propose that transposed allylic alcohols can be trapped by preinstalled electrophiles 
for the syntheses of small cyclic ethers.53 (Scheme 2.2, equation a) Pre-installed stereogenic 
centers might be able to affect the overall stereochemical outcome by thermodynamically driven 
equilibration processes (Scheme 2.2, equation b), facilitating the stereoselective syntheses of 
these small cyclic ethers, which are ubiquitous and important moieties in organic chemistry. 
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2.2 RESEARCH RESULTS AND DISCUSSIONS 
Ph
O
OH
OPh O PhO
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2-10
2-11 (20%)
+
2-13 2-14 2-15
a)
b)
Scheme 2.3 Initial cyclization studies 
2.2.1 Application to the synthesis of medium-sized cyclic ethers 
We tested the applicability of the transposition/hemicacetal formation to form small rings 
(Scheme 2.3) by subjecting alcohol 2-10 to 5 mol% Re2O7 in CH2Cl2. After stirring at room 
temperature for 30 min, we observed complete consumption of the starting material and the 
formation of lactol 2-11, but the yield was only 20%. The major product 2-12 resulted from 
dehydrative coupling reactions of 2-11 via tetrahydrofuryl oxocarbenium ion formation50, 54 and 
nucleophilic addition. This pathway could be suppressed by conducting the reaction with acetal 
2-13, whereby the Lewis acidity of Re2O7 acted to form oxocarbenium ion 2-14, which trapped 
the transposed alcohol to form 2-15 in 83% yield. No stereocontrol was observed in this reaction, 
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which is consistent with our expectations based on thermodynamic considerations. Enone 2-16 
was also exposed to the reaction conditions to explore the viability of an allylic alcohol 
transposition and oxa-Michael reaction55 sequence and tetrahydropyran 2-18 was formed as a 
single stereoisomer in nearly quantitative yield within 10 min at room temperature. α,β-
Unsaturated esters and nitriles are not sufficiently electrophilic for these reactions. These 
substrates only equilibrate with the corresponding transposed allylic alcohols when exposed to 
the standard reaction conditions (Scheme 2.4, equation b and c).   
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N
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X
X
Scheme 2.4 Trapping transposed allylic alcohol with Michael acceptors 
The scope of these monocyclization reactions is shown in Table 2.1. Entries 1-3 show 
that acetals containing primary allylic alcohols are suitable substrates, and the formation of five-, 
six-, and seven-membered rings proceeds smoothly with nearly equivalent efficiency. As shown 
in Scheme 2.3, no stereoselectivity was observed in these reactions, which is consistant with the 
fact that no significant difference in thermodynamic stability exists between the corresponding 
isomers. Ketals react with even greater efficiency, as shown in entry 4, where 2-32 was formed 
as a single stereoisomer within 10 min at lowered temperature. In fact when the reaction was 
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performed at room temperature, a low yield was observed resulting from the generation of a 
significant amount of byproducts, perhaps forming via the carbocation intermediates.  
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Table 2.1 Exploration of the reaction scope 
OBn
O
OBnO
OBn
O
HO OBn
OBn
OBn
OBn
HO
OBn
OBn
HO
HO Ph
MeO OMe
O PhOMe
OBn
OBn
OBn
OBnOH
HO Ph
MeO OMe
OBn
OBn
HO
O
OH O
O OBn
O PhOMe
O OBn
O
O
O
O
O OBn
Substrate Product Time %Yield
30 min
30 min
30 min
10 min
30 min
30 min
20 min
30 min
48 h
60 min
84
81
81
85
99
dr = 1:1
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dr>10:1
81
dr = 10:1
91
88
90
1
2
3
4
5
6
7
8
9
10
2-25 2-26
2-27 2-28
2-29 2-30
2-31 2-32
2-33 2-34
2-35 3-36
2-37 2-38
2-39 2-40
2-41 2-42
2-43 2-44
HO
HO
Entry
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No stereocontrol is observed in acetal substrates that contain a stable stereocenter and a 
primary allylic alcohol (entry 5), but excellent stereocontrol arises from subjecting the 
corresponding secondary alcohol to the reaction conditions (entry 6). Ketal substrates that 
contain a stereocenter and primary alcohol group show high stereocontrol (entry 7), with 2-28 
being formed as nearly a single stereoisomer from 2-37 within 30 min. Trisubstituted alkene 
substrates are also viable participants in this reaction, as shown by the conversion of 2-39 to 2-40 
(entry 8). Stereoselective transformations can also be achieved with enone electrophiles, as seen 
in entries 9 and 10. Equilibration is much faster for secondary allylic alcohol 2-43 in comparison 
to primary alcohol 2-41.   
R
OReO3 X
R'O OR'
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XO3ReO
O R'
R
XO3ReO
O R'
OR X
OR'
OR X
OR'
X = H or alkyl
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OR'
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O
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X
OR'
2-45
2-46 2-47 (Major)
2-48 2-49 (Minor)
2-50 2-51  
Scheme 2.5 Pathways for stereochemical isomerization 
 
Scheme 2.5 provides a consistent explanation based on fundamental principles for the 
results shown in Table 1. Rearrangement of the initially formed perrhenate ester 2-45 proceeds 
with little or no stereocontrol to form a mixture of esters 2-46 and 2-48. Cyclization follows 
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oxocarbenium ion formation to yield 2-47 and 2-49, respectively, as the kinetic products. Ring 
formation is reversible, however, leading to thermodynamic equilibration in some cases. The 
equilibration most likely results from perrhenate ester ionization to form an allylic cation 
followed by ion-pair collapse to yield a mixture of stereoisomers. Secondary allylic alcohols 
ionize more readily than primary allylic alcohols due to the cation-stabilizing effect of the 
additional alkyl group. Thus, the superior stereocontrol in the cyclization of 2-35 relative to 2-33 
(enties 5 and 6 in Table 2.1) can be ascribed to the greater potential for the stereomutation in the 
short-lived acyclic intermediate. The heightened stability of the oxocarbenium  ion from the 
ionization  of ketals rather than acetals promotes ring opening and enhances opportunities for 
stereochemical editing by conferring a longer lifetime to the acyclic intermediate. This difference 
accounts for the excellent level of stereocontrol that was observed in the cyclization of 2-37 
(entry 7). Trisubstituted alkene substrates can yield products with a single alkene geometry when 
sufficient  energetic preference exists (entry 8). The cyclization of 2-39 is also noteworthy 
because the dehydrooxecane that would form via a direct cyclization of the starting alcohol into 
the intermediate oxocarbenium ion is not observed. The corresponding primary alcohol yields a 
mixture of tetrahydropyran and dehydrooxecane products (not shown), again highlighting the 
benefits of utilizing secondary alcohols on isomerization kinetics.  Thermodynamics dictate the 
stereochemical orientation of the anomeric centers, with isomer 2-50 and 2-51 having similar 
energies when X = H, and 2-50 being significantly less stable than 2-51 when X = alkyl. The 
same products are observed when secondary alcohol substrates are single stereoisomers or 
diastereomeric mixtures, confirming that stereocontrol arises from thermodynamic control rather 
than kinetical control. Ketone products equilibrate through retro oxa-Michael reactions. Again, 
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additonal alkyl substituent facilitates ionization and leads to a more rapid equilibration. This is 
the reason why the formation of 2-44 took only 60 minutes while that of 2-42 took two days.  
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Scheme 2.6 Double isomerization/cyclization route to bridged structures 
2.2.2 Application to the synthesis of bridged bicyclic acetals 
Upon establishing the basic reactivity patterns of the process, we turned our attention toward its 
application to the construction of more complex bicyclic structures. In these reactions, the acetal 
group serves as an electrophile for consecutive nucleophilic additions. Bridged bicyclic 
structures of this type that are found in a number of biologically active compounds such as the 
didemniserinolipids56 and the pinnatoxins.57 The reaction of diol acetal 2-53 with Re2O7 provides 
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diastereomeric bicycles 2-54 and 2-55 as a separable 3:4 mixture after 21 h. This reaction 
proceeded through an initial isomerization/cyclization to form 2-56, which underwent a second 
isomerization to yield 2-58 as a mixture of diastereomers. Ring closure provided the observed 
products. Resubmitting pure 2-55 to the reaction conditions yielded only a minimal amount of 2-
54, indicating that the product ratio can be attributed to kinetic rather than thermodynamic 
factors. Diol 2-59 was prepared as a mixture of stereoisomers in an effort to facilitate 
equilibration. Exposing 2-59 to the standard conditions resulted in the formation of bicycles 2-60 
and 2-61 in 53% yield as a 7.3:1 mixture, indicating that the increased substitution in the allylic 
system promotes thermodynamic equilibration in accord with prior results. Resubjecting 2-61 to 
the reaction conditions provided a similar ratio of 2-60 and 2-61. This ratio is consistent with the 
energetic difference between the isomers that was calculated by Spartan.58 We also examined the 
cyclization of ketone 2-62 based on our supposition that intramolecular addition into the 
oxocarbenium ion that formed from ionization of the initial lactol would be faster than the 
bimolecular addition that was observed in the reaction of 2-10. While 2-62 proceeded through 
the sequence with slightly lower efficiency than 2-53, the reaction yielded 2-54 and 2-55 in the 
same ratio. 
2.2.3 Application to the synthesis of bicyclic spiroketals 
This strategy can also be applied to the synthesis of spirocyclic structures59 as shown in Scheme 
2.7. Diol acetal 2-63 reacted with Re2O7 under standard condition to provide a 1.1:1 mixture of 
spiroketals 2-64 and 2-65 within 30 min at rt. Allowing the reaction to proceed for 12 h 
improved the ratio of 2-64 and 2-65 to > 20: 1 in which the major product has the anomerically 
preferred stereochemical orientation at the ketal center, and both vinyl groups have equatorial 
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alignments. Ketones also serve as useful substrates for the process though the isomerization 
process is slower, with 2-66 providing 2-64 in 61% yield after 48 h. Notably, equilibration in this 
reaction required the addition of MeOH. We postulate that the addition of MeOH facilitates the 
ring-opening event to a greater degree than water, or water suppresses the catalytic efficiency of 
Re2O72c because the cyclization of the ketone substrate will generate one equivalent of water. As 
expected, secondary diol 2-67 equilibrated more rapidly, providing 2-68 as a single stereoisomer 
within 1 h at 0 °C. Reaction of the secondary diol substrate at higher temperature results in 
decomposition, this is again due to the increased stability of the allylic cation when an additional 
alkyl group is introduced. 
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Scheme 2.7 Synthesis of spiroketals 
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Scheme 2.8 Remote stereoinduction and intramolecular redox isomerization 
 
Next, diol acetals 2-69 and 2-71 were prepared to study the influence of a non-
equilibrating secondary alcohol on remote stereochemical induction. These compounds 
proceeded through the cyclization reactions (Scheme 2.8) efficiently to form spiroketals 2-70 and 
2-71 in 60% and 65% yield, respectively. Consistent with previous studies, the reaction of 
secondary alcohol 2-71 converged to a single stereoisomer much more rapidly (30 min vs. 24 h) 
than the cyclization of primary alcohol 2-69. When enantiomerically pure 2-69 was used in the 
reaction, minimal racemization (~2%) was observed by HPLC detection (Figure 2.1). Thus this 
transformation demonstrates that a high level of relayed 1,9-stereoinduction can be obtained 
based on thermodynamic control. The isolation of tetrahydropyranyl ketones 2-75 and 2-76 as 
minor products from the cyclization of 2-69 is also noteworthy. These products arise from the 
ionization of the spiroketal to form oxacarbenium ions 2-73 and 2-74. Reduction of these ions by 
 32 
intramolecular hydride transfer leads to the tetrahydropyranyl ketones, with conjugate addition of 
MeOH to the intermediate enone ultimately providing 2-76. These transformations, while not 
resulting from predominant pathways, are nonetheless mechanistically intriguing because the 
stereocenter that directs the creation of the two stereocenters in the product is ultimately 
destroyed in this process. 
 
 
Figure 2.1 HPLC traces of racemic (black) and enantioenriched (pink) 2-70 from racemic and enantioenriched 
substrate 2-69 using a chiral stationary phase 
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2.2.4 Application to the synthesis of spirotricycles 
Re2O7
O OO O OO
2-78 : 44% 2-79 : 43%
O
O
OH
OH
Re2O7
CH2Cl2
0 oC, 1 h
54% (one recycling)64% (one recycling)
2-77
 
Scheme 2.9 Synthesis and equilibration of spirotricycles 
 
We explored the capacity for remote stereochemical induction across a spirotricyclic system by 
preparing diketone diol 2-77 through an oxidative enolate coupling reaction60 (see experimental 
details). Exposing 2-77 to Re2O7 at 0 °C for 1 h provided spirotricycles 2-78 and 2-79 in 44% 
and 43% yield, respectively (see Scheme 2.9). Confirmation for these structures was provided by 
HPLC experiments (see Figure 2.2) where racemic 2-78 showed 2 peaks of equal intensities 
when a chiral stationary phase was employed while meso isomer 2-79 showed only one peak. 
The formation of a diastereomeric mixture is a result of the lack of a strong thermodynamic 
preference for either compound that results from the numerous low energy conformations of the 
central tetrahydrofuran unit.61 Re-subjecting either of the products to the reaction conditions 
quickly resulted in the formation of the thermodynamic mixture of diastereoisomers. Therefore 
one recycling of 2-79 provided 2-78 in an overall yield of 64% While one recycling of 2-78 
provided 2-79 in 54% overall yield. The ratio of products that was formed in the equilibration 
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reaction was slightly different from the ratio that was observed in the initial cyclization. We 
postulate that the liberation of water in the initial cyclization reaction could have a subtle 
influence on the rate of equilibration since water was excluded from the equilibration protocol. 
The important conclusion from this study is that either stereoisomer can be accessed in 
reasonable yield through a rapid sequence of reactions. The stereochemical arrangement around 
the tetrahydrofuran ring in 2-78 matches the orientation that is seen in azaspiracid-162 while the 
arrangement in 2-79 matches the pinnatoxins.57 Multiple studies have shown63 that the 
thermodynamic preferences in these spirotricycles can be manipulated by subtle structural 
changes, indicating that this protocol could be broadly applicable to the synthesis of this 
molecular class, particularly in the consideration of the improved access to 1,4-diketones that has 
resulted from advances in oxidative enolate heterocoupling reactions.64 This sequence produced 
compounds in which stereocenters in the product arose from prochiral sites that had a 1,12-
relationship in the starting material. 
 
Figure 2.2 HPLC traces of 2-78 (pink) and 2-79 (black) using chiral stationary phase 
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2.3 CONCLUSION 
It has been demonstrated that the experimentally facile sequence of Re2O7-mediated allylic 
alcohol isomerization followed by nucleophilic addition into an oxocarbenium ion can be used to 
generate stereocenters with high levels of diastereocontrol. Stereocontrol is maximized when the 
energetic difference between diastereomeric products is sufficient to create a strong preference, 
when reversibility in the cyclization reaction is facilitated by increasing the stability of the 
oxocarbenium ion intermediate and when stereochemical scrambling is promoted by increasing 
the substitution on the intermediate allyl cation. Application of these principles in more complex 
substrates lead to the syntheses of bridged and spirocyclic ketals with good to excellent levels of 
stereocontrol. This method is particularly effective for setting remote stereocenters in spirocycle 
synthesis, where a relayed 1,9- and 1,12-stereoinduction was demonstrated. Applying 
thermodynamic equilibration to establish remote stereocenters alleviates the need for labor- and 
material-intensive reagent-controlled asymmetric transformations, thereby enhancing the overall 
efficiency of complex molecule synthesis. 
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3.0  CASCADE APPROACH TO STEREOSELECTIVE POLYCYCLIC ETHER 
FORMATION: EPOXIDES AS TRAPPING AGENTS FOR TRANSPOSING ALLYLIC 
ALCOHOLS 
In the previous chapter, Re2O7-catalyzed allylic alcohol transposition reactions and their 
application in the stereoselective ring-forming processes were studied. These reactions 
proceeded through intramolecular trapping of the hydroxyl group with an pendent electrophile, 
followed by thermodynamically controlled equilibration.53 These initial studies employed achiral 
electrophiles such as ketals and enones, therefore requiring a stereogenic center in the tether 
between the nucleophile and the electrophile in order to control the stereochemical outcome. 
However, trapping transposed alcohols with chiral electrophiles offers significant advantages for 
the preparation of enantiomerically pure molecules via this isomerization/cyclization sequence. 
Epoxide groups are particularly attractive for this sequence because they are easily incorporated 
into a molecule and there are several well-documented methods to prepare epoxides in 
enantiomerically pure form.65 Moreover, epoxides can act as electrophiles to liberate 
nucleophilic hydroxyl groups upon opening,66 or as nucleophiles to create electrophilic 
epoxonium ions upon reacting with a cation.67 These features have led to the development of 
numerous epoxide-opening cascade reactions and have been applied commonly in natural 
product synthesis.68 In this chapter, the application of epoxides as trapping agents for allylic 
alcohols in rhenium oxide-mediated transposition reactions is studied. 
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Scheme 3.1 Adjustment of regio- and stereochemistry in rhenium oxide-catalyzed allylic alcohol transposition 
3.1 RESEARCH DESIGN AND OBJECTIVES 
Rhenium oxide-mediated allylic alcohol transposition can be applied in the design of 
thermodynamically controlled reactions due to its capacity to adjust regiochemistry and 
stereochemistry (Scheme 3.1) in response to structural influences. This has been demonstrated in 
its increased applications in complex molecule synthesis40-47 as well as chapter 2. Here we 
propose that coupling this reaction to a trapping by epoxides offer an another opportunity for 
stereoselective synthesis.69 As shown in Scheme 3.2, stereoselective synthesis of tetrahydropyran 
will be realized if either one of the two proposed pathways can work. In pathway a, a fast 
equilibration is established between two diastereomeric intermediates 3-10 and 3-11, the 
formation of 3-12 is faster compared to that of 3-13 due to pseudoaxial vinyl group in the 
transition state for the conversion of 3-11 to 3-13, leading to the selective formation of 3-12. In 
pathway b, the cyclization of 3-10 and 3-11 to 3-12 and 3-13 is much faster compared to the 
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equilibration between 3-10 and 3-11, however the cyclization is a reversible process and the 
thermodynamically less stable isomer 3-13 undergoes ring opening, and stereoinversion followed 
by ring closure to deliver the thermodynamically more stable isomer 3-12. This approach is 
studied and its application in complex structure synthesis is detailed in the following sections. 
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Scheme 3.2 Stereoselective tetrahydropyran formation using epoxides as trapping electrophiles (Same molecules are 
drawn from different perspective for a and b) 
3.2 INITIAL RESULTS ON MONOCYCLIZATION AND DISCUSSIONS 
3.2.1 Results for monocyclization  
The general applicability of epoxides as trapping agents was demonstrated with substrates 3-15 
and 3-16. When exposing 3-15 to Re2O7 (5 mol%) for 4 h at rt, tetrahydropyrans 3-16 and 3-17 
were produced in 51% and 38% yields, respectively. This result showed that the reaction exhibits 
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a slight preference for the formation of the thermodynamically more stable isomer 3-16. 
Resubjecting either isomer to the reaction conditions resulted in no change, thereby establishing 
that this result does not arise from thermodynamic equilibration. The reaction of secondary 
alcohol 3-18 proved to be much more complicated than that of 3-15. A mixture of oxepanes 3-19 
and 3-20 was produced after a reaction time of 45 min. However, prolonged exposure with 
increased catalyst loading (15 mol%) resulted in the formation of tetrahydropyrans 3-21 and 3-22 
in a nearly 1:1 ratio. Resubjection of 3-19 to the reaction conditions yields predominantly 3-21 
while resubjection of 3-20 provides predominantly 3-22. Similar to 3-16 and 3-17, 3-21 and 3-22 
interconvert extremely slowly when resubjected the reaction condition. 
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Scheme 3.3 Epoxides as the trapping agent in alcohol transposition reactions 
 
These studies showed that primary and secondary allylic alcohols react via different pathways 
although both produced similar final products when given sufficient reaction time. As shown in 
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Scheme 3.4, primary allylic alcohol 3-15 undergoes isomerization to form a diastereomeric 
mixture of secondary alcohols 3-23. The secondary alcohols then undergo nucleophilic attack 
toward the Re2O7 activated epoxide group to deliver the tetrahydropyran products. On the other 
hand, secondary allylic alcohol 3-18 reacts with Re2O7 to form allyl cation 3-24 due to the 
stabilization by the additional alkyl group. The epoxide then undergoes nucleophilic attack 
toward the allyl cation to form epoxonium ion 3-25, which reacts with perrhenate anion via a 
kinetically preferred67e endo-pathway to provide an oxepanyl perrhenate ester that decomposes to 
deliver the initially observed oxepanyl alcohol products. Another possible explanation for the 
formation of these oxepanyl alcohol products is the direct nucleophilic attack of the transposed 
allylic alcohol toward the Re2O7 activated epoxide group via a 7-endo-pathway, and the 
corresponding products from this mechanism have the opposite stereochemistry compared to 
those from the former mechanism. However, crystallographic70 and Mosher ester71 analysis of 
the products from enantiomerically enriched substrates showed that the absolute stereochemistry 
at the distal carbon of the epoxide (with respect to the allylic alcohol) was retained while 
absolute stereochemistry at the proximal carbon was inverted, providing strong evidence for the 
first pathway. Oxepanyl alcohol products 3-19 and 3-20 then undergo Re2O7-mediated ionization 
to yield allyl cations 3-26, then 3-26 react with the pendant free hydroxyl groups to yield the 
tetrahydropyrans as the thermodynamic products which appear to be inert toward further 
ionization. The process proceeds predominantly with stereochemical retention, as the 
isomerization of 3-19 gives 3-21 while that of 3-20 gives 3-22. Racemization in these processes 
is minimal, indicating that the allylic ethers undergo ionization at much faster rates than aliphatic 
ethers.  
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Scheme 3.4 Mechanistic details 
3.2.2 Efforts toward understanding the lack of selectivity 
Although epoxides can act as effective trapping agents for the transposed allylic alcohol, there is 
almost no stereoselectivity for such a transposition/cyclization sequence. Many expreriments 
were conducted in order to confirm either one of the two pathways in Scheme 3.2. For example, 
to validate the first pathway, substrates 3-27 with different substituents at the epoxide or/and 
allylic alcohol moiety were synthesized in order to create a larger energetic difference between 
the two transition states, so that the cyclization of the less energetically favorable intermediate is 
hampered. However, in all these substrates, the cyclization was much faster than the 
interconversion of the two intermediate structures and a near 1:1 mixture of diastereomers were 
obtained for most substrates tested (equation a in talbe 3.1). Lowering the reaction temperature 
resulted in the increased selectivity at the expense of a reduced yield. This is because the low 
temperature created a larger energetic difference for cyclization, however, reduced 
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stereoinversion of the allylic alcohol (e.g. 3-28) also significantly slowed down and the 
diastereomer that lead to the minor isomer is enriched over time without converting to the other 
isomer, supported by of the recovery of starting material. For example, 1H and 13C NMR of the 
recovered starting material from entry 7 showed that only one diastereomer remained. This result 
provides strong evidence that the increased selectivity is a result of intramolecular kinetic 
resolution rather than thermodynamic equilibration, and explains why the overall yield decreased 
as the diastereoselectivity increased. 
 
Table 3.1 Efforts toward improving the diastereoselectivity in the epoxide opening 
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25 ºC 3 h 92% 1.5:1
0 ºC 18 h 88% 1.5:1
25 ºC 15 min 63% 2.6:1
0 ºC 30 min 54% 3.7:1
-25 ºC 30 min 31% 6.0:1
-78 ºC 6 h 38% 11.0:1
Entry
1
2
3
4
5
6
a)
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The failure of the first pathway (Scheme 3.2a) left the second one (Scheme 3.2b) as the 
only option. However, unlike the products arising from other trapping agents such as ketals and 
enones in the previous chapter, the cyclization products using epoxides as trapping agents do not 
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undergo thermodynamic equilibration, which was proved after extensive screening of substrates 
and reaction conditions. The slowed isomerization of 3-21 and 3-22 compared to that of 3-19 and 
3-20 led to the speculation that the exocyclic hydroxyalkyl group suppresses the allyl cation 
formation, an important step for post cyclization equilibration. To test this hypothesis, ketone 3-
31 was prepared as a 5:4 ratio of stereoisomers by oxidation of a crude mixture of 3-21 and 3-22. 
When subjecting 3-231 to Re2O7 at rt for 4 h, a significant enhancement (11.5:1) of the 
thermodynamically favored cis-isomer was observed (Scheme 3.5). However, a similar substrate 
with terminal alkene showed little isomerization after extended exposure to the reaction 
conditions, confirming the importance of cation stabilization in stereochemical equilibration. 
Another substrate, 3-32, with the free hydroxyl group protected as methyl ether was prepared in 
a 1:1 mixture of stereoisomers in order to determine whether the enhancement of ionization rate 
resulted from the absence of hydroxyl group or from an increased inductive effect. This mixture, 
when exposed to the standard reaction conditions for 5 h, produced the cis-isomer as nearly 
exclusive product, thereby confirming the role of hydrogen bonding in suppressing ionization-
based isomerization. 
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Scheme 3.5 Stereochemical isomerization 
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3.3 INCORPORATION OF EPOXIDE OPENING INTO A CASCADE PROCESS 
When epoxides were used as trapping agents in the transposition/cyclization sequence, no 
selectivity was observed in tetrahydropyran formations. Studies showed that the free hydroxyl 
group after the epoxide opening is responsible for this lack of selectivity. However, these results 
indicated that these processes have the capability to provide stereochemically pure products if 
the hydroxyl group that results from epoxide opening is consumed in a subsequent step in a 
cascade process. 
3.3.1 Trapping the hydroxyl group following epoxide opening 
To test the validity of this cascade process, substrates were synthesized with electrophiles or pro-
electrophiles incorporated at their termini in order to trap the hydroxyl groups after epoxide 
opening.  When exposing epoxy ester 3-33 to Re2O7, lactone 3-34 was produced as a single 
stereoisomer in 71% yield, although removal of MeOH proved to be important for equilibration. 
Epoxy acetal 3-35 was prepared to study the capability of rhenium oxide to promote the 
formation of oxocarbenium ion53, 72-73 as trapping group. Exposing 3-35 to Re2O7 at room 
temperature lead to decomposition of the starting materials without any production of the desired 
product, and lowering the reaction temperature only gave a low yield of 3-36. However, when 
switching to the more soluble catalyst, Ph3SiOReO3 and initiating the reaction at -25 ºC followed 
by warming to room temperature to effect the stereochemical equilibration, 3-36 was isolated as 
a single stereoisomer and as a 5:2 mixture at the anomeric site. More stereoisomeric products 
were observed if the reaction was stopped early, confirming that equilibration follows the initial 
cyclization.  
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Scheme 3.6 Cascade reactions 
 
Enones could also be used as trapping agents for this cascade reaction, as shown by the 
conversions of 3-37 to 3-38 and 3-39 to 3-40 and 3-41. The reaction of 3-37 yielded a 
diastereomeric mixture of bis-tetrahydropyrans after 20 hours and required 3.5 days at room 
temperature for the mixture to converge and provide the product as a single stereoisomer. The 
reaction of 3-39 proceeded to completion within 20 h to provide a mixture of 3-40 and 3-41 in a 
ratio of 1.5:1. Reexposing either 3-40 or 3-41 to the reaction conditions lead to the production of 
the same 1.5:1 ratio of product, thereby confirming the thermodynamic ratio of the product 
mixture. This observation led to the somewhat surprising conclusion that axial tetrahydropyranyl 
groups are only modestly disfavored relative to axial methyl groups.  The reactions with enones 
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as electrophiles are significant because they have demonstrated bidirectional stereogenesis, in 
which the introduction of new stereogenic centers from distal prochiral units are directed by the 
stereochemistry of the epoxide group. Additionally, these transformations with enone substrates 
proceed with perfect atom economy.74 
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Scheme 3.7 Ketones as stereochemical conduits 
3.3.2 Cascade reactions using ketones as stereochemical conduits 
Consumption of the free hydroxyl group from epoxide opening with a trapping agent eradicates 
the influence of hydrogen bonding on the ionization-based equilibration, thereby allowing 
stereoselective synthesis through post-cyclization equilibration. Another way to overcome 
influence of the hydroxyl group is to separate it from the stereogenic center that needs to be 
edited through thermodynamic equilibration. In such an approach, a ketone group is chosen as a 
nucleophile to open the epoxide, thereby generating a chiral oxocarbenium ion that acts as an 
electrophile to trap the transposed allylic alcohol. This product of this process is a spiroketal with 
a hydroxyl group that is far from the allylic system, as a result, stereochemical editing through 
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acetal ionization and allylic alcohol transposition without the influence from the free hydroxyl 
group is possible. Additionally, ketones can act as stereochemical conduits and provide an 
alternate strategy to transfer the chirality of epoxide groups to remote sites. As shown in Scheme 
3.7, this approach is demonstrated by the reaction of 3-42 with Re2O7, which gives spiroketal 3-
43 as a single stereoisomer in 93% yield within 20 h at room temperature. Secondary alcohol 
substrate 3-44 decomposed under these reaction conditions, presumably due to the various 
pathways that are possible upon the formation of an allylic cation intermediate. However, 
success was achieved by using Ph3SiOReO3 and initializing the reaction at -78 ºC followed by a 
slow and controlled process of warming. This improved protocol resulted in 71% yield of 3-45 
from 3-44. A minor diastereomer was isolated in 4% yield, but the overall yield of 3-45 was 
compromised if the reaction was allowed to run to complete equilibration. 
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Scheme 3.8 Possible reaction pathways with ketones as stereochemical conduits 
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Scheme 3.9 Additional studies of hemiacetals as nucleophiles 
 
A plausible mechanism for this transformation is shown in Scheme 3.8 (pathway a). 
When subjecting 3-46 to Re2O7, it undergoes Lewis acid-mediated opening of the epoxide by the 
oxygen of the ketone to yield oxocarbenium ion 3-47. The allylic alcohol reversibly transposes to 
form a mixture of secondary allylic alcohols 3-48, which add to the oxocarbenium ion to form 3-
49 and 3-50. This mixture will finally converge to yield the thermodynamically preferred 
spiroketal 3-49 as the sole product of this transformation because the thermodynamically less 
stable 3-50 can revert to a single diastereomer 3-48, which undergoes stereochemical editing 
through ionization/recombination. An alternative mechanism is shown as pathway b, in which 
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the transposing alcohols add into ketone to form a mixture of hemiacetals that add into epoxide 
to form 3-49 and 3-50 followed by stereochemical editing to provide exclusively 3-49. However, 
this second mechanism is less likely due to the information gained from studies using 
intermediate hemiacetals as nucleophiles in cascade reactions (Scheme 3.9). Substrate 3-53, 
when exposed to Re2O7, undergoes allylic alcohol transposition followed by nucleophilic 
addition to ketone to deliver intermediate hemiacetal 3-54, which could give spiroketal 3-55 if 
hemiacetal underwent 1,4-addition into the enone. However, an interesting compound 3-58 was 
the only product isolated, and no trace of 3-55 was detected. The compound 3-58 is generated 
through the dehydration of hemiacetal 3-54 to form 3-56, and then the cyclic enol ether 
undergoes a Michael addition followed by proton transfer to deliver the product 3-58 as a 
mixture of 1:1 diastereomers. A cyclic substrate 3-59 undergoes a similar process to give 3-60 as 
a single diastereomer as a result of the constraint the macrocycle imposes on the system. Efforts 
to form spiroketals by using other electrophile or pre-electrophiles such as ester (3-61) and acetal 
(3-62) also did not lead to any success. These results lead to the speculation that hemiacetals 
might not be good nucleophiles in the current system. As a result, pathway b in scheme 3.8 is 
less likely to be the true mechanism because a step using a hemiacetal as a nucleophile is 
included. 
Lower homologs are also suitable substrates for these cascade reactions, however 
stereocontrol of the product is lost in these transformations due to the greater conformational 
freedom of the tetrahydrofurans in comparision to tetrahydropyrans. As shown in Scheme 3.10, 
exposing 3-63 to Re2O7 lead to a combined 94% yield of 3-64 and 3-65 in a 1:1 mixture after 3 h 
at room temperature. Despite the failure to deliver a major product under thermodynamic control, 
the yield of either isomer could be increased to useful levels through a simple recycling protocol. 
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As a result, 3-64 can be isolated in 69% yield by resubjecting 3-65 to the reaction conditions and 
in 78% yield after two recyclings. On the other hand, 3-65 can be obtained in 66% yield after 
subjecting 3-64 to one recycling and in 76% yield after two recyclings. The stereochemical relay 
can also be conducted through two ketone groups. When diketone epoxide substrate 3-66 was 
subjected to the reaction conditions, spirotricycles 3-67 and 3-68 were produced in 35% and 45% 
yields, respectively. The lack of selectivity was, again, due to the thermodynamic freedom of the 
central tetrahydrofurans. As in previous examples, improved yields of each isomer can be 
accessed via recycling, with 3-67 being isolated in 50% yield upon resubjecting 3-68 to the 
reaction conditions and 3-68 being isolated in 62% yield after resubjecting 3-67 to the reaction 
conditions. 
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Scheme 3.10 Formation and equilibration of spirocyclic tetrahydrofurans 
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3.3.3 Combined use of a ketone as a stereochemical conduit and an enone as a trapping 
agent
The use of ketone as stereochemical conduits can be combined with enones as terminal 
electrophiles to provide structures with impressive molecular complexity through bidirectional 
stereogenesis. As shown in scheme 3.11, when a judiciously designed substrate 3-69 was 
subjected to the standard reaction conditions for 8 h, a single isomer 3-70 was isolated in 84% 
yield with complete stereocontrol. This transformation is impressive in that a compound with one 
ring and two stereogenic centers is converted to a structure with three rings and five stereogenic 
centers. The overall stereochemistry is determined by a single epxoide and the reaction is 
completely atom economical. 
OH
O
O
O
O
O O
O
H HH
HRe2O7, CH2Cl2
rt, 8 h, 84%
3-69 3-70
Scheme 3.11 Bidirectional stereogenesis with ketone conduit 
3.4 DEVELOPMENT OF A EASILY USABLE CATALYST 
During our research with Re2O7 as a catalyst for allylic alcohol transformation, difficulty was 
encountered while delivering small amounts of this catalyst. While no precautions were required 
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to prevent Re2O7 from being exposed to air or moisture, and most reactions can be performed 
under air without any special handling needed, the Re2O7 quickly liquefies in ambient condition, 
which makes it difficult to precisely measure small amounts of the catalyst. This led us to 
explore an alternative reagent preparation protocol. We found that a supported catalyst could be 
prepared simply by stirring a mixture of Re2O7 and silica gel in anhydrous Et2O for several 
hours, followed by solvent removal under vacuum. By using this protocol, we prepared a 10% 
(w/w) mixture of Re2O7 on SiO2, which was shown to be a competent catalyst for the 
transformations developed previously. There is no significant difference in yields or reactions 
times when either immobilized or free catalysts were employed. For example, when immobilized 
catalyst was used instead of a free catalyst, 3-42 was converted to 2-43 in 93% yield after 12 h, 
3-66 was converted to 3-67 and 3-68 in 82% yield after 2.5 h and 3-69 was converted to 3-70 in 
76% yield after 24h. More notably, the immobilized catalyst could effect the conversion of 3-35 
to 3-36 in 60% yield, which indicated that the more expensive Ph3SiOReO3 could be replaced by 
this easily accessible catalyst. This immobilized catalyst can be easily weighed, even in humid 
environments which causes the free catalyst to liquefy, and can be stored without any loss of 
reactivity for at least six months. Moreover, the immobilized catalyst yields superior dispersion 
of the Re2O7, eliminating the need for an induction period as often observed for the free catalyst. 
Reuse of the immobilized catalyst by filtering of the catalyst from the reaction resulted in 
diminished activity, indicating that partial leaching of Re2O7 occurs during the reaction. 
Although this protocol does not provide a completely reusable catalyst, it significantly facilitates 
the transformations from an operational perspective, particularly for reactions that utilize high 
molecular weight substrates that only require small amounts of catalyst. 
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3.5 CONCLUSION 
The application of epoxides as trapping agents has been studied, and the mechanistic details of 
this transformation have been unveiled. Based on this information, epoxide cascade reactions 
initiated by rhenium oxide mediated allylic alcohol transposition have been realized. The success 
of these transformations are due to the roles of rhenium oxide as both a transposition catalyst and 
an acid that enhances the electrophilicity of the epoxide to promote product ionization, thereby 
enabling thermodynamically controlled stereochemical equilibration. This approach for 
diastereoselective synthesis relies on the functionalization of prochiral carbons rather than the 
generation of stereochemically defined nucleophiles for epoxide opening. Reactions proceed 
either via direct addition of transposed alcohol to the activated epoxide or by using ketones as 
conduits that relay the stereochemical information from the epoxide to distal sites of the product. 
Molecular complexity could be maximized when an electrophile is present for the trapping of the 
hydroxyl group that is generated upon epoxide opening. When enones are used in this strategy, 
bidirectional stereogenesis could be achieved, in which the stereochemical information in the 
epoxide is transferred to opposite ends of the product. This reaction is atom-ecnomical. 
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4.0  HETEROCYCLE SYNTHESIS BASED ON ALLYLIC ALCOHOL 
TRANSPOSITION USING TRACELESS TRAPPING GROUPS 
In previous chapters, the use of allylic alcohols for stereocontrolled heterocycle syntheses has 
been explored.53, 69 An isomerization/cyclization sequence has been developed in which Re2O7 
has been employed as a catalyst to initiate reversible allylic alcohol isomerization and promote 
ring formation through nucleophilic addition of the transposed hydroxyl group to a pendant 
electrophile. A variety of electrophiles are capable of trapping the transposed hydroxyl group, 
and thermodynamically controlled stereochemical editing can be achieved if there is significant 
energetic difference among different products, and if the reactions leading to these products are 
reversible. This new strategy allows for fast access to functionalized cyclic and polycyclic ethers, 
and minimizes the need for reagent-based stereoselective protocols. In this chapter, the 
application of allylic alcohols in the stereoselective synthesis of cyclic ethers is further expanded 
by the development of a new sequence of allylic alcohol transposition, intramolecular trapping, 
oxocarbenium ion formation, and intermolecular nucleophilic addition. 
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4.1 RESEARCH DESIGN AND OBJECTIVES 
The previously discussed isomerization/cyclization sequences required preinstalled electrophiles 
as trapping groups, and generally contained a vestige of the electrophile. While the presence of 
vestige provided the opportunity for further elaboration of the resulting product, more freedom 
could be provided to this methodology if this process was achieved using a traceless trapping 
group.75 As shown in Scheme 4.1, it is proposed that this approach can be realized by adding the 
transposed allylic alcohol to a carbonyl group to form a cyclic hemiacetal 4-2, which 
subsequently can undergo ionization to form an oxocarbenium ion 4-3, and followed by trapping 
with an additional nucleophile to terminate the sequence, product 4-4 can be produced. This 
sequence, once proved valid, could significantly expand the scope of products that can be 
accessed via this method by utilizing different nucleophiles in the termination step, and eliminate 
the remnant of the original trapping group.  
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OH
O
R'
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R
R'HO
n
O
R
R'
n
O
R
R'Nu
n
Nu
Re2O7
4-1 4-2
4-3 4-4  
Scheme 4.1 Transposition, trapping, ionization, and nucleophilic termination (R, R’ = H or alkyl, Nu = nucleophile) 
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4.2 RESULTS AND DISCUSSIONS 
4.2.1 Validation of the new method and initial substrate reactivity studies 
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O O
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Ph
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Ph
4-5
R, R' = H, n = 1
48 h, 85%
4-6
R = Me, R' = H, n = 1
20 h, 90%
4-7
R, R' = H, n = 2
96 h, 70%
4-8
R = Me, R' = H, n = 2
36 h, 87%
4-9
R = H, R' = (CH2)2Ph
n = 1
20 h, 86%
cis:trans = 5 : 4
4-10
R = Me, R' =  (CH2)2Ph
n = 1
24 h, 0 ºC, 57%
cis:trans = 5 : 4
4-11
 R = H, R' = (CH2)2Ph
n = 2
15 h, 91%
single isomer
4-12
R = Me, R' =  (CH2)2Ph
n = 2
30 h, 0 ºC, 62%
single isomer
R
OH
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R'
n
O
R
R'H
n
Re2O7, Et3SiH
CH2Cl2
4-1 4-4
 
Scheme 4.2 Reactivity in tetrahydrofuran and tetrahydropyran formation 
 
In order to demonstrate the feasibility of this approach, triethylsilane was chosen as the 
terminating reagent based on its proven ability in the reduction of oxocarbenium ions.76 As 
shown in Scheme 4.2, several substrates with the general structure 4-1 were synthesized to test 
this approach. These reactions were conducted with 3 mol% Re2O7, and two equivalents of 
Et3SiH at room temperature. Most of these reactions proceeded in excellent yield, although 
prolonged reaction time was required for completion. This was a result of the initial products 
arising from alcohol addition to the intermediate oxocarbenium ion, which was consistent with 
observations made by Dussault and coworkers.77 The rate for the formation of these initial acetal 
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products is fast, and the final products are formed via the ionization of the intermediate acetals 
followed by oxocarbenium ion reduction. This second step is rate determining, and requires a 
much longer time to finish. 
Although various factors can influence the rates of these reactions, several trends become 
apparent after analyzing the results from Scheme 4.2. Reaction rates for secondary allylic 
alcohols are usually faster than those of primary allylic alcohol substrates (4-6 and 4-8 versus 4-5 
and 4-7). This result might arise from the increased access to the oxocarbenium ions, since the 
increased steric interactions in the intermediate mixed acetals from secondary allylic alcohol 
substrate can promote ionization, and as a result, reduction. Tetrahydrofurans form more quickly 
than tetrahydropyrans with similar substitution patterns (4-5, 4-6, 4-9, and 4-10 versus 4-7, 4-8, 
4-11, and 4-12). This also arises from the increased access to the oxocarbenium ion intermediates 
because the tetrahydrofuranyl ethers ionize faster than tetrahydropyranyl ethers.78 Reactions of 
ketone substrates are faster than aldehyde substrates (4-9, 4-10, 4-11, and 4-12 versus 4-5, 4-6, 4-
7, and 4-8). This is again a result of the increased accessibility of the corresponding 
oxocarbenium ions due to the extra stabilization of the additional alkyl groups in ketone 
substrates. However, dehydration becomes a competitive side reaction for ketone substrates with 
secondary allylic alcohols. This might be because the relative stability of ketone-derived 
oxocarbenium ions reduces the rate of trapping, and increased substitution augments the 
potential for allylic cation formation, and as a result, enhances opportunities for dehydration via 
an E1 pathway. Acceptable yields could still be achieved for these substrates, however, by 
simply lowering the reaction temperature. For ketone substrates, stereocontrol was perfect for 
tetrahydropyran formation, but was poor for tetrahydrofuran formation, which agrees with 
established models for nucleophilic additions to cyclic oxocarbenium ions.79 
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4.2.2 Establishment of the reaction scope 
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85%
Et3SiH, rt, 36 h
68%
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Scheme 4.3 Reaction scope  
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Scheme 4.4 Reaction scope (continued) 
 
The scope of this reaction was established by variations in the substrate, through the use of 
different ketones as trapping groups (Scheme 4.3), or through the use of different nucleophiles 
(Scheme 4.4). As shown in Scheme 4.3, various functional groups were well tolerated by this 
method, including esters (4-13, 4-23), bromides (4-15), alkenes (4-17), and phenyl groups (4-21), 
which can stabilize the carbonyl group via conjugation. Substrate 4-17, when exposed to Re2O7 
without the addition of Et3SiH, delivered a combined yield of 90% of 4-18 and 4-19 in a 10:4 
ratio through Prins cyclization.73 However, when the reaction was conducted with the presence 
of Et3SiH, 4-18 was isolated as the major product in 90% yield, while the combined yield of 4-18 
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and 4-19 was reduced to less than 10%. This is an interesting observation because it shows that 
the intermolecular trapping by Et3SiH is 10 times faster than intramolecular trapping by an 
alkene. Another interesting substrate is 4-23, which contains a β-keto ester moiety; the presence 
of a second carbonyl group slows down the reaction by destabilizing the intermediate 
oxocarbenium ion via induction, the reaction of this substrate needed either elevated reaction 
temperature or extended reaction time. This product of this substrate is 4-24, which is an 
apparent product of isomerization/cyclization sequence, however, previous studies have shown 
that α,β-unsaturated esters are not good trapping agents for transposed allylic alcohols (Scheme 
2.4). This lends further justification for the development of a traceless trapping agent. Utilizing 
an epoxide (4-25) as the trapping group provides the opportunity for cascade cyclizations68a, 75 in 
which stereochemical information from the epxoide is transferred to both ends of the product (4-
26).  
A limited number of nucleophiles have been studied to explore the potential application 
of this protocol in fragment coupling reactions. Potassium alkynyltrifluoroborate (4-28),80 
allylsilane (4-30),77 and silyl ketene acetal (4-32) add to the tetrahydrofuranyl oxocarbenium ions 
to yield 4-29, 4-31 and 4-33, respectively. No stereocontrol was observed, which is consistent 
with the reductive quenching experiments of tetrahydrofuranyl oxocarbenium ions. Although 
heteroatom-based nucleophiles such as alcohol (4-35) and thiol (4-37) add successfully to 
tetrahydropyranyl oxocarbenium ions, carbon-based allyl trimethylsilane does not, presumably 
because these reaction conditions do not induce a sufficient level of ionization to promote 
reactions with weak π-nucleophiles. However, this problem could be circumvented by adding an 
anion-binding catalyst into the reaction. A quick screening revealed that several common anion-
binding catalysts81 showed enhancement effects, with both 4-41 and 4-42 giving more than 80% 
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yield. Literature precedent82 suggests that the enhanced reactivity was due to the increased Lewis 
acidity of Re2O7 or HReO4 by binding of the perrhenate anion to hydrogen bonding catalysts via 
adducts III, IV or V. This result is significant because it shows that thermodynamically 
disfavored isomers can be accessed by using this newly developed method, and that reductive 
and alkylative oxocarbenium ion quenching can provide complementary 2,6-stereochemical 
relationship in the products. 
 
OH
O
Re2O7, CH2Cl2
0 ºC, 20h
H-Cat
SiMe3
OH H
S OO NNAr Ar
H H
P
S
ArAr
H HH
Ar NN
Ar Ar
H H
S
4-34 4-40
HCat-1 HCat-2 HCat-3
(83%, dr = 1 : 0) (84%, dr = 1 : 0) (70%, dr = 1 : 0)
S OO NNAr Ar
H H
P
S
ArAr
H HH
Ar
ORe O
O
O ORe O
O
O
O
O
OReO
P
S
ArAr
H HH
Aror
4-41 4-42 4-43III IV V  
Scheme 4.5 Enhancement effect of hydrogen-bonding catalyst (Ar = 3,5-trifluoromethylphenyl) 
 
A limitation of this reaction emerges when a π nucleophile is incorporated into the 
substrate, as shown in Scheme 4.6 for the conversion 4-44 to 4-45 and 4-46. The intermediate 
oxocarbenium ion 4-47 exists in equilibrium with the enol ether 4-48. Intramolecular Michael 
addition of the enol ether into the enone is faster than the reduction by Et3SiH, thereby 
generating a second oxocarbenium ion 4-49, which exists in the form of a diastereomeric 
mixture. Subsequent reduction of 4-49 delivers a combined 91% yield of 4-45 and 4-46 in a 2:1 
ratio. This pathway is interesting because it suggests the possibility of developing a reaction that 
utilizes the trapping group first as an electrophile, and then as a nucleophile. 
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Scheme 4.6 Reaction in the presence of a π nucleophile 
4.2.3 Development of a reaction with diastereocontrol 
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Scheme 4.7 An analysis of competitive processes for relative diastereocontrol 
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After the establishment of the general substrate scope, attention was turned to the study of the 
impact of a pre-existing stereogenic center on the stereochemical outcome of the reaction.50, 53, 69 
Unlike examples shown in previous chapters, in which cyclization is reversible and a 
thermodynamically driven stereochemical editing is possible, the final step in this new sequence 
is irreversible and the stereochemical editing will need the cyclic ether to ionize at the allylic 
carbon. While this is possible for internal alkenes, it is less likely to happen for terminal alkenes. 
Success in stereoselective synthesis is, however, achievable if a proper balance between the rates 
of equilibration with the rates of oxocarbenium ion formation and trapping. As shown in Scheme 
4.7, stereoselective synthesis could be achieved if the equilibration between 4-50 and 4-54 is 
rapid, if the equilibrium between the hydroxyl carbonyl compound (4-50, 4-54) and the cyclic 
hemiacetal (4-51, 4-55) does not strongly favor the cyclic hemiacetal, if the ionization step is 
readily reversible (step c), and if the nucleophilic trapping step is slow (step d). In order to 
achieve high stereocontrol in this protocol, there should be sufficient energetic difference 
between the equilibrating lactols, so that one isomer is more thermodynamically favored over the 
other. 
Further studies were carried out to show the relationship between the allylic alcohol 
structure, trapping group, product substitution pattern, and termination agent on reaction 
disastereocontrol. As shown in table 4.1, substrate 4-58 was chosen to study the influence of 
each step in scheme 4.7 on the stereochemical outcome of the reaction. When subjecting 4-58 to 
the standard reaction conditions with Et3SiH as the termination agent, a combined 96% yield of 
4-59 and 4-60 was obtained, although the diastereoselectivity was only 3:1 (entry 1). Adding 
Et3SiH slowly over a period of 24 hours otherwise increased the diastereoselectivity to 6.5:1 
despite the concomitant decrease in the total yield (entry 2). This outcome is consistent with 
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ionization being reversible and slowed termination allowing greater opportunity for 
stereochemical equilibration. This result also led to the study of the relationship between the 
silane reactivity and stereoselectivity. Less reactive silanes such as benzyldimethylsilane (entry 
3) and triphenylsilane (entry 5) usually provided a greater degree of stereocontrol compared to 
more reactive silanes (entry 4, 6-7).83 A brief solvent screening also showed that chlorinated 
solvents such as dichloromethane and 1,2-dichloroethane gave the best diastereoselectivity. 
Table 4.1 Factors that influence the diastereoselectivity 
O
Ph
HO
O
Ph
H H O
Ph
H H
+
Solvent Time Yield dr
20 h 96% 3.0:1
24 h 59% 6.5:1
6 h 96% 6.2:1
6 h 94% 1.7:1
6 h 95% 9.1:1
6 h 95% 1.2:1
Entry
1
2a
3b
4b
5b
6b
7b 6 h 0 % N.A
CH2Cl2
Silane
Et3SiH
CH2Cl2 Et3SiH
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
Benzyldimethylsilane
Phenyldimethylsilane
Triphenylsilane
Ethoxydimethylsilane
Triethoxysilane
8b CH2Cl2 2-thiophenyldimethylsilane 6 h 93% 2.1:1
9b
10b
11b
12b
13b
Toluene Triphenylsilane 24 h 0% N.A
ClCH2CH2Cl Triphenylsilane 12 h 96% 9:1
Et2O Triphenylsilane 24 h 0% N.A
THF Triphenylsilane 24 h 0% N.A
CH3CN Triphenylsilane 12 h 88% 5.9:1
4-58 4-59 4-60
Reaction was conducted at room temperature with 2 equivalents of silane, 3 mol% Re2O7
unless otherwise mentioned: a) slow addition of silane over 24 hrs; b) reaction was 
performed at 5.0 mg scale with 5 mol% Re2O7, yield and dr were determined by taking the 
1H NMR of the crude with an internal standard (DMAP).
Re2O7, rt
Solvent
 
As shown in scheme 4.8 and 4.9, all tetrahydropyran-forming reactions provided a 2,6-
cis-stereochemical relationship, which is consistent with previous studies. Several trends become 
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apparent after analyzing these results. Substrates with secondary allylic alcohols show higher 
selectivity than similarly substituted primary alcohol substrates (equation 2 in Scheme 4.8). This 
difference is attributed to the higher rate of stereochemical equilibration via a cationic 
intermediate (step a in Scheme 4.7). The equilibrium of the cyclization step (step b in Scheme 
4.7) also influences the stereocontrol: aldehydes are more prone to exist in the lactol form than 
ketones, thus limiting the concentration of the stereochemically labile allylic alcohol, and leading 
to diminished level of 2,3-stereocontrol (equations 4, 5 vs equations 2, 3, Scheme 4.8)  
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Scheme 4.8 Stereocontrolled synthesis  
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Scheme 4.9 Stereocontrolled synthesis (continued) 
 
Substrates bearing a β-keto ester moiety showed increased diastereoselectivity compared 
to those containing simple ketone moieties (equations 6, 7 vs equations 1, 3). This is because the 
ionization step is slowed down, allowing longer time for stereochemical editing (step a and step 
b, scheme 4.7). Stereocontrol is enhanced for reactions that establish a 2,4-stereochemical 
relationship in the product (equations 3, 5, 7 versus equations 1, 4, 6). A significant steric 
interaction between an axially oriented substituent and the silane is present in the termination 
step, which leads to the minor product in these reactions. This steric interaction effectively slows 
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down the reduction, and allows for equilibration to the more reactive precursor, yielding the 
major product. Allytrimethylsilane can also add to tetrahydropyranyl oxocarbenium ion with 
good diastereocontrol (equation 8). 
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Scheme 4.10 Stereocontrol in tetrahydrofuran formation 
 
Lower levels of stereocontrol were observed in tetrahydrofuran formation compared to 
that in tetrahydropyran formation. However, interesting trends were observed after analyzing the 
data. For example, ketone 4-74 underwent reductive cyclization to give a combined 75% yield of 
three isomers in a 5:3:1 ratio, with isomer 4-75 being the major product. As shown in Scheme 
4.10, this reaction proceeds via the oxocarbenium ions 4-78 and 4-79, with the 2,3-trans-isomer 
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4-78 being the dominant intermediate, avoiding eclipsing interactions in the ionization step.84 
Approach of the silane shows modest selectivity for the concave face, opposite the methyl group, 
which is consistent with the model developed by Woerpel and coworkers.79c Allylative 
cyclization of aldehyde 4-76 also delivers a mixture of three isomers, with 4-77 being the major 
product and stereochemical complementarity being observed for the two major products. The 
stereochemical preference for 4-82 over 4-83 is diminished compared to the preference of 4-78 
over 4-79, as was observed in the tetrahydropyran series. However, the Woerpel selectivity in the 
termination step was higher in this process, probably due to the reduced reactivity of the 
nucleophile, thereby leading to a 58% yield of the major product. Resubjecting the product 
mixture to Re2O7 in refluxing CH2Cl2 lead to the increased selectivity for the formation of 4-77, 
with the ratio of 4-77:4-84:4-85 changing to 8.7:1:1.3 from 3:1:0.6. This increased selectivity 
results from the ionization of 4-84 to form an allylic cation intermediate, which undergoes 
stereochemical equilibration and subsequent ring closure to give the more stable 2,3-trans-
isomer. 
4.3 CONCLUSION 
A new sequence of allylic alcohol transposition, intramolecular trapping, ionization, and 
intermolecular termination was developed and applied successfully to heterocycle synthesis. This 
protocol renders the initial trapping group traceless, thereby greatly increasing the reaction 
substrate scope. In this new sequence, primary and secondary allylic alcohols can be used as 
substrates, ketones and aldehydes are suitable trapping groups, and silanes, π-nucleophiles, and 
alcohols serve as terminating agents in the formation of cyclic ethers. Reactivity can be mediated 
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by controlling the concentration of the intermediate oxocarbenium ion, and by using trapping 
agents of appropriate nucleophilicity. It was found that the substitution patterns of the allylic 
alcohol, the trapping group, and the nucleophile influence the rate of this process. Relative 
stereocontrol is achievable through rational tuning of each step in this sequence, and 
complementary stereoisomers can be accessed via reductive and alkylative terminations. High 
stereocontrol can be achieved when the rate of the termination is low, while the rates for all other 
steps are high for sufficient thermodynamic equilibration of the reaction intermediates. 
Successful coupling ring formation with equilibrating stereocenter generation provides a useful 
alternative to reagent-based method for stereocontrol in the synthesis of stereochemically rich 
cyclic or polycyclic structures. 
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APPENDIX A 
STEREOSELECTIVE HETEROCYCLE SYNTHESIS THROUGH A REVERSIBLE 
ALLYLIC ALCOHOL TRANSPOSITION AND NUCLEOPHILIC ADDITION 
SEQUENCE 
General Information 1H NMR and 13C NMR spectra were taken on a Bruker Avance 300 
spectrometer at 300 MHz and 75 MHz respectively, a Bruker Avance 400 spectrometer at 400 
MHz and 100 MHz, or a Bruker Avance 500 spectrometer at 500 MHz and 125 MHz, as 
specified. The chemical shifts are reported in parts per million (ppm) on the delta (δ) scale. The 
solvent peak was used as a reference value, for 1H NMR: CDCl3 = 7.27 ppm, CD2Cl2 = 5.31 
ppm,  C6D6 = 7.16 ppm, for 13C NMR: CDCl3 = 77.23, CDCl3 = 53.52, C6D6 = 128.37. Data are 
reported as follows: m = multiplet, s = singlet; d = doublet; t = triplet; q = quartet; p = pentet; dd 
= doublet of doublets; dt = doublet of triplets; br = broad. High resolution mass spectra were 
recorded on a Micromass UK Limited Q-Tof  Ultima API or a Fissions VG Autospec 
spectrometer.  Infrared (IR) spectra were taken on a Mattson Cygnus 100 spectrometer. Samples 
for IR were prepared as thin films on a NaCl plates by dissolving the corresponding compounds 
in CH2Cl2 followed by evaporation of the CH2Cl2. Methylene chloride was distilled under N2 
from CaH2. Analytical TLC was performed on E. Merck pre-coated (25 mm) silica gel 60F-254 
71 
plates. Visualization was done under UV (254 nm). Flash chromatography was done using ICN 
SiliTech 32-63 60 Å silica gel. Reagent grade ethyl acetate, diethyl ether, pentane and hexanes 
(commercial mixture) were purchased from EM Science and used as is for chromatography. All 
reactions were performed in oven or flame-dried glassware under a positive pressure of N2 with 
magnetic stirring unless otherwise noted.   
General procedure for the Re2O7-mediated cyclization To a solution of the substrate in freshly 
distilled CH2Cl2 (~0.05-0.10M) was added Re2O7 (Used as received, 0.05 equiv). The reaction 
mixture was stirred at rt (unless otherwise mentioned) until the starting was completely 
consumed as determined by TLC, then the reaction was quenched with a few drops of pyridine 
or triethylamine and the solvent was removed under vacuum The final products were isolated 
after purification by flash chromatography or preparative TLC.  
HPh
OH
O
HPh
OH
MeO OMe
OH a-d e
Reagents and conditions
a) DIBAL-H, THF, -78 ºC, then I2, 52%; b)IBX, DMSO, 84%; c) (MeO)3CH, PPTS, MeOH, 88%;
d) tBuLi, THF, -78 ºC, then PhCH2CH2CHO, 50%; e)HOAc, H2O, 100%.
Scheme A1 Synthesis of substrates 2-10 and 2-13 
(E)-6-hydroxy-8-phenyloct-4-enal (2-10) 
1H NMR (400 MHz, CD2Cl2) δ 9.73 (t, J = 1.2 Hz, 1H), 7.26-7.29 
(m, 2H), 7.15-7.21 (m, 3H), 5.65 (dtd, J = 0.4, 6.4, 15.6 Hz, 1H), 5.54 (tdd, J = 1.2, 6.4, 15.6 Hz, 
1H), 4.04 (app q, J = 5.6 Hz, 1H), 2.59-2.73 (m, 2H), 2.51 (t, J = 8.0 Hz, 2H), 2.35 (q, J = 4.8 
Hz, 2H), 1.70-1.87 (m, 2H); 13C NMR (100 MHz, CD2Cl2) δ 202.3, 142.6, 134.7, 129.8, 128.8, 
Ph
OH
H
O
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128.7, 126.1, 72.3, 43.5, 39.3, 32.1, 25.1; IR (neat) 3439, 3063, 3031, 2954, 2925, 2867, 1605, 
1496, 1453, 1375, 1179, 1121,1024 cm-1; HRMS (ESI) calcd for C14H18O2Na [M+Na]+ 241.1204, 
found 241.1211. 
 
5-(4-phenylbut-1-en-1-yl)tetrahydrofuran-2-ol (2-11) 
The general cyclization procedure was followed with 2-10 (50 mg, 
0.23 mmol), Re2O7 (5.5 mg, 0.011 mmol), and CH2Cl2 (3 mL). The reaction was stirred at rt for 
30 min and then was quenched with pyridine (25 mL). After evaporation of the solvent, the crude 
mixture was purified by flash chromatography (10-20% ethyl acetate in hexanes) to give the 
product (10 mg, 20%, dr = 1.2:1). 1H NMR (400 MHz, CD2Cl2) δ 7.24-7.28 (m, 2H), 7.14-7.19 
(m, 3H), 5.70 (app q, J = 6.4 Hz, 0.45H), 5.67 (app q, J = 6.4 Hz, 0.55H), 5.54 (dt, J = 1.2, 7.6 
Hz, 0.45H), 5.49-5.52 (m, 0.55H), 5.44 (dt, J = 1.2, 7.2, Hz 0.45H), 5.39-5.41 (m, 0.55H), 4.54 
(q, J = 6.8 Hz, 0.55H), 4.33 (q, J = 6.8, 0.45H),  2.65-2.72 (m, 2H), 2.57-2.63 (m, 1H), 2.30-2.43 
(m, 2H), 1.82-2.16 (m, 2.4H), 1.70-1.82 (m, 1H), 1.46-1.55 (m, 0.6H); 13C NMR (100 MHz, 
CD2Cl2) δ 141.9, 133.0, 131.6, 131.4, 131.0, 128.4, 128.2, 125.7, 98.5, 98.4, 81.4, 78.8, 35.5, 
34.2, 34.0, 33.8, 33.2, 30.4, 30.0; IR (neat) 3402, 3060, 3025, 2933, 2857, 1603, 1495, 1453, 
1191, 1018; HRMS (ESI) calcd for C14H18O2Na [M+Na]+ 241.1204, found 241.1228. 
 
(E)-8,8-dimethoxy-1-phenyloct-4-en-3-ol (2-13) 
1H NMR (400 MHz, CDCl3) δ 7.28-7.32 (m, 2H), 7.18-7.22 (m, 
3H), 5.68 (ddt, J = 0.4, 6.4 Hz, 15.2, 1H), 5.55 (ddt, J = 1.2, 6.8, 15.2 Hz, 1H), 4.40 (t, J = 5.6 
Hz, 1H), 4.09 (q, J = 5.7 Hz, 2H), 3.34 (s, 6H), 2.64-2.77 (m, 2H), 2.10-2.15 (q, J = 7.1 Hz, 2H), 
1.77-1.94 (m, 2H), 1.74 (br, 1H), 1.70-1.70 (m, 2H);  13C NMR (100 MHz, CDCl3) δ 142.0, 
Ph O
OH
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133.4, 131.2, 128.5, 128.4, 125.8, 103.9, 72.2, 52.76, 53.74, 38.8, 32.0, 31.8, 27.3; IR (neat) 
3426, 3060, 3025, 2941, 2857, 2831, 1669, 1602, 1495, 1452, 1385, 1190, 1127, 1058 969, 913, 
747 cm-1; HRMS (APCI) calcd for C16H24O3Na [M+Na]+ 287.1623, found 287.1632. 
2-methoxy-5-(4-phenylbut-1-en-1-yl)tetrahydrofuran (2-15) 
The general cyclization procedure was followed with 2-13 (50 mg, 
0.19 mmol), Re2O7 (4.6 mg, 0.010 mmol), DCM (3 mL), the reaction was stirred at rt for 30 min, 
then was quenched with pyridine (25 mL). After evaporation of the solvent, the crude mixture 
was purified by flash chromatography (1%-3%  ethyl acetate in hexanes) to give the product (36 
mg, 83%, dr = 3:2). 1H NMR (400 MHz, CDCl3) δ. 7.28-7.35 (m, 2H), 7.18-7.25 (m, 3H), 5.69-
5.84 (m, 1H), 5.43-5.65 (m, 1H), 5.08 (dd, J = 2.0, 5.2 Hz, 0.6H), 4.99 (d, J = 4.4 Hz, 0.4H), 
4.50 (q, J = 7.1 Hz, 0.6H), 4.45 (q, J = 7.7 Hz, 0.4H), 3.39 (s, 1.8H), 3.37 (s, 1.2H), 2.62-2.82 
(m, 2H), 2.26-2.53 (m, 2H), 1.70-2.20 (m, 3.4H), 1.50-1.62 (m, 0.6H); 13C NMR (100 MHz, 
CDCl3) δ 141.8, 132.8, 132.3, 131.8, 130.6, 128.5, 128.4,128.32, 128.30, 125.9, 125.8, 105.3, 
105.0, 81.5, 78.7, 54.9, 54.5, 35.53, 35.49, 34.1, 34.0, 33.5, 32.4, 30.3, 30.1; IR (neat) 3061, 
3026, 2984, 2928, 2828, 1684, 1603, 1495, 1453, 1363, 1203, 1098, 1034, 966, 746 cm-1; HRMS 
(ESI) calcd for C15H20O2Na [M+Na]+ 255.1361, found 255.1374. 
HO OMe
OMe a-d
HO
O
Reagents and conditions
a) HOAc, H2O. b) TBDPSCl, imidazole, DMAP, DMF. c) (EtO)2P(O)CH2C(O)CH3,
NaH, THF. d) HF•pyridine, THF.
Scheme A2 Synthesis of substrate 2-16 
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 (3E,8E)-10-hydroxydeca-3,8-dien-2-one (2-16) 
1H NMR (400 MHz, CH2Cl2) δ 6.77 (dt, J = 7.2, 16.0 Hz, 1H), 
6.03 (dt, J = 1.4, 16.0 Hz, 1H), 5.59-5.70 (m, 2H), 4.04 (d, J = 3.6 Hz, 2H), 2.22 (dt, J = 1.4, 7.2 
Hz, 2H), 2.19 (s, 3H), 2.03-2.11 (m, 2H), 1.56 (p, J = 7.6 Hz, 2H); 13C NMR (100 MHz, CH2Cl2) 
δ 198.3, 147.9, 131.7, 131.4, 130.1, 63.4, 31.8, 31.6, 27.6, 26.6; IR (neat) 3427, 3004, 2928, 
2857, 1672, 1625, 1431, 1362, 1431,1362, 1257, 1089, 972 cm-1; HRMS (ESI) calcd for 
C10H16O2Na [M+Na]+ 191.1048, found 191.1066. 
 
1-((2S,6R)-6-vinyltetrahydro-2H-pyran-2-yl)propan-2-one (2-18) 
The general rearrangement procedure was followed with 2-16 (14.2 mg, 
0.084 mmol), Re2O7 (2.1 mg, 0.004 mmol), and CD2Cl2 (1.5 mL). The reaction was stirred at 20 
°C for 10 min, after which the catalyst was removed by filtration through a small pad of Celite. 
1H NMR was taken directly to show a quantative conversion. 1H NMR (400 MHz, CD2Cl2) δ 
5.90 (ddd, J = 5.2, 10.4, 17.2 Hz, 1H), 5.16 (dt, J = 1.6, 17.2 Hz, 1H), 5.02 (dt, J = 1.6, 10.4 Hz, 
1H), 3.75-3.85 (m, 2H), 2.63 (dd, J = 7.6, 15.6 Hz, 1H), 2.42 (dd, J = 5.2, 15.6 Hz, 1H), 2.13 (s, 
3H), 1.79-1.87 (m, 1H), 1.51-1.65 (m, 3H), 1.13-1.29 (m, 2H); 13C NMR (100 MHz, CD2Cl2) 
207.1, 139.6, 113.7, 78.1, 74.1, 50.3, 31.19, 31.16, 30.6, 20.3; IR (neat) 2934, 2857, 1717, 1438, 
1358, 1199, 1089, 1045, 989, 916 cm-1; HRMS (EI) calcd for C10H15O2 [M–H]+ 167.1072, found 
167.1100. 
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TBDPS H
O
HO H
H
HO H
H O
O
N
a
b-c
d-e
a) TBDPSCl, imidazole, CH2Cl2, rt, 67%; b) ethyl 2-(diethoxyphosphoryl)acetate, NaH, THF, 0 ºC, 32%; c) 
HF•pyridine, pyridine, Et2O, rt, 81%, d) diethyl (cyanomethyl)phosphonate, NaH, THF, 0 ºC; e) HF•pyridine, 
pyridine, Et2O, RT, 28% for two steps.
Reagents and conditions:
 
Scheme A3 Synthesis of substrates 2-16 and 2-22 
 
 Ethyl (2E,7E)-9hydroxynona-2,7-dienoate (2-19) 
1H NMR (300 MHz, CD2Cl2) δ 6.92 (dt, J = 7.2, 15.6 Hz, 1H), 
5.79 (dt, J = 1.5, 15.6, 1H), 5.55-5.71 (m, 2H), 4.13 (q, J = 7.2 Hz, 2H), 4.02 (d, J = 3.6 Hz, 2H), 
2.20 (dq, J = 1.5, 7.2 Hz, 2H), 2.00-2.10 (m, 2H), 1.95 (br, 1H), 1.53 (p, J = 7.5 Hz, 2H), 1.24 (t, 
J = 7.2 Hz, 3H); 13C NMR (75 MHz, CD2Cl2) δ 166.5, 148.9, 131.6, 130.1, 121.4, 63.3, 60.1, 
31.54, 31.53, 27.5, 14.0; IR (neat) 3424, 2982, 2932, 28591718, 1652, 1443, 1368, 1269, 1188, 
1153, 1092, 1042, 972 cm-1. 
 
 (7E)-9-hydroxynona-2,7-dienenitrile (2-22) 
1H NMR (300 MHz, CD2Cl2) δ 6.71 (dt, J = 6.9, 16.2 Hz, 0.48H), 
6.48 (dt, J = 7.8, 10.8, 0.52H), 5.55-5.71 (m, 2H), 5.28-5.40 (m, 1H), 2.36-2.48 (m, 1H), 2.17-
2.27 (m, 1H), 2.00-2.16 (m, 2H), 1.67 (br, 1H), 1.47-1.63 (m, 2H); 13C NMR (75 MHz, CD2Cl2) 
δ 155.8, 154.9, 131.16, 131.11, 130.5, 130.3, 99.8, 99.7, 60.3, 60.2, 32.6, 31.3, 31.1, 27.5, 27.1; 
IR (neat) 3414, 2932, 2860, 2222, 1670, 1631, 1438, 1088, 999, 970, 740 cm-1. 
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nHO
a) BnOH, PTSA.H2O, Na2SO4, DCM, RT, 64% (n=1), 51% (n=2), 52% (n=3). b) Hoveyda-Grubbs 2nd,
Methyl Acrylate, DCM, reflux, 89% (n=1), 97% (n=2), 99% (n=3). c) DIBAL,DCM, -78 °C, 90% (n=1),
89% (n=2), 86% (n=3).
Reaction Conditions:
 
Scheme A4 Synthesis of substrates 2-25, 2-22, and 2-29 
 
 (E)-6,6-bis(benzyloxy)hex-2-en-1-ol (2-25) 
1H NMR (400 MHz, CDCl3) δ 7.34-7.45 (m, 10H), 5.62-5.76 (m, 
2H), 4.83 (t, J = 6.0 Hz, 1H), 4.74 (d, J = 12.0 Hz, 2H), 4.64 (d, J = 12.0 Hz, 2H), 4.07 (d, J = 
4.8 Hz, 2H), 2.40 (br, 1H), 2.24 (q, J = 7.0 Hz, 2H), 1.93 (q, J = 7.0 Hz, 2H); 13C NMR (100 
MHz, CDCl3) δ 138.3, 131.6, 129.8, 128.6, 127.9, 127.8, 101.6, 67.4, 63.4, 32.8, 27.6; IR (neat) 
3401, 3087, 3062, 3030, 2930-2868, 1670, 1605, 1496, 1453, 1385, 1353, 1208, 1124, 1023,737 
cm-1; HRMS (APCI) calcd for C20H24O3Na [M+Na]+ 355.1623, found 355.1608. 
 
2-(Benzyloxy)-5-vinyltetrahydrofuran (2-26) 
The general cyclization procedure was followed with 2-25 (100 mg, 0.32 
mmol), Re2O7 (7.8 mg, 0.016 mmol), and CH2Cl2 (5 mL). The reaction was stirred at rt for 30 
min and then was quenched with pyridine (25 mL). After evaporation of the solvent, the crude 
mixture was purified by flash chromatography (1%-3%  ethyl acetate in hexanes) to give the 
product (55 mg, 84%, dr = 3:2). 1H NMR (400 MHz, CDCl3) δ 7.28-7.40 (m, 5H), 5.95 (ddd, J = 
7.2, 10.0, 17.2 Hz, 0.4H), 5.90 (ddd, J = 6.8, 10.4, 17.2 Hz, 0.6H), 5.23-5.33 (m, 2H), 5.13-5.18 
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OBn
O
OBn
 77 
(m, 1H), 4.82 (d, J = 12.0 Hz, 0.4H), 4.81 (d, J = 12.0 Hz, 0.6H), 4.81 (q, J = 6.8 Hz, 0.6H), 
4.50-4.55 (m, 1.4H), 2.20-2.30 (m, 0.6H), 2.08-2.16 (m, 1.5H), 1.88-2.04 (m, 1.5H), 1.61-1.70 
(m,0.8H); 13C NMR (100 MHz, CDCl3) 140.5, 138.5, 138.34, 138.32, 128.4, 127.94, 127.88, 
127.5, 115.7, 115.6, 103.5, 103.2, 81.8, 78.9, 69.0, 68.6, 33.5, 32.1, 30.02, 30.0; IR (neat) 
3064,3030, 2924, 2853, 1605, 1455,1273, 1205, 1025, 733 cm-1; HRMS (APCI) calcd for 
C13H16O2Na [M+Na]+ 227.1048, found 227.1049. 
 
 (E)-7,7-bis(benzyloxy)hept-2-en-1-ol (2-27) 
1H NMR (300 MHz, CDCl3) 7.33-7.44 (m, 10H), 5.62-5.76 (m, 2H), 
4.83 (t, J = 6.0 Hz, 1H), 4.75 (d, J = 11.7 Hz, 2H), 4.65 (d, J = 11.7 Hz, 2H), 2.14 (q, J = 6.5 Hz, 
2H), 1.86 (q, J = 7.2 Hz, 2H), 1.95 (p, J = 7.6 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 138.4, 
132.1, 129.8, 128.6, 127.9, 127.8, 102.1, 67.3,63.4, 32.9, 32.1, 24.4; IR 3403, 3062, 3030, 2932, 
2865, 1669, 1605,1496, 1454,1384, 1351, 1208, 1124, 1023, 736 (neat) cm-1; HRMS (ESI) calcd 
for C21H26O3Na [M+Na]+ 349.1780, found 349.1754. 
 
2-(benzyloxy)-6-vinyltetrahydro-2H-pyran (2-28) 
The general rearrangement procedure was followed with 2-27 (100 mg, 
0.31 mmol), Re2O7 (7.4 mg, 0.015 mmol), and DCM (5 mL). The reaction was stirred at rt for 30 
min and then was quenched with pyridine (25 mL). After evaporation of the solvent, the crude 
mixture was purified by flash chromatography (1%-3%  ethyl acetate in hexanes) to give the 
product (55 mg, 81%, dr = 7:3). 1H NMR (400 MHz, CDCl3) δ 7.28-7.41 (m, 5H), 5.95 (ddd, J = 
5.2, 10.4, 17.2 Hz, 0.3H), 5.88 (ddd, J = 6.0, 10.8, 17.2 Hz, 0.7), 5.31 (dt, J = 1.6, 17.2 Hz, 
0.3H), 5.26 (dt, J = 1.6, 17.6 Hz, 0.7H), 5.14 (dt, J = 1.4, 10.8 Hz, 0.3H), 5.13 (dt, J = 1.4, 10.4 
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Hz, 0.7H), 5.00 (d, J = 1.6 Hz, 0.7H), 4.95 (d, J = 12.0 Hz, 0.3H), 4.76 (d J = 12.0 Hz, 0.7H), 
4.65 (d, J = 12.0 Hz, 0.3H), 4.55 (dd, J = 2.0, 9.2 Hz, 0.3H), 4.52 (d, J = 12.0 Hz, 0.7H), 
4.31(ddddd, J = 1.6, 1.6, 1.6, 5.6, 10.4 Hz, 0.7H), 3.93 (ddddd, J = 1.2, 1.6, 2.4, 5.2, 11.2 Hz, 
0.3H),  1.25-2.05 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 139.3, 138.6, 138.4, 138.1, 128.4, 
128.0, 127.8, 127.6, 127.5, 114.8, 114.6, 101.0, 96.7, 76.5, 69.8, 69.7, 68.5, 31.1, 31.0, 30.8, 
29.5, 22.0, 18.0; IR (neat) 3065, 3030, 2940, 2867, 1646, 1604, 1496, 1454, 1357, 1261, 1205, 
1121, 1023, 736 cm-1; HRMS (APCI) calcd for C14H18O2Na [M+Na]+ 241.1204, found 241.1184. 
 
 (E)-8,8-bis(benzyloxy)oct-2-en-1-ol (2-29) 
1H NMR (400 MHz, CDCl3) δ 7.34-7.46 (m, 10H), 5.64-5.76 (m, 
2H), 4.83 (t, J = 5.6 Hz, 1H), 4.74 (d, J = 12.0 Hz, 2H), 4.65 (d, J = 12.0 Hz, 2H), 4.09  (d, J = 
4.8 Hz, 2H), 2.64 (br, 1H), 2.12 (q, J = 6.1 Hz, 2H), 1.86 (q, J = 6.8 Hz, 2H), 1.41-1.58 (m, 4H); 
13C NMR (100 MHz, CDCl3) δ 138.4, 132.5, 129.5, 128.5, 127.9, 127.7, 102.2, 67.3, 63.4, 33.2, 
32.2, 29.0, 24.3; IR (neat) 3406, 3062, 3030, 2932, 2861, 1669, 1605, 1494, 1454, 1384, 1351, 
1205, 1125, 1022, 736  cm-1; HRMS (APCI) calcd for C22H28O3Na [M+Na]+ 363.1936, found 
363.1925. 
 
2-(Benzyloxy)-7-vinyloxepane (2-30)  
The general rearrangement procedure was followed with 2-29 (100 mg, 
0.29 mmol), Re2O7 (7.1 mg, 0.015 mmol), and CH2Cl2 (5 mL). The reaction was stirred at rt for 
30 min and then was quenched with pyridine (25 mL). After evaporation of the solvent, the crude 
mixture was purified by flash chromatography (1%-3%  ethyl acetate in hexanes) to give the 
product (55 mg, 81%, dr = 9:1).1H NMR (400 MHz, CDCl3) δ 7.28-7.40 (m, 5H), 5.94 (ddd, J = 
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5.2, 10.4, 17.2 Hz, 1H), 5.34 (dt, J = 1.6, 17.2 Hz, 1H), 5.14 (dt, J = 1.6, 10.4 Hz, 0.1H), 5.13 
(dt, J = 1.6, 10.4 Hz, 0.9H), 4.93 (dd, J = 5.6, 8.8 Hz, 0.9H), 4.88 (d, J = 12.0 Hz, 0.1H), 4.81 (d, 
J = 11.6 Hz, 0.9H), 4.70 (dd, J = 3.6, 7.6 Hz, 0.1H), 4.57 (d, J = 12.0 Hz, 0.1H), 4.52 (d, J = 11.6 
Hz, 0.9H), 4.45 (dd, J = 5.2, 9.6 Hz, 0.9H), 4.01-4.04 (m, 0.1H), 2.13-2.22 (m, 1H), 1.88-1.98 
(m, 1H), 1.65-1.87 (m, 3H), 1.36-1.60 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 140.3, 139.5, 
138.4, 138.1, 128.4, 128.1, 128.0, 127.5, 113.6, 103.3, 100.3, 77.8, 71.1, 69.2, 69.1, 36.5, 35.9, 
35.7, 35.4, 29.5, 24.7, 23.3, 22.5; IR (neat) 3064, 3030, 2931, 2856, 1645, 1605, 1496, 1452, 
1356, 1206, 1131, 1055, 1024, 735 cm-1; HRMS (APCI) calcd for C15H20O2Na [M+Na]+ 
255.1361, found 255.1359. 
 
HO Ph
MeO OMe
H
O
Ph
a-e
Reagents and conditions:
a) Pentenylmagnesium bromide, THF, 0 ºC, 89%; b) PCC, Celite, CH2Cl2, 96%; c) p-TsOH,
(MeO)3CH, MeOH, 50 ºC, 93%; d) Ethyl acrylate, Grubbs-Hoveyda metathesis catalyst 2nd
CH2Cl2, reflux; e) DIBAL-H, CH2Cl2, -78 ºC.  
Scheme A5 Synthesis of substrate 2-31 
 
 (E)-7,7-Dimethoxy-9-phenylnon-2-en-1-ol (2-31) 
1H NMR (400 MHz, C6D6) δ 7.04-7.18 (m, 5H), 5.47-5.57 
(m, 2H), 3.87 (br, 2H), 3.05 (s, 6H), 2.58-2.63 (m, 2H), 1.94 -2.01 (m, 2H), 1.89-1.93 (m, 2H), 
1.66-1.71 (m, 2H), 1.40 (p, J = 7.6 Hz, 2H); 13C NMR (100 MHz, C6D6) δ 142.1, 131.1, 130.3, 
128.4, 128.2, 125.8, 102.8, 63.1, 47.2, 34.7, 32.3, 32.2, 30.4, 23.5; IR (neat) 3400, 3025, 2949, 
2829, 1669, 1603, 1495, 1454, 1368, 1181, 1054, 971, 743 cm-1; HRMS (ESI) calcd for 
C17H26O3Na [M+Na]+ 301.1780, found 301.1811. 
MeO OMe
HO
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(±)-(2S, 6R)-2-methoxy-2-phenethyl-6-vinyltetrahydro-2H-pyran (2-32) 
The general rearrangement cyclization procedure was followed with 2-31 (11  
mg, 0.039 mmol), Re2O7 (2.0  mg, 0.004 mmol), and CD2Cl2 (1.0 mL). The reaction was stirred 
at 0 °C for 2 min, after which the cold bath was removed, and the reaction was stirred for another 
8 min and then was quenched with pyridine (25 mL). Me2(Bn)SiH (5 µl) was added as an 
internal standard and crude NMR was used to determine the yield of 85%. 1H NMR (400 MHz, 
C6D6) δ 7.12-7.19 (m, 2H), 7.04-7.11 (m, 3H), 5.88 (ddd, J = 5.6, 9.8, 17.2 Hz, 1H), 5.29 (dt, J = 
1.8, 17.2 Hz, 1H), 5.03 (dt, J = 1.6, 17.2 Hz, 1H), 4.08 (ddddd, J = 1.2, 1.6, 2.4, 5.2, 11.6 Hz, 
1H), 3.07 (s, 3H), 2.53-2.69 (m, 2H), 1.99-2.09 (m, 1H), 1.81-1.98 (m, 2H), 1.72 (dddd, J = 1.6, 
1.6, 1.6, 12.8 Hz, 1H) 1.36-1.51 (m, 2H), 1.19-1.30 (m, 2H); 13C NMR (100 MHz, C6D6) δ 
142.3, 139.8, 128.4, 128.3, 125.7, 113.3, 99.1, 70.7, 46.7, 38.4, 32.2, 31.0, 30.0 18.9; IR (neat) 
3063, 3026, 2941, 2867, 1646, 1603, 1496, 1454, 1367, 1273, 1216, 1104, 1024, 924, 755, 738 
cm-1; HRMS (ESI) calcd for C16H22O2Na [M+Na]+ 269.1517, found 269.1548. 
 
I OH a-b I OBn
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Ph
OH
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H
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Ph
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f OBn
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O
O
g OBn
OBn
HO
a) IBX, DMSO, DCM. b) BnOH, PTSA.H2O, Na2SO4, DCM, rt, 27% for 2 steps. c) Propionic Anhydride,
Et3N, DCM,  0 °C, 73%. d) nBuLi, iPr2NH, BH3.NH3, THF. e) IBX, DMSO, rt, 73% for 2 steps. f) NaH in
Mineral Oil,Triethyl phosphonoacetate,THF,  0 °C, 99%. g) DIBAL, DCM, -78 °C, 92%.
Reaction Conditions:
 
Scheme A6 Synthesis of substrate 2-33 
OH OMe
 81 
 (S,E)-7,7-Bis(benzyloxy)-4-methylhept-2-en-1-ol (2-33) 
1H NMR (300 MHz, CDCl3) δ 7.31-7.45 (m, 10H),  5.53-5.66 (m, 
2H), 4.79 (t, J = 5.7 Hz, 1H), 4.73 (d, J = 11.7 Hz, 2H), 4.63 (d, J = 11.7 Hz, 2H), 4.10 (d, J = 
4.2 Hz, 2H), 2.19 (heptet, J = 6.6 Hz, 1H), 1.94 (br, 1H), 1.74-1.88 (m, 2H), 1.40-1.54 (m, 2H), 
1.06 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 138.3, 138.1, 128.5, 127.9, 127.7, 102.3, 
67.28, 67.26, 67.23, 63.6, 36.3, 31.7, 31.2, 20.5; IR (neat) 3403, 3063, 3030, 2926, 2867, 1667, 
1605, 1493, 1454, 1380, 1349, 1208, 1122, 1022, 736 cm-1; HRMS (ESI) calcd for C22H28O3Na 
[M+Na]+ 363.1936, found 363.1973. 
 
(2S,3S,6S)-6-(Benzyloxy)-3-methyl-2-vinyltetrahydro-2H-pyran (2-34) 
The general rearrangement procedure was followed with 2-33 (50 mg, 
0.16 mmol), Re2O7 (2 mg, 0.004 mmol), and CH2Cl2 (5 mL). The reaction was stirred at rt for 20 
min and then was quenched with pyridine (25 mL). After evaporation of the solvent, the crude 
mixture was purified by flash chromatography (1%-3%  ethyl acetate in hexanes) to give the 
product (33 mg, 100%, dr = 3:3:1:1). 1H NMR (400 MHz, C6D6) δ 7.29-7.34 (m, 2H), 7.16-7.20 
(m,2H), 7.07-7.12 (m, 1H), 5.74 (ddd, J = 4.8, 10.8, 17.2 Hz, 1H), 5.39 (dt, J = 2.0, 17.2 Hz, 
1H), 5.10 (dt, J = 2.0, 10.8 Hz, 2H), 4.85 (d, J = 3.2 Hz, 1H), 4.70 (d, J = 12.0 Hz, 1H), 
4.51(dddd, J = 0.5, 1.4, 1.6, 2.4 Hz, 1H), 4.37 (d, J = 12.0 Hz, 1H), 2.13 (dddd, J = 4.6, 4.6, 13.6, 
13.6 Hz, 1H), 1.68 (dddd, J = 4.4, 4.4, 14.0, 14.0 Hz, 1H), 1.54 (m, 1H), 1.45 (dddd, J = 1.2, 2.8, 
4.4, 14.0 Hz, 1H ), 1.21 (dddd, J = 2.4, 2.8, 5.2, 13.6 Hz, 1H), 0.93 (d, J = 7.2 Hz, 3H); 13C NMR 
(100 MHz, C6D6) δ 138.7,138.4, 128.2, 127.8, 127.3, 113.6, 96.4, 70.8, 68.3, 31.3, 25.3, 24.2, 
11.4; IR (neat) 3065, 3030, 2938, 2892, 1645, 1606, 1453, 1351, 1211, 1126, 1019, 729 cm-1; 
HRMS (APCI) calcd for C15H20O2Na [M+Na]+ 255.1361, found 255.1372. 
OH
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(2R, 3S, 6S)-6-(Benzyloxy)-3-methyl-2-vinyltetrahydro-2H-
pyran and (2S, 3S, 6R)-6-(benzyloxy)-3-methyl-2-
vinyltetrahydro-2H-pyran 
1H NMR (400 MHz, C6D6) δ 7.28-7.36 (m, 2H), 7.13-7.19 (m, 2H), 7.05-7.11 (m, 1H), 5.87 
(ddd, J = 6.8, 10.4, 17.2 Hz, 0.75H), 5.81 (ddd, J = 5.2, 10.8, 17.2 Hz, 0.25H), 5.35 (dt, J = 2, 
17.2 Hz, 0.25H), 5.27 (ddd J = 0.8, 2.0, 17.2 Hz, 0.75H), 5.06-5.11 (m, 1H), 4.96 (d, J = 12.0 
Hz, 0.25H), 4.89 (d, J = 3.2 Hz, 0.75H), 4.73 (d, J = 12.0 Hz, 0.75H), 4.53 (d, J = 12.0 Hz, 
0.25H), 4.41 (dd, J = 2.8, 8.4 Hz, 0.25H), 4.40 (d, J = 12.0 Hz, 0.75H), 3.91 (dd, J = 7.2, 9.6 Hz, 
0.75H), 3.84 (dddd, J = 1.6, 1.6, 3.8, 5.8 Hz, 0.25H), 1.45-1.85 (m, 3H), 1.25-1.45 (m, 2H), 0.87 
(d, J = 6.4 Hz, 0.75H), 0.71 (d, J = 6.4 Hz, 2.25H); 13C NMR (100 MHz, C6D6) δ 138.8, 138.7, 
138.2, 137.7, 128.21, 128.17, 127.8, 127.3, 116.0, 114.3, 100.9, 95.9, 69.3, 68.2, 35.1, 31.4, 30.2, 
28.3, 26.8, 26.7, 17.7, 12.5; IR (neat) 3066, 3030, 2930, 2876, 1645, 1604, 1455, 1376, 1232, 
1123, 1023, 923, 730 cm-1; HRMS (APCI) calcd for C15H20O2Na [M+Na]+ 255.1361, found 
255.1377. 
 
 (2R, 3S, 6R)-6-(Benzyloxy)-3-methyl-2-vinyltetrahydro-2H-pyran 
1H NMR (400 MHz, C6D6) δ 7.33-7.37 (m, 2H), 7.13-7.20 (m, 2H), 7.06-
7.12 (m, 2H), 5.89 (ddd, J = 6.8, 10.4, 17.2 Hz, 1H), 5.29 (ddd, J = 1.2, 2.0, 17.2 Hz, 1H), 5.09 
(ddd, J = 0.8, 2.0, 10.4 Hz, 1H), 4.98 (d, J = 12.0 Hz, 1H), 4.57 (d, J = 12.0 Hz, 1H), 4.37 (dd, J 
= 2.8, 8.8 Hz, 1H), 3.25 (dd, J = 2.8，10.0 Hz, 1H), 1.60-1.75 (m, 2H), 1.41-1.48 (dt, J = 3.6, 
13.6 Hz, 2H), 1.15-1.28 (m, 2H), 0.80-0.91 (m, 2H), 0.61 (d, J = 6.4 Hz, 3H); 13C NMR (100 
MHz, C6D6) δ 138.8, 137.6, 128.2, 127.8, 127.3, 115.8, 100.7, 82.7, 69.5, 34.7, 31.7, 31.1, 16.8; 
O OBn
+
O OBn
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IR (neat) 3065, 3029, 2952, 2929, 2873, 2853, 1645, 1606, 1496, 1362, 1146, 1055,  1091, 920, 
736 cm-1; HRMS (APCI) calcd for C15H20O2Na [M+Na]+ 255.1361, found 255.1342. 
 
OBn
OBn
O
H
OBn
OBnO
OBn
OBnOH
a b
a) 60 % NaH in Mineral Oil, Diethyl (2-Oxopropyl) Phosphonate, THF, 83%. b) (R) or (S)-CBS, BH3, THF,
-25 °C, 80%. (Either (R) or (S)-CBS give a dr of  2:1, however this mixture, even with different major isomer,
gave same cyclization product)
Reaction Conditions:
 
Scheme A7 Synthesis of substrate 2-35 
 
 (5S,E)-8,8-Bis(benzyloxy)-5-methyloct-3-en-2-ol (2-35) 
1H NMR (400 MHz, CDCl3) δ 7.29-7.44 (m, 10H), 5.44-5.56 (m, 2H), 4.76 
(t, J = 5.6 Hz, 1H), 4.69 (d, J = 12.0 Hz, 2H), 4.59 (d, J = 12.0 Hz, 2H), 4.26 (p, J = 5.6 Hz, 1H), 
2.07-2.18 (m, 1H), 1.72-1.82 (m, 2H), 1.65 (br, 1H) 1.37-11.49 (m, 2H), 1.27 (d, J = 6.4 Hz, 
3H), 1.02 (d, J = 6.8 Hz, 1H) 1.01 (d, J =6.8 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 138.3, 
136.1, 136.0, 133.08, 133.04, 128.5, 127.8, 127.7, 102.27, 102.25, 68.9, 68.8, 67.24, 67.15, 67. 
13, 36.2, 36.1, 31.7, 31.6, 31.1, 23.6, 23.5, 20.6, 20.5 IR (neat) 3417, 3063, 3030, 2958, 2869, 
1666, 1605, 1496, 1453, 1369, 1207, 1124, 1023, 972, 736 cm-1; HRMS (ESI) calcd for 
C23H30O3Na [M+Na]+ 377.2093, found 377.2063. 
 
(2S, 3S, 6S)-6-(Benzyloxy)-3-methyl-2-((E)-prop-1-en-1-yl)tetrahydro-2H-
pyran (2-36) 
The general cyclization procedure was followed with 2-35 (50 mg, 0.14 mmol), Re2O7 (3 mg, 
0.007 mmol), and CH2Cl2 (3 mL). The reaction was stirred at rt for 30 min and then was 
OH
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quenched with pyridine (25 mL). After evaporation of the solvent, the crude mixture was 
purified by flash chromatography (1%-3%  ethyl acetate in hexanes) to give the product (30 mg, 
86%, dr = 3:1, trans: cis > 10:1 as determined by the 1H NMR spectrum of the crude mixture). 
1H NMR (400 MHz, CD2Cl2) δ7.24-7.36 (m, 5H), 6.66 (dq, J = 6.4, 15.2 Hz, 1H), 5.39 (ddq, J = 
1.6, 8, 15.2 Hz, 1H), 4.88 (dd, J = 2.0, 2.4 Hz, 1H), 4.67 (d, J = 12.0 Hz, 1H), 4.42 (d, J = 12.0 
Hz, 1H), 3.74 (dd, J = 8.8, 9.2 Hz, 1H) 1.66-1.75 (m, 2H), 1.70 (dd, J = 1.6, 6.4 Hz, 3H), 1.48-
1.58 (m, 2H), 1.35-1.47 (m, 1H), 0.77 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CD2Cl2) δ 
138.8, 131.2, 128.8, 128.2, 127.8, 127.3, 96.4, 76.4, 68.3, 35.0, 30.2, 26.7, 17.8, 17.5. IR (neat) 
3063, 3030, 2929, 2876, 1676, 1604, 1454, 1376, 1230, 1049, 1022, 972, 920, 730 cm-1; HRMS 
(ESI) calcd for C16H22O2Na [M+Na]+ 269.1517, found 269.1558 . 
 
(2S, 3S, 6R)-6-(Benzyloxy)-3-methyl-2-((E)-prop-1-en-1-yl)tetrahydro-2H  
1H NMR (400 MHz, C6D6) δ 7.35-7.38 (m, 2H), 7.14-7.19 (m, 2H), 7.05-7.11 
(m, 1H), 5.67 (ddq, J = 0.8, 6.0, 15.2 Hz, 1H), 5.58 (ddq, J = 1.6, 6.8, 15.2 Hz, 1H), 5.01 (d, J 
=12.0 Hz, 1H), 4.59 (d, J = 12.0 Hz, 1H), 4.40 (dd, J = 2.8, 8.8 Hz, 1H), 3.28 (dd, J = 6.8, 9.6 
Hz, 1H), 1.63-1.79 (m, 2H), 1.59 (d, J = 6.4 Hz, 3H), 1.49 (dq, J = 3.6, 13.2 Hz, 1H), 1.19-1.33 
(m, 1H), 0.83-0.95 (m, 1H), 0.65 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, C6D6) δ 138.8, 131.3, 
128.2, 127.8, 127.4, 127.2, 100.7, 82.6, 69.4, 34.9, 31.8, 31.2, 17.5, 17.1; IR (neat) 3030, 2950, 
2929, 2853, 1676, 1606, 1454, 1365, 1146, 1102, 1078, 1031, 966, 735 cm-1; HRMS (ESI) calcd 
for C16H22O2Na [M+Na]+ 269.1517, found 269.1529. 
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OO OO
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a b-c
d e
a) Hydrocinnamaldehyde, THF, 0 °C, 68%. b) PCC, Celite, DCM, rt, 81%. c) PTSA.H2O, CH(OMe)3, MeOH, 
50 °C, 92%. d) 2-Vinyloxirane, Hoveyda-Grubbs 2nd, DCM, reflux, 25%. e) 6 equiv MeCuCNLi, THF, -78 °C to rt, 60 %.
Reaction Conditions:
O
 
Scheme A8 Synthesis of substrate 2-37 
 
 (E)-7,7-dimethoxy-4-methyl-9-phenylnon-2-en-1-ol (2-37) 
1H NMR (500 MHz, C6D6) δ 7.05-7.21 (m, 5H), 5.48 (dt, J = 
5.5, 15.5, 1H), 5.42 (ddt, J = 1.0, 7.5, 15.5 Hz, 1H), 3.86 (br, 2H), 3.07 (s, 3H), 3.06 (s, 3H), 
2.62-2.66 (m, 2H), 1.95-2.04 (m, 3H), 1.65-1.80 (m, 2H), 1.34 (q, J = 7.0 , 2H), 0.95 (d, J = 7.0 
Hz, 3H); 13C NMR (125 MHz, C6D6) δ 142.1, 136.8, 128.6, 128.4, 128.3, 125.8, 102.9, 63.1, 
47.2, 36.7, 34.6, 30.9, 30.4, 30.3, 20.4; IR (neat) 3403, 3025, 2955, 2869, 1667, 1603, 1454, 
1374, 1299,1185, 1058, 972, 741 cm-1; HRMS (APCI) calcd for C18H29O3 [M+H]+ 293.2117, 
found 293.2088. 
 
(±)-(2S, 5R, 6S)-2-Methoxy-5-methyl-2-phenethyl-6-vinyltetrahydro-2H-
pyran (2-38) 
The general rearrangement procedure was followed with 2-37 (50 mg, 0.17 mmol), Re2O7 (4  mg, 
0.008 mmol), and CD2Cl2 (3.0 mL). The reaction was stirred at 0 °C for 30 min, after which the 
cold bath was removed, the reaction was stirred for another 10 min, then was quenced with 
pyridine (25 mL). BnMe2SiH (5 µl) was added as an internal standard, and a 1H NMR spectrum 
was taken of the crude mixture to determine the yield (81%, dr = 10:1). 1H NMR (500 MHz, 
HO
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CD2Cl2) δ 7.24-7.29 (m, 2H), 7.14-7.22 (m, 2H), 5.78 (ddd, J = 7.5, 10.0, 17.5 Hz, 1H), 5.23 (dd, 
J = 17.5, 2.0 Hz, 1H), 5.14 (dd, J = 10.0,  17.5 Hz, 1H), 3.60 (dd, J = 7.5, 10.0 Hz, 1H), 2.61 (m, 
2H), 1.97 (ddd, J = 5.0, 12.0, 14.0 Hz, 2H), 1.81-1.85 (m, 1H), 1.76 (ddd, J = 4.5, 12.5, 14.0 Hz, 
2H), 1.50-1.62 (m, 3H), 1.31-1.38 (m, 1H), 0.82 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, 
CD2Cl2) 142.4, 138.1,128.3, 128.2, 125.7, 116.5, 98.8, 78.1, 47.1, 38.0, 34.5, 32.9, 29.8, 27.6, 
17.5; IR 3063, 3026, 2953, 2875, 1645, 1605, 1496, 1455, 1368, 1236, 1079, 1041, 932, 740 
(neat) cm-1; HRMS (ESI) calcd for C17H24O2Na [M+Na]+ 283.1674, found 283.1700. 
 
OBn
OBn
O
H
OBn
OBn
H
OH
a-d
Reagents and conditions:
a) Diethyl phosphonopropionate, NaH, THF, 0 ºC, 65%; b) DIBAL-H, CH2Cl2, -78 ºC, 95%;
c) IBX, DMSO, 100%; d) MeMgBr, THF, 0 ºC, 100%, dr = 2.2 :1.  
Scheme A9 Synthesis of substrate 2-39 
 
(5S, Z)-8,8-Bis(benzyloxy)-3,5-dimethyloct-3-en-2-ol (2-39) 
Major isomer: 1H NMR (400 MHz, C6D6) δ 7.31-7.36 (m, 2H), 7.16-
7.21 (m, 2H), 7.09-7.12 (m, 1H), 4.83 (d, J = 10.0 Hz, 1H), 4.71 (t, J = 5.6 Hz, 1H), 4.61 (dd, J = 
4.8, 12.0 Hz, 2 H), 4.52-4.58 (m, 1H), 4.49 (d, J = 12.0 Hz, 2H), 2.27-2.39 (m, 1H), 1.70-1.87 
(m, 2H), 1.70 (d, J = 0.8 Hz, 3H), 1.38-1.46 (m, 1H), 1.22-1.34 (m, 1H), 1.13 (dd, J = 2.8, 6.4 
Hz, 3H), 0.84 (d, J =6.4 Hz, 3H); 13C NMR (100 MHz, CD2Cl2) δ 138.62, 138.58, 137.2, 132.5, 
128.3, 127.8, 127.9,127.50, 127.49, 102.55, 67.4, 67.2, 65.6, 32.5, 31.4, 31.3, 21.52, 21.49, 16.8; 
IR (neat) 3439, 3063, 3030, 2954, 2867, 1605, 1496, 1453, 1375, 1121, 1024, 736 cm-1; HRMS 
(ESI) calcd for C24H32O3Na [M+Na]+ 391.2249, found 391.2263. Minor isomer: 1H NMR (400 
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MHz, C6D6) δ 7.29-7.35 (m, 2H), 7.14-7.21 (m, 2H), 7.07-7.13 (m, 1H), 4.85 (d, J = 9.6 Hz, 1H), 
4.68 (t, J = 5.6 Hz, 1H), 4.60 (dd, J = 3.6, 12.0 Hz, 2H), 5.53-4.60 (br, 1H), 4.47 (d, J = 12.0 Hz, 
2H), 2.25-2.40 (m, 1H), 1.60-1.80 (m, 2H), 1.70 (s, 3H), 1.35-1.45 (m, 1H), 1.23-1.34 (m, 1H), 
1.50 (dd, J = 1.2, 6.4 Hz, 3H), 0.60 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, C6D6) δ 138.8, 
137.4, 132.2, 128.3, 127.6, 127.4, 102.1, 66.9, 66.8, 65.4, 32.6, 31.5, 31.4, 21.6, 21.5, 17.1; IR 
(neat) 3415, 3063, 3030, 2920, 1605, 1496, 1453, 1376, 1119, 1024, 898, 735 cm-1; HRMS 
(APCI) calcd for C24H32O3Na [M+Na]+ 391.2249, found 391.2242. 
 
(2S, 3S, 6S)-6-(Benzyloxy)-2-((E)-but-2-en-2-yl)-3-methyltetrahydro-2H-
pyran (2-40) 
The general cyclization procedure was followed with 2-39 (50 mg, 0.14 mmol), Re2O7 (3 mg, 
0.007 mmol), and CH2Cl2 (1.5 mL), the reaction was stirred at rt for 30 min and then was 
quenched with pyridine (25 mL). After evaporation of the solvent, the crude mixture was 
purified by flash chromatography (1%-3%  ethyl acetate in hexanes) to give the product (32 mg, 
91%, dr = 3:1). 1H NMR (400 MHz, C6D6) δ 7.34-7.37 (m, 2H), 7.14-7.20 (m, 2H), 7.06-7.11 
(m, 1H), 5.44 (qq, J = 1.2, 6.8 Hz, 1H), 4.92 (d, J = 3.2 Hz, 1H), 4.79 (d, J = 12.4 Hz, 1H), 4.43 
(d, J = 12.4 Hz, 1H), 3.92 (d, J = 10.4 Hz, 1H), 1.66-1.78 (m, 2H), 1.71 (d, J = 1.2 Hz, 3H), 
1.52-1.63 (m, 2H), 1.53 (dq, J = 1.2, 6.4 Hz, 3H), 1.39-1.46 (m, 1H), 0.68 (d, J = 6.4 Hz, 3H); 
13C NMR (100 MHz, C6D6) δ 139.0, 135.2, 128.2, 127.6, 127.2, 122.8, 96.1, 91.8, 68.1, 32.1, 
20.4,27.0, 17.8, 12.7, 10.8; IR (neat) 3030, 2950, 2927, 2888, 1671, 1604, 1485, 1376, 1231, 
1123, 1020, 920, 727 cm-1; HRMS (APCI) calcd for C17H24O2Na [M+Na]+ 283.1674, found 
283.1665. 
 
O OBn
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(2S, 3S, 6R)-6-(Benzyloxy)-2-((E)-but-2-en-2-yl)-3-methyltetrahydro-2H-
pyran 
1H NMR (400 MHz, C6D6) δ 7.32-7.37 (m, 2H), 7.13-7.19 (m, 2H), 7.05-7.10 (m, 1H), 5.42 (q, J 
= 6.4 Hz, 1H), 4.97 (d, J = 12.o Hz, 1H), 4.57 (d, J = 12.0 Hz, 1H), 4.20 (dd, J = 2.4, 9.2 Hz, 
1H), 1.62-1.79 (m, 2H), 1,72 (s, 3H), 1.53 (d, J = 6.8 Hz, 3H), 1.48-1.56 (m, 1H), 1.37-1.48 (m, 
1H), 0.85-0.97 (m, 1H), 0.58 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, C6D6) δ 138.9, 135.2, 
128.1, 127.8, 127.2, 122.4, 101.0, 88.5, 69.4, 31.9, 31.7, 31.2, 17.0, 12.7, 12.7, 11.1; IR (neat) 
3063, 3029, 2950, 2926 2854, 1672, 1607, 1454, 1375, 1308, 1148, 1056, 1021, 734 cm-1; 
HRMS (APCI) calcd for C17H24O2Na [M+Na]+ 283.1674, found 283.1685. 
 
HO
O
a-f
Reagents and conditions:
a) O3, CH2Cl2, -78 ºC, then Me2S, 33%; b) (MeO)3CH,  p-TsOH, MeOH, 50 ºC, 52%;
c) Methyl acrylate, Grubbs-Hoveyda second generation metathesis catalyst, CH2Cl2;
reflux, 85%; d) DIBAL-H, CH2Cl2, -78ºC, 58%; e) HOAc, H2O, 95%; f) NaH, THF, 0 ºC
 (EtO)2P(O)CH2C(O)CH3, 58%.  
Scheme A10 Synthesis of substrate 2-41 
 
 (7S,3E,8E)-10-hydroxy-7-methyldeca-3,8-dien-2-one (2-41) 
1H NMR (300 MHz, CD2Cl2) δ 6.77 (dt, J = 6.9, 15.9 Hz, 1H), 
6.01 (dt, J = 1.5, 15.9 Hz, 1H), 5.45-5.64 (m, 2H), 4.03 (d, J = 5.1 Hz, 2H), 2.08-2.26 (m, 4H), 
2.18 (s, 3H), 1.39-1.49 (m, 2H), 0.99 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CD2Cl2) δ 198.6, 
148.5, 137.1, 131.2, 128.5, 63.2, 36.0, 35.0, 30.2, 26.6, 20.2; IR (neat) 3426, 2957, 2924, 2868, 
O OBn
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1672, 1625, 1427, 1363, 1256, 975 (neat) cm-1; HRMS (ESI) calcd for C11H18O2Na [M+Na]+ 
205.1204, found 205.1235. 
 
1-((2R,5S,6R)-5-methyl-6-vinyltetrahydro-2H-pyran-2-yl)propan-2-one (2-
42) 
The general rearrangement procedure was followed with 2-41 (26.5 mg, 0.145 mmol), Re2O7 
(3.5 mg, 0.007 mmol), and CH2Cl2 (1.5 mL). The reaction was stirred at rt for 24hr and then 
quenched with pyridine (25 mL). Me2(Bn)SiH (5 µl) was added as an internal standard and crude 
NMR was used to determine the yield of 88%. 1H NMR (400 MHz, CH2Cl2) δ 5.75 (ddd, J = 6.8, 
10.4 Hz, 17.2, 1H), 5.18 (ddd, J = 1.2, 2.0, 17.2 Hz, 1H), 5.11 (ddd, J = 0.8, 2.0, 10.4 Hz, 1H) 
3.71-3.78 (m, 1H) 3.36 (dd, J = 7.2, 8.8 Hz, 1H), 2.62 (dd, J = 7.6, 15.6 Hz, 1H), 2.42 (dd, J = 
5.2, 15.6 Hz, 1H), 2.12 (s, 3H), 1.77-1.82 (m, 1H), 1.60-1.65 (m, 1H), 1.17-1.36 (m, 3H), 0.78 
(d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CH2Cl2) δ 207.0, 137.9, 116.2, 85.1, 73.7, 50.2, 34.9, 
32.3, 31.8, 30.5, 17.4; IR (neat) 3079, 2927, 2873, 2851,1716, 1457, 1425, 1356, 1225, 1152, 
1072, 1018, 991, 923 cm-1; HRMS (ESI) calcd for C11H18O2Na [M+Na]+ 205.1204, found 
205.1224. 
 
OOH
OMe
OMe
a-d
Reagents and conditions:
a) Methyl vinyl ketone, Grubbs-hoveyda second generation metathesis catalyst, CH2Cl2,
reflux, 85%; b) DIBAL-H, CH2Cl2, -78 ºC, 45%, two steps; c) HOAc, H2O, 82%, d) NaH,
THF, (EtO)2P(O)CH2C(O)CH3, 85%.  
Scheme A11 Synthesis of substrate 2-43 
 
O
O
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 (3E,7S,8E)-10-hydroxy-7-methylundeca-3,8-dien-2-one (2-43) 
1H NMR (300 MHz, CD2Cl2) δ 6.76 (dt, J = 6.9, 15.9 Hz, 1H), 6.03 
(dd, J = 1.2, 15.9 Hz, 1H), 5.38-5.52 (m, 2H), 4.26 (q, J = 6.0 Hz, 2H), 2.21 (s, 3H), 2.04-2.21 
(m, 3H), 1.38-1.47 (m, 2H), 1.23 (d, J = 6.3 Hz, 3H), 0.98 (d, J = 6.6 Hz, 1.5H), 0.97 (d, J = 6.6 
Hz, 1.5H); 13C NMR (75 MHz, CD2Cl2) δ 198.8, 148.47, 148.42, 135.4, 135.3, 133.5, 131.2, 
68.7, 68.6, 35.89, 35.87, 35.0, 30.2, 26.9, 23.6, 23.56, 20.4; IR (neat) 3431, 2966, 2925, 2870, 
1672, 1625, 1453, 1364, 1255, 1140, 1059, 975 cm-1; HRMS (ESI) calcd for C12H20O2Na 
[M+Na]+ 219.1361, found 219.1392. 
 
1-((2R,5S,6S)-5-methyl-6-((E)-prop-1-en-1-yl)tetrahydro-2H-pyran-2-yl) 
propan-2-one (2-44) 
The general rearrangement procedure was followed with 2-43 (20.0 mg, 0.102 mmol), Re2O7 
(2.5 mg, 0.005 mmol), and CH2Cl2 (1.5 mL). The reaction was stirred at rt for 50 min and then 
was quenched with pyridine (25 mL). Me2(Bn)SiH (5 µl) was added as an internal standard. 
Crude 1H NMR was used to determine the yield of 90%. 1H NMR (400 MHz, CH2Cl2) δ 5.68 
(ddq, J = 0.8, 6.4, 15.2 Hz, 1H), 5.40 (ddq, J = 1.6, 7.6, 15.2 Hz, 1H), 3.77 (dddd, J = 2.4, 2.4, 
6.4, 10.8 Hz, 1H) 3.35 (dd, J = 8.4, 8.8 Hz, 1H), 2.74 (dd, J = 6.4, 15.6 Hz, 1H), 2.47 (dd, J = 
6.0, 15.6 Hz, 1H), 2.17 (s, 3H), 1.78-1.84 (m, 1H), 1.70 (dd, J = 1.6, 6.4 Hz, 3H), 1.64-1.69 (m, 
1H), 1.20-1.37 (m, 3H), 0.78 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CH2Cl2) δ 207.5, 130.9, 
129.0, 85.1, 73.6, 50.3, 35.0, 32.3, 31.9, 31.0, 17.9, 17.8; IR (neat) 2925, 2872, 2852, 1716, 
1676, 1453, 1357, 1224, 1186, 1169, 1151, 1069, 1014, 965 cm-1; HRMS (APCI) calcd for 
C12H20O2Na [M+Na]+ 219.1361, found 219.1383. 
 
O
O
H H
OOH
 91 
a-b
MeO OMe MeO OMeOH
HO
OH
HO
O
c
Reagents and conditions
a) Butenediol bis(triethylsilyl) ether, Grubbs-Hoveyda metathesis catalyst, CH2Cl2, reflux, 42%. b) Bu4NF, THF, 97%. c) HOAc, H2O, 85%.  
Scheme A12 Synthesis of substrates 2-53 and 2-62 
 
 (E)-8,8-Dimethoxy-10-phenyldec-3-ene-1,2-diol (2-53) 
1H NMR (500 MHz, CD2Cl2) δ 7.23-7.29 (m, 2H), 7.14-
7.21 (m, 3H), 5.76 (ddt, J = 2.0, 7.0, 15.5 Hz, 1H), 5.47 (ddt, J = 1.2, 6.5, 5.0 Hz, 1H), 4.11-4.18 
(m, 1H), 3.54-3.60 (m, 1H), 3.39-3.45 (m, 1H), 3.24 (s, 6H), 2.51-2.56 (m, 2H), 2.24 (br, 1H), 
2.04-2.10 (q, J = 7.0 Hz, 2H), 2.04-2.10 (br, 1H), 1.81-1.86 (m, 2H), 1.59-1.64 (m, 2H), 1.34-
1.41 (m, 2H); 13C NMR (125 MHz, CD2Cl2) δ 142.2, 133.2, 129.4, 128.3, 128.2, 125.8, 102.8, 
73.1, 66.6, 47.5, 34.2, 32.3, 31.8, 30.1, 23.2; IR (neat) 3399, 3061, 3025, 2949, 2828, 1669, 
1603, 1495, 1454, 1303, 1182, 1072, 971, 742 cm-1; HRMS (ESI) calcd for C18H28O4Na 
[M+Na]+ 331.1885, found 331.1889. 
(E)-9,10-Dihydroxy-1-phenyldec-7-en-3-one (2-62) 
1H NMR (400 MHz, CD2Cl2) δ 7.23-7.30 (m, 2H), 7.14-
7.20 (m, 3H), 5.69 (ddt, J = 1.2, 6.8, 15.2 Hz, 1H), 5.43 (ddt, J = 
1.4, 6.4, 15.2 Hz, 1H), 4.09-4.17 (m, 1H), 3.56 (dd, J = 2.0, 10.8 Hz, 1H), 3.41 (dd, J = 7.4, 11.2 
Hz, 1H), 2.85 (t, J = 7.4 Hz, 2H), 2.85 (br, 1H), 2.71 (t, J = 7.4 Hz, 2H), 2.71 (br, 1H), 2.38 (t, J 
= 7.4 Hz, 2H), 2.01 (q, J  = 7.4 Hz, 2H), 1.62 (p, J = 7.4 Hz, 2H); 13C NMR (100 MHz, CD2Cl2) 
δ 210.0, 141.4, 132.5, 129.6, 128.4, 128.3, 126.0, 73.0, 66.6, 44.1, 42.0, 31.6, 29.6, 23.0; IR 
(neat) 3378, 3030, 2929, 1709, 1603, 1495, 1453, 1408, 1372, 1074, 1029, 972, 748 cm-1; HRMS 
(ESI) calcd for C16H22O3Na [M+Na]+ 285.1467, found 285.1470. 
 
MeO OMeOH
HO
OH
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 (±)-(1R, 5S, 7S)-5-Phenethyl-7-vinyl-6,8-dioxabicyclo[3.2.1]octane (2-
55) 
The general rearrangement procedure was followed with 2-53 (100  mg, 0.32 mmol), Re2O7 (8 
mg, 0.02 mmol), and CH2Cl2 (5.0 mL). The reaction was stirred at rt for 21 h then was quenched 
with pyridine (25 mL). The crude material was purified by flash chromatography (1%-3% ethyl 
acetate in hexanes) to give the product (39 mg, 49%, dr = 4:3, for substrate 2-62, 40%, dr = 4:3). 
1H NMR (400 MHz, CD2Cl2) δ 7.22-7.29 (m, 2H), 7.18-7.22 (m, 2H), 7.12-7.18 (m, 1H), 6.05 
(ddd, J = 6.8, 10.4, 17.2 Hz, 1H), 5.42 (dt, J = 1.6, 17.2 Hz, 1H), 5.29 (ddd, J = 1.2, 1.6, 10.4, 
1H),  4.49 (ddq, J = 1.2, 4.4, 6.8, 1H), 4.30 (t, J = 4.0), 2.73-2.79 (m, 2H), 1.94-2.00 (m, 2H), 
1.90-2.00 (m, 1H), 1.72-1.83 (m, 1H), 1.63-1.79 (m, 2H), 1.53-1.63 (m, 2H); 13C NMR (100 
MHz, CD2Cl2) δ 142.7, 133.3, 128.34, 128.25, 125.6, 118.4, 108.7, 81.6, 77.7, 39.9, 33.4, 29.0, 
24.6, 17.1; IR (neat) 3062, 2954, 2915, 1603, 1496, 1456, 1373, 1253, 1236, 1099, 1028, 988, 
862,749 cm-1; HRMS (APCI) calcd for C16H21O2 [M+H]+ 245.1442, found 245.1521. 
 
(±)-(1R, 5S, 7R)-5-Phenethyl-7-vinyl-6,8-dioxabicyclo[3.2.1]octane (2-
54) 
1H NMR (400 MHz, CD2Cl2) δ 7.23-7.28 (m, 2H), 7.13-7.21 (m, 3H), 5.88 (ddd, J = 7.2, 10.0, 
17.2 Hz, 1H), 5.24 (ddd, J = 1.2, 1.6, 17.2 Hz, 1H), 5.10 (ddd, J = 0.8, 1.6, 10.0 Hz, 1H), 4.44 
(dd, J = 0.4, 3.6 Hz, 1H), 4.20 (br, 1H), 2.72-2.78 (m, 2H), 1.94-2.00 (m, 2H), 1.85-1.94 (m, 
1H), 1.75-1.84 (m, 1H), 1.61-1.69 (m, 3H), 1.54-1.61 (m, 1H); 13C NMR (100 MHz, CD2Cl2) δ 
142.6, 139.0, 128.32, 128.27, 125.6, 115.3, 109.3, 80.8, 79.8, 39.6, 33.9, 29.4, 28.1, 17.1; IR 
(neat) 3062, 3026, 2925, 2871, 1728, 1607, 1496, 1457, 1374, 1343, 1278, 1234, 1179, 1111, 
O
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1085, 1032, 1004, 924, 750 cm-1; HRMS (APCI) calcd for C16H21O2 [M+H]+ 245.1442, found 
245.1581. 
 
a-d
OH
OH
MeO OMe
Reagents and conditions
a) AD-Mix β, CH3SO2NH2, tBuOH, H2O, 0 °C. b) TESCl, imidazole, DMAP, DMF, 74%
(two steps). c) Alkenyl ketal, Grubbs-Hoveyda metathesis catalyst, CH2Cl2, reflux, 27%.
d) Bu4NF, THF, 75%,  
Scheme A13 Synthesis of substrate 2-59  
 
 (E)-9,9-dimethoxy-11-phenylundec-4-ene-2,3-diol (2-59) 
1H NMR (400 MHz, CD2Cl2) δ 7.25-7.30 (m, 2H), 7.15-7.21 
(m, 3H), 5.75 (ddt, J = 0.8, 6.8, 15.2 Hz, 1H), 5.46 (ddt, J = 1.4, 7.2, 15.2 Hz, 1H), 3.74 (t, J = 
6.8 Hz, 1H), 3.60 (t, J = 6.4 Hz, 1H), 3.15 (s, 6H), 2.51-2.56 (m, 2H), 2.08 (q, J = 6.8 Hz, 2H), 
1.82-1.88 (m, 2H), 1.60-1.65 (m, 2H), 1.35-1.43 (m, 2H), 1.12 (d, J =6.0 Hz, 3H); 13C NMR 
(100 MHz, CD2Cl2) δ 142.2, 133.9, 130.0, 128.4, 128.2, 125.8, 102.9, 77.8, 70.8, 47.5, 34.2, 
32.4, 31.9, 30.1, 23.2, 18.8; IR (neat) 3411, 3061, 3025, 2951, 2829, 1669, 1603, 1495, 1454, 
1368, 1266, 1181, 1055, 972, 742 cm-1; HRMS (EI) calcd for C19H30O4Na [M+Na]+ 345.2042, 
found 345.2051. 
 
(1R, 5S, 7R)-5-Phenethyl-7-((E)-prop-1-en-1-yl)-6,8-
dioxabicyclo[3.2.1]octane (2-60) 
The general cyclization procedure was followed with 2-59 (50  mg, 0.16 mmol), Re2O7 (4 mg, 
0.008 mmol), and CH2Cl2 (5.0 mL). The reaction was stirred at rt for 15 h and then was 
quenched with pyridine (25 mL). The crude mixture was purified by flash chromatography (1%-
OH
OH
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3%  ethyl acetate in hexanes) to give the product (21 mg, 53%, dr = 7.5 : 1). 1H NMR (400 MHz, 
CD2Cl2) δ 7.23-7.29 (m, 2H), 7.18-7.22 (m, 2H), 7.12-7.18 (m, 1H), 5.67 (ddt, J = 0.4, 6.4, 15.2 
Hz, 1H), 5.52 (ddt, J = 1.4, 8.0, 15.2 Hz, 1H), 4.40 (d, J = 8.0 Hz, 1H), 2.72-2.78 (m, 2H), 1.91-
1.98 (m, 2H), 1.83-1.91 (m, 1H), 1.73-1.81 (m, 1H), 1.69 (dd, J = 1.6, 6.4 Hz, 3H), 1.59-1.66 (m, 
3H), 1.52-1.58 (m, 1H); 13C NMR (100 MHz, CD2Cl2) δ 142.7, 132.1, 128.33, 128.25, 127.3, 
125.6, 108.9, 80.7, 79.9, 39.6, 34.0, 29.4, 28.1, 17.3, 17.1; IR (neat) 3061, 3026, 2950, 1671, 
1603, 1496, 1453, 1373, 1344, 1175, 1067, 1024, 990, 906, 751 cm-1; HRMS (APCI) calcd for 
C17H23O2 [M+H]+ 259.1698, found 259.1673. 
 
MgBr
OH
OO
OO
HO OH HO OH
O
a b-c
d-e f
a) Ethyl Formate , THF, 0 °C, 82%. b) PCC, Celite, DCM, rt, 81%. c) PTSA.H2O, CH(OMe)3, MeOH, 50 °C, 92%.
d) Methyl Acrylate, Hoveyda-Grubbs 2nd,  DCM, reflux, 68.2%. e) DIBAL, DCM, -78 °C, 77%. f) 50% HOAc, rt, 
84%.
Reaction Conditions:
 
Scheme A14 Synthesis of substrates 2-63 and 2-66 
 
 (2E,11E)-7,7-dimethoxytrideca-2,11-diene-1,13-diol (2-63) 
1H NMR (400 MHz, C6D6) δ 5.53-5.75 (m, 4H), 4.06 (br, 4H), 3.22-
3.38 (br, 2H), 3.07 (s, 6H), 2.00 (q, J = 3.2 Hz, 4H), 1.65-1.71 (m, 4H), 1.42 (p, J = 7.6 Hz, 4H); 
13C NMR (100 MHz, C6D6) δ 131.2, 130.3, 103.3, 62.9, 47.2, 32.3, 32.1, 23.5; IR (neat) 3384, 
2946, 1710, 1670, 1457, 1369, 1314, 1180, 1088, 970 cm-1; HRMS (ESI) calcd for C15H28O4Na 
[M+Na]+ 295.1885, found 295.1860. 
OH MeO OMe OH
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 (2E,11E)-1,13-dihydroxytrideca-2,11-dien-7-one (2-66) 
1H NMR (400 MHz, CD2Cl2) δ 5.60-5.70 (m, 4H), 4.06 (br, 
4H), 2.42 (t, J = 7.2 Hz, 4H), 2.25-2.35 (br, 2H), 2.02-2.09 (m, 4H), 1.66 (p, J = 7.2 Hz, 4H); 13C 
NMR (100 MHz, CD2Cl2) δ 211.0, 131.5, 130.1, 63.2, 41.8, 31.5, 23.1; IR (neat) 3250, 3052, 
3011, 2933, 2865, 1698, 1457, 1415, 1371, 1266, 1088, 1016, 970  cm-1; HRMS (EI) calcd for 
C13H22O3Na [M+Na]+ 249.1467, found 249.1451. 
 
 (±)-(2R, 6R, 8R)-2,8-Divinyl-1,7-dioxaspiro[5.5]undecane (2-64) 
The general rearrangement procedure was followed with 44 (14  mg, 0.051 
mmol), Re2O7 (1.2  mg, 0.0025 mmol), and CD2Cl2 (1.0 mL). The reaction was stirred at rt for 
30 min. BnMe2SiH (5 µl) was added as an internal standard, and a 1H NMR spectrum was taken 
of the crude mixture to show an 88% yield and 1:1 ratio of two stereoisomers. Additional stirring 
(>12 h) resulted in the mixture giving essentially a single diastereomer (dr > 20:1) with a 
decrease in overal yield (60%). The general rearrangement cyclization procedure was also 
followed with 2-66 (50  mg, 0.221 mmol), Re2O7 (5.4 mg, 0.011 mmol), and CD2Cl2 (3.0 mL). 
The reaction was stirred at rt for 30 min. BnMe2SiH (5 µl) was added as an internal standard, and 
a 1H NMR spectrum was taken of the crude mixture to show a 94% yield and 1:1 ratio of two 
stereoisomers. Additional stirring (48 h) with the addition of MeOH showed isomerization of the 
mixture to give essentially a single stereoisomer with a decrease in overall yield (61%). 1H NMR 
(400 MHz, C6D6) δ 5.89 (ddd, J = 5.2, 10.4, 17.2 Hz, 2H), 5.30 (dt, J = 1.6, 17.2 Hz, 2H), 5.02 
(dt, J = 1.6, 10.4 Hz, 2H), 4.17 (ddddd, J = 1.2, 1.6, 2.4, 5.6, 11.2 Hz, 2H), 2.03 (dq, J = 4.0, 13.2 
Hz, 2H), 1.63 (dddd, J = 1.6, 2.4, 4.0, 13.2 Hz, 2H), 1.41-1.49 (m, 2H), 1.34-1.41 (m, 2H), 1.17-
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1.34 (m, 4H); 13C NMR (100 MHz, C6D6) δ 140.0 113.2, 95.9, 69.7, 35.2, 31.1, 18.8; IR 3012, 
2927, 2854, 1646, 456, 1374, 1279, 1220, 981, 917 (neat) cm-1; HRMS (APCI) calcd for 
C13H21O2 [M+H]+ 209.1542, found 209.1567. 
 
OO a-b OH OHOO
Reagents and conditions:
a) Methyl vinyl ketone, Grubbs-Hoveyda metathesis catalyst, CH2Cl2, reflux, 44%; b) DIBAL-H,
CH2Cl2, -78 ºC, 81%.  
Scheme A15 Synthesis of substrate 2-67 
 
 (3E, 12E)-8,8-dimethoxypentadeca-3,12-diene-2,14-diol (2-67) 
1H NMR (400 MHz, C6D6) δ 5.52-5.62 (m, 4H), 4.21 (p, J = 5.2 Hz, 2H), 3.07 (s, 6H), 2.89 (br, 
2H), 1.94-2.0 (m, 4H), 1.65-1.70 (m, 4H), 1.37-1.45 (m, 4H), 1.25 (d, J = 6.4 Hz, 6H); 13C NMR 
(100 MHz, C6D6) δ 135.5, 129.1, 103.2, 68.1, 47.1, 32.1, 32.0, 23.6, 23.5; IR (neat) 3388, 2950, 
1711, 1670, 1455, 1368, 1294, 1181, 1060, 969, 941, 864 cm-1; HRMS (APCI) calcd for 
C17H32O4Na [M+Na]+ 323.2198, found 323.2199. 
 
 (±)-(2R, 6R, 8R)-2,8-Di((E)-prop-1-en-1-yl)-1,7-dioxaspiro[5.5]undecane (2-
68) 
The general rearrangement procedure was followed with 2-67 (44 mg, 0.15 
mmol), Re2O7 (4 mg, 0.007 mmol), and CD2Cl2 (3.0 mL). The reaction was stirred at 0 °C for 60 
min. BnMe2SiH (5 µl) was added as an internal standard, and a 1H NMR spectrum was taken of 
the crude mixture to show a 54% yield. 1H NMR (400 MHz, CDCl3) δ 5.70 (ddq, J = 1.2, 6.4, 
15.2 Hz, 2H), 5.52 (ddq, J = 1.6, 6.4, 15.2 Hz, 2H), 4.04 (ddp, J = 1.2, 6.4, 11.6 Hz, 2H), 1.94 
OH MeO OMe OH
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(tq, J = 4.0, 13.2 Hz, 2H), 1.71 (dd, J = 1.6, 6.4 Hz, 6H), 1.52-1.67 (m, 6H), 1.36-1.45 (m, 2H), 
1.25-1.36 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 132.7, 126.4, 96.4, 69.6, 35.1, 31.0, 18.8, 
17.9; IR 2937, 2867, 1731, 1676, 1452, 1438, 1377, 1279, 1219, 1201,1036, 979, 964 (neat) cm-
1; HRMS (APCI) calcd for C15H25O2 [M+H]+ 237.1855, found 237.1837. 
 
O OHOO
HO
a-h
Reagents and conditions:
a) Butenylmagnesium bromide, CuCN, Et2O, 0 ºC, 30%; b) Me3CC(O)Cl, Et3N, DMAP,
CH2Cl2; c) O3, CH2Cl2, -78 ºC, then Me2S, 27%, 2 steps; d) Pentenylmagnesium bromide,
Et2O, 0 ºC, 56%; e) PCC, Celite, CH2Cl2, 86%; f) (MeO)3CH, p-TsOH, MeOH, 100%; 
g) Methyl acrylate, Grubbs-Hoveyda second generation metathesis catalyst, CH2Cl2, reflx,
96%; h) DIBAL-H, CH2Cl2, -78 ºC, 66%.  
Scheme A16 Synthesis of substrate 2-69 
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OO OHOO
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O
O OH
OO
HO
a-b c-d
e f
a) THF, -78 °C to rt, 77%. b) PTSA•H2O, CH(OMe)3, MeOH, 50 °C, 95%. c) DIBAL, DCM, -78 °C, 74%. d) 
MeMgBr, Et2O, 0 °C to rt, 90%. e) Methyl Acrylate,  Hoveyda-Grubbs 2nd, DCM, reflux. 82%. f)  DIBAL, DCM, -78 
°C, 72%.
Reaction Conditions:
MgBr
+
 
Scheme A17 Synthesis of substrate rac-2-69 
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 (S, E)-7,7-dimethoxydodec-2-ene-1,11-diol (2-69) 
1H NMR (400 MHz, C6D6) δ 5.58-5.71 (m, 2H), 4.04 (br, 2H), 
3.63-3.70 (m, 1H), 3.09 (s, 3H), 3.08 (s, 3H), 1.95-2.05 (m, 2H), 1.62-1.76 (m, 4H), 1.28-1.60 
(m, 6H), 1.12 (d, J = 6.0, 3H); 13C NMR (100 MHz, C6D6) δ 131.1, 130.5, 103.4, 67.2, 62.9, 
47.2, 39.4, 32.6, 32.1, 31.8, 23.6, 23.4, 20.1; IR (neat) 3396, 2949, 2871, 1669, 1458, 1372, 
1131, 1041, 971 cm-1; HRMS (ESI) calcd for C14H28O4Na [M+Na]+ 283.1885, found 283.1915; 
[α]D = + 6.26 (c 0.91, CHCl3); ee>99% as determined by Mosher ester analysis. 
 
(2S, 6R, 8R)-2-methyl-8-vinyl-1,7-dioxaspiro[5.5]undecane (2-70) 
The general rearrangement procedure was followed with 2-69 (50 mg, 0.19 
mmol) and Re2O7 (5 mg, 0.01 mmol) in CD2Cl2 (3.0 mL), the reaction was stirred at rt for 24 h. 
BnMe2SiH (5 µl) was added as an internal standard, and a 1H NMR spectrum was taken of the 
crude mixture to show a 61% yield. 1H NMR (400 MHz, CDCl3) δ 5.88 (ddd, J = 5.2, 10.4, 17.2 
Hz, 1H), 5.26 (dt, J = 1.6, 17.2 Hz, 1H), 5.09 (dt, J = 1.6, 10.4 Hz, 1H), 4.08 (ddddd, J = 1.2, 1.6, 
2.4, 5.2, 10.4 Hz, 1H)，3.72 (ddddd, J = 2.0, 6.0, 6.0, 6.0, 8.0 Hz, 1H), 1.86-2.02 (m, 2H), 1.49-
1.70 (m, 6H), 1.35-1.46 (m 2H), 1.18-1.35 (m, 2H), 1.15 (d, J = 6.4, 3H); 13C NMR (100 MHz, 
CDCl3) δ 139.8, 114.0, 96.3, 69.5, 65.2, 35.2, 35.1 32.7, 30.8, 21.9, 18.9, 18.8; IR (neat) 2924, 
2853, 1658, 1459, 1377, 1224, 1087, 992 cm-1; HRMS (ESI) calcd for C12H20O2Na [M+Na]+ 
219.1361, found 219.1387. [α]D = – 43.2 (c 0.31, CHCl3); ee: 96% as determined by HPLC 
analysis using a Phenomenex Lux 5m Cellulose-3 column (250 x 4.60 mm) with MeOH/H2O 
(60/40, v/v) as the mobile phase.   
 
 
OH MeO OMe OH
O
O
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5-((2S, 6R)-6-vinyltetrahydro-2H-pyran-2-yl)pentan-2-one (2-75) 
1H NMR (400 MHz, CD2Cl2) δ 5.82 (ddd, J = 5.2, 10.4, 17.2 Hz, 1H), 5.18 
(dt, J = 1.6, 17.2 Hz, 1H), 5.02 (dt, J = 1.6, 10.4 Hz, 1H), 3.77 (ddddd, J = 1.2, 1.6, 2.4, 5.2, 10.8 
Hz, 1H), 3.30 (dddd, J = 2.0, 5.2, 7.6, 10.8 Hz, 1H), 2.41 (t, J = 7.2 Hz, 2H), 2.08 (s, 3H), 1.78-
1.85 (m, 2H), 1.35-1.70 (m, 6H), 1.08-1.27 (m, 4H); 13C NMR (100 MHz, CD2Cl2) δ 208.7, 
140.0, 113.5, 78.0, 77.3, 43.5, 35.8, 31.6, 31.3, 29.6, 23.5, 20.0; IR 3080, 2933, 2857, 1715, 
1647, 1440, 1410, 1364, 1201, 1167, 1090, 1046, 990,919 (neat) cm-1; HRMS (APCI) calcd for 
C12H21O2 [M+H]+ 197.1542, found 197.1566. 
 
1-methoxy-6-((2S,6S)-6-methyltetrahydro-2H-pyran-2-yl)hexan-3-
one (2-76) 
1H NMR (400 MHz, CD2Cl2) δ 3.58 (t, J = 6.4, 2H), 3.36 (ddddd, J = 2.0, 6.0, 6.0, 6.0, 11.2, 
1H), 3.22 (dddd, J = 2.0, 5.2, 7.2, 10.8, 1H), 1.72-1.81 (m, 1H), 1.58-1.78 (m, 1H), 1.47-1.58 (m, 
4H), 1.27-1.47 (m, 3H), 1.09 (d, J = 6.4, 3H), 1.05-1.15 (m, 1H). 13C NMR (100 MHz, CD2Cl2) 
δ 209.0, 77.3, 73.6, 67.6, 58.5, 43.1, 42.7, 35.9, 33.4, 31.3, 23.7, 22.0, 19.8. IR (neat) 2967, 
2930, 2860, 1714, 1452, 1387, 1373, 1322, 1202, 1118, 1083, 1041, 963 cm-1; HRMS (ESI) 
calcd for C13H24O3Na [M+Na]+ 251.1623, found 251.1637. 
 
OH
OO OHOO
OHa-b
Reagents and conditions:
a) Methyl vinyl ketone, Grubbs-Hoveyda metathesis catalyst, CH2Cl2, reflux, 53%; b) DIBAL-H, 
CH2Cl2, -78 ºC, 61%.  
Scheme A18 Synthesis of substrate 2-71 
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 (E)-8,8-dimethoxytridec-3-ene-2,12-diol (2-71) 
1H NMR (400 MHz, C6D6) δ 5.48-5.64 (m, 2H), 4.20 (p, J = 6.0 Hz, 2H), 3.65 (q, J = 5.2 
Hz, 1H), 3.091 (s, 3H), 3.087 (s, 3H), 2.79 (d, J = 14.8 Hz, 1H), 2.52 (d, J = 15.6 Hz, 1H), 1.95-
2.02 (q, J = 7.2 Hz, 2H), 1.66-1.77 (m, 3H), 1.27-1.59 (m, 6H), 1.24 (d, J = 6.4 Hz, 3H), 1.10 (d, 
J = 6.4 Hz, 3H); 13C NMR (100 MHz, C6D6) δ 135.73, 135.68, 129.1, 103.3, 68.12,68.09, 67.16, 
67.10, 47.1, 39.4, 32.61, 32.59, 32.0, 31.8, 31.7, 23.7, 23.53. 23. 48, 23.44, 20.12, 20.08 IR 
(neat) 3391, 2952, 2830, 1170, 1670, 1457, 1370, 1313, 1126, 1064, 969, 941 cm-1; HRMS (ESI) 
calcd for C15H30O4Na [M+Na]+ 297.2042, found 297.2065. 
 
(2S, 6R, 8R)-2-methyl-8-((E)-prop-1-en-1-yl)-1,7-dioxaspiro[5.5]undecane 
(2-72) 
The general cyclization procedure was followed with 2-71 (50  mg, 0.18 mmol) 
and Re2O7 (4 mg, 0.009 mmol) in CDCl3 (3.0 mL). The mixture was stirred at rt for 30 min after 
which the reaction was quenched with pyridine (25 mL). BnMe2SiH (5 µl) was added as an 
internal standard, and a 1H NMR spectrum was taken of the crude mixture to show a 65% yield. 
1H NMR (400 MHz, CD2Cl2) δ 5.69 (ddq, J = 1.2, 6.4, 15.2 Hz, 1H), 5.51 (ddq, J = 1.6, 6.0, 15.2 
Hz, 1H), 4.02 (ddp, J = 1.2, 6.0, 11.6 Hz, 1H), 3.72 (ddq, J = 2.0, 6.4, 11.2 Hz, 1H), 1.85-1.99 
(m, 2H), 1.71 (dd, J = 2.4, 6.4, 3H), 1.49-1.66 (m, 6H), 1.41 (ddd, J = 4.4, 8.4, 13.2, 2H), 1.28-
1.36 (m, 1H), 1.18-1.28 (m, 1H), 1.15 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 132.8, 
126.2, 96.3, 69.5, 65.1, 35.21., 35.16, 32.8, 31.0, 21.9, 18.9, 18.8, 17.9; IR (neat) 2936, 2869, 
1676, 1440, 1383, 1280, 1224, 1204,1087, 991, 964 cm-1; HRMS (APCI) calcd for C13H23O2 
[M+H]+ 211.1698, found 211.1716. 
 
MeO OMe OHOH
O
O
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HO
a-g
OH O
O OH
Reagents and conditions
a) PCC, Celite, CH2Cl2. b) MeMgBr, THF, 0 °C, 58% (two steps). c) PCC, Celite, CH2Cl2. 
d) (Z)-Hex-3-ene-2,5-diol, Grubbs-Hoveyda 2nd generation metathesis catalyst, CH2Cl2.
e) TBDMSCl, imidazole, DMAP, DMF, 50% (three steps). f) LDA, THF, 0 °C, then CuCl2,
26%. g) Bu4NF, THF.  
Scheme A19 Synthesis of substrate 2-77 
 
(3E,15E)-2,17-dihydroxyoctadeca-3,15-diene-8,11-dione 
(2-77) 
1H NMR (400 MHz, CDCl3) δ 5.48-5.61 (m, 4H), 4.25 (q, J = 6.0 Hz, 2H), 2.65 (s, 4H), 2.46 (t, 
J = 7.2 Hz, 4H), 2.02 (q, J = 6.8 Hz, 4H), 1.67 (p, J = 7.2 Hz, 4H), 1.24 (d, J = 6.4 Hz, 6H); 13C 
NMR (100 MHz, CDCl3) δ 209.6, 135.2, 129.7, 68.8, 41.9, 36.1, 31.5, 23.4, 22.9; IR (neat) 
3406, 2968, 2928, 1707, 1639, 1450, 1369, 1139, 1062, 970, 938 cm-1; HRMS (ESI) calcd for 
C18H30O4Na [M+Na]+ 333.2042, found 333.2075. 
 
Spirotricycles 2-78 and 2-79 
The general rearrangement procedure was followed with 2-77 (110 mg, 
0.354 mmol), Re2O7 (8.6 mg, 0.018 mmol), and CH2Cl2 (3.0 mL). The 
reaction was stirred at 0 °C  for 2 h and then was quenched with pyridine 
(25 mL). After evaporation of the solvent, the crude mixture was purified 
by flash chromatography 1%-3%  ethyl acetate in hexanes) to give the 
product (87 mg, 84%, dr = 1:1, 2-78: 43 mg, 2-79: 44 mg).  
 
Faster eluting major isomer 2-78: 1H NMR (400 MHz, CD2Cl2) δ 5.60 (ddq, J = 0.8, 6.4, 15.2 
Hz, 2H), 5.40 (ddq, J = 1.6, 6.8, 15.2 Hz, 2H), 4.21 (dd, J = 7.2, 11.2 Hz, 2H), 1.85-1.98 (m, 
OH O
O OH
O OO
2-78
O OO
2-79
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4H), 1.79-1.83 (m, 2H), 1.65 (d, J = 6.4 Hz, 6H), 1.54-1.70 (m, 8H), 1.20-1.31 (m, 2H); 13C 
NMR (100 MHz, CD2Cl2) δ 133.0, 125.8, 106.8, 71.4, 36.7, 34.8, 31.2, 20.3, 17.5; IR (neat) 
3023, 2981, 2937, 2864, 1731, 1676, 1452, 1439, 1375, 1314, 1266, 1231,1072, 1028, 968, 874 
cm-1; HRMS (ESI) calcd for C18H28O3Na [M+Na]+ 315.1936, found 315.1919. The 
stereochemical arrangement was established by HPLC analysis using a Phenomenex Lux 5m 
Cellulose-3 column (250 x 4.60 mm) with MeOH/H2O (Black line: 60/40 or Purple Line: 70/30, 
v/v) as the mobile phase.  
Slower eluting minor isomer 2-79: 1H NMR (400 MHz, CD2Cl2) δ 5.58 (ddq, J = 0.8, 6.4, 
15.6 Hz, 2H), 5.41 (ddq, J = 1.6, 6.8, 15.6 Hz, 2H), 4.28 (dd, J = 7.2, 10.8 Hz, 2H), 2.01-2.07 
(m, 2H), 1.81-1.91 (m, 2H), 1.73-1.79 (m, 2H), 1.65 (d, J = 6.4 Hz, 6H), 1.48-1.63 (m, 8H), 
1.22-1.33 (m, 2H); 13C NMR (100 MHz, CD2Cl2) δ 133.0, 126.2, 107.2, 72.6, 37.4, 34.8, 31.1, 
20.1, 17.5; IR (neat) 3022, 2936, 2864, 1676, 1453, 1439, 1377, 1301, 1233, 1165, 1073, 1028, 
964, 866 cm-1; HRMS (ESI) calcd for C18H28O3Na [M+Na]+ 315.1936, found 315.1918.   
The two stereoisomers were resubjected to the following isomerization condition: 7.2 mg 
Re2O7 (0.015 mmol) and 1.5 ml CD2Cl2. After stirring at 0 °C for 4 h, the isomerizations were 
quenched with pyridine (25 mL). BnMe2SiH (5 µl) was added as an internal standard to each 
isomerization mixture, and a 1H NMR spectrum was taken of the crude mixture to show that the 
equilibration of 2-78 provided 51% of 2-78 and 27% of 2-79. The equilibration of 2-79 provided 
52% of 2-78 and 29 % of 2-79. Thus, after one cycle of isomerization: a total yield of 64% could 
be obtained for 2-78 and a total yield of 54% could be obtained for 2-79. 
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APPENDIX B 
CASCADE APPROACH TO STEREOSELECTIVE POLYCYCLIC ETHER 
FORMATION: EPOXIDES AS TRAPPING AGENTS FOR TRANSPOSING ALLYLIC 
ALCOHOL 
General Information 1H NMR and 13C NMR spectra were taken on a Bruker Avance 300 
spectrometer at 300 MHz and 75 MHz respectively, a Bruker Avance 400 spectrometer at 400 
MHz and 100 MHz, a Bruker Avance 500 spectrometer at 500 MHz and 125 MHz if specified. 
The chemical shifts are given in parts per million (ppm) on the delta (δ) scale. The solvent peak 
was used as a reference value, for 1H NMR: CDCl3 = 7.27 ppm, CD2Cl2 = 5.31 ppm,  C6D6 = 
7.16 ppm,  for 13C NMR: CDCl3 = 77.23, CDCl3 = 53.52, C6D6 = 128.37. Data are reported as 
follows: m=multiplet, s = singlet; d = doublet; t = triplet; q = quartet; p = pentet; h = hexet; dd = 
doublet of doublets; dt = doublet of triplets; br = broad. High resolution and low resolution mass 
spectra were collected on a VG 7070 spectrometer. Infrared (IR) spectra were taken on a Mattson 
Cygnus 100 spectrometer. Samples for IR were prepared as thin films on a NaCl plates by 
dissolving the corresponding compounds in CH2Cl2 followed by evaporation of the CH2Cl2. 
Methylene chloride was distilled under N2 from CaH2. Analytical TLC was performed on E. 
Merck pre-coated (25 mm) silica gel 60F-254 plates. Visualization was done under UV (254 nm). 
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Flash chromatography was done using Silicycle SiliaFlash P60 40-63 µm silica gel (230-400 
mesh). Reagent grade ethyl acetate, diethyl ether, pentane and hexanes (commercial mixture) 
were purchased from EM Science and used as is for chromatography. All reactions were 
performed in oven or flame-dried glassware under a positive pressure of N2 with magnetic 
stirring unless otherwise noted. 
 
Preparation of Re2O7 supported on SiO2 
A slurry of 1.8 g of SiO2 and 200mg of Re2O7 in Et2O was stirred at rt for 3 h, followed by 
removal of Et2O under reduced pressure, the obtained powder was dried under vacuum 
overnight. The catalyst was stored in dessicator and shielded from light by wrapping the sample 
container with aluminium foil.  
 
General procedure for rearrangement cyclization catalyzed by Re2O7 
To a solution  (~10 mM)  of corresponding substrate in CH2Cl2 was added 0.05 equivalent of 
Re2O7,  the reaction mixture was stirred at rt (unless otherwise mentioned in the substrate tables) 
and monitored by TLC until complete consumption of the starting material, then the reaction was 
quenched with a few drops of pyridine or triethylamine and the solvent was removed under 
vacuum, followed by purification by flash chromatography or preparation TLC to give the 
product.  
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Ph Ph
O
HO
e-f
Reaction Conditions:
a) DIBAL, hexanes, then I2, THF, -78 ºC, 51%; b) PhCH2MgCl, Cl2Pd(dppf)2, THF, 20 ºC, 95%;
c) PCC, celite, DCM, 20 ºC; d) 60% NaH dispersed in mineral oil, triethyl phosphonoacetate, THF, 
0 ºC,77% for two steps; e) Shi ketone derived from D-fructose, oxone, Na2B4O7, Na2(EDTA), K2CO3,
Nu4NHSO4, MeCN, H2O, 0 ºC, 39%; f) DIBAL, DCM, -78 ºC, 91%.
O
O
HO Ph
OH a-b c-d
 
Scheme B1 Synthesis of substrate 3-15 
 
(E)-6-((2R,3R)-3-benzyloxiran-2-yl)hex-2-en-1-ol (3-15) 
1H NMR (400 MHz, CDCl3) δ 7.31-7.38 (m, 2H), 7.23-7.30 (m, 3H), 5.57-5.72 (m, 2H), 4.08 (d, 
J = 5.2, 2H), 2.90-2.98 (m, 2H), 2.77-2.86 (m, 2H), 2.03-2.13 (m, 2H), 1.83 (br, 1H), 1.45-1.65 
(m, 4H); 13C NMR (100 MHz, CDCl3) 137.4, 132.3, 129.6, 128.9, 128.6, 126.6, 63.5, 58.8, 58.6, 
38.5, 31.8, 31.3; IR (neat) 3407, 3027, 2973, 2929, 2857, 1669, 1604, 1494, 1370, 1088, 1001, 
971, 932, 743 cm-1; HRMS (ESI) calcd for C15H20O2Na [M + Na]+ 255.1361, found 255.1387. 
 
(R)-2-phenyl-1-((2S,6R)-6-vinyltetrahydro-2H-pyran-2-yl)ethanol (3-
16) 
The general rearrangement procedure was followed with 3-15 (28.0 mg, 0.121 mmol), Re2O7 
(2.9 mg, 0.006 mmol), and CH2Cl2 (12 mL). The reaction was stirred at 20 °C for 4 h and then 
quenched with five drops of pyridine. After evaporation of the solvent, the crude mixture was 
purified by flash chromatography (10%-20% ethyl acetate in hexanes) to give the product (25.0 
mg, 89%, dr = 59:44). 1H NMR (400 MHz, CDCl3) δ 7.29-7.35 (m, 2H), 7.21-7.28 (m, 3H), 5.89 
(ddd, J = 5.2, 10.8, 17.2, 1H), 5.26 (dt, J = 1.6, 17.2, 1H), 5.12 (dt, J = 1.6, 10.8, 1H), 3.94 (h, J 
O
OH
PhH H
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= 4.0, 1H), 3.88 (ddddd, J = 1.2, 1.6, 2.8, 5.2, 10.8, 1H), 3.35 (ddd, J = 2.0, 4.4, 10.8, 1H), 2.89 
(dd, J = 4.8, 13.6, 1H), 2.80 (dd, J = 8.4, 13.2, 1H), 2.04 (d, J = 4.0, 1H), 1.92-1.99 (m, 1H), 
1.62-1.77 (m, 2H), 1.41-1.62 (m, 2H), 1.28-1.39 (m, 1H); 13C NMR (100 MHz, CDCl3) 139.4, 
138.5, 129.4, 128.5, 126.3, 114.4, 79.5, 78.4, 74.7, 38.7, 31.6, 25.1, 23.0; IR (neat) 3446, 3027, 
2934, 2855, 1646, 1603, 1495, 1453, 1306, 1201, 1077, 1046, 915, 748; HRMS (ESI) calcd for 
C15H20O2Na [M + Na]+ 255.1361, found 255.1378.  
 
(R)-2-phenyl-1-((2S,6S)-6-vinyltetrahydro-2H-pyran-2-yl)ethanol (3-
17) 
1H NMR (400 MHz, CDCl3) δ 7.29-7.34 (m, 2H), 7.21-7.28 (m, 3H), 5.92-6.02 (m, 1H), 5.25-
5.27 (m, 1H), 5.21-5.24 (m, 1H), 4.45-4.51 (m, 1H), 3.89 (h, J = 4.4, 1H), 3.63 (ddd, J = 2.0, 5.2, 
9.2, 1H), 2.93 (dd, J = 4.0, 14.0, 1H), 2.69 (dd, J = 8.8, 14.0, 1H), 1.91 (d, J = 3.6, 1H), 1.77-
1.88 (m, 1H), 1.63-1.75 (m, 4H), 1.52-1.63 (m, 2H); 13C NMR (100 MHz, CDCl3) 138.6, 138.1, 
129.4, 128.5, 126.4, 116.4, 74.1, 73.3, 73.0, 39.0, 28.6, 25.5, 18.3; IR (neat) 3439, 3027, 2930, 
2858, 1669, 1603, 1494, 1453, 1407, 1338, 1203, 1121, 1048, 1039, 921, 891, 748 cm-1; HRMS 
(ESI) calcd for C15H20O2Na [M + Na]+ 255.1361, found 255.1376. 
 
HO Ph
Ph
OOHa-d
Reaction Conditions:
a) PCC, celite, DCM, 20 ºC; b) 60% NaH dispersed in Mineral oil, Diethyl (2-oxopropyl)phosphonate, THF, 
0 ºC, 66% for two steps; c) Shi ketone derived from D-fructose, oxone, Na2B4O7, Na2(EDTA), K2CO3, 
Bu4NHSO4, MeCN, H2O, 0 ºC, 58%; f) DIBAL, DCM, -78 ºC, 91%.
(From Scheme B1)
 
Scheme B2 Synthesis of substrate 3-18 
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(E)-7-((2R, 3R)-3-benzylloxiran-2-yl)hept-3-en-2-ol (3-18)                
1H NMR (300 MHz, CDCl3) δ 7.30-7.38 (m, 2H), 7.23-7.30 (m, 
3H), 5.46-5.66 (m, 2H), 4.26 (p, J = 6.3, 1H), 2.90-2.98 (m, 2H), 2.77-2.85 (m, 2H), 2.05 (q, J = 
6.6, 2H), 1.78 (br, 1H), 1.46-1.62 (m, 4H), 1.26 (d, J = 6.3, 3H); 13C NMR (75 MHz, CDCl3) δ 
137.4, 134.8, 130.0, 128.9, 128.5, 126.6, 68.7, 58.8, 58.6, 38.5, 31.7, 31.3, 25.5, 23.5; IR (neat) 
3412, 3027, 2971, 2925, 2857, 1604, 1494, 1453, 1367,1145, 1063, 969, 798, 743 cm-1; HRMS 
(ESI) calcd for C16H22O2Na [M + Na]+ 269.1517, found 269.1529. 
 
(2R,3S,7R)-2-benzyl-7-((E)-prop-1-en-1-yl)oxepan-3-ol (3-19) 
The general rearrangement procedure was followed with 3-18 
(25.0 mg, 0.102 mmol), Re2O7 (2.5 mg, 0.005 mmol), and CH2Cl2 (10.2 mL). The reaction was 
stirred at 20 °C for 45 min and then quenched with five drops of pyridine. After evaporation of 
the solvent, the crude mixture was purified by flash chromatography (20%-30% ethyl acetate in 
hexanes) to give the product (22.3 mg, 89%, dr = 6:7). 1H NMR (400 MHz, C6D6) δ 7.35-7.37 
(m, 2H), 7.18-7.22 (m, 2H), 7.08-7.12 (m, 1H), 5.39-5.51 (m, 2H), 3.62-3.67 (m, 1H), 3.42-3.45 
(m, 1H), 3.38 (dt, J = 3.2, 8.4, 1H), 3.04 (dd, J = 3.0, 13.8, 1H), 2.78 (dd, J = 8.6, 13.8, 1H), 
1.70-1.79 (m, 1H), 1.49-1.58 (m, 2H), 1.53 (d, J = 5.2, 3H), 1.35-1.48 (m, 3H). 0.78 (br, 1H); 13C 
NMR (100 MHz, CDCl3) 139.5, 132.3, 129.5, 128.1, 126.0, 125.8, 86.2, 82.4, 75.3, 40.7, 36.2, 
35.8, 19.4, 17.8; IR (neat) 3415, 3027, 2926, 2857, 1672, 1604, 1495, 1452, 1133, 1101, 1037, 
999, 966, 750 cm-1; HRMS (ESI) calcd for C16H22O2 [M]+ 246.1620, found 246.1629. 
 
(2R,3S,7S)-2-benzyl-7-((E)-prop-1-en-1-yl)oxepan-3-ol (3-20) 
1H NMR (400 MHz, C6D6) δ 7.29-7.33 (m, 2H), 7.17-7.22 (m, 2H), 
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7.07-7.12 (m, 1H), 5.24 (ddq, J = 1.2, 6.4, 15.6, 1H), 4.91 (ddq, J= 1.6, 5.6, 15.6, 1H), 3.92 (p, J 
= 5.2, 1H), 3.46 (dt, J = 2.8, 9.2, 1H), 3.12 (dt, J = 4.4, 9.2, 1H), 3.17 (dd, J = 2.8, 13.6, 1H), 
2.64 (dd, J = 9.2, 13.6, 1H), 1.79-1.87 (m, 1H), 1.48-1.56 (m, 1H), 1.35-1.47 (m, 2H), 1.39 (d, J 
= 6.4, 3H), 1.18-1.35 (m, 3H), 0.90 (br, 1H); 13C NMR (100 MHz, CDCl3) 139.4, 132.3, 130.0, 
128.0, 125.9, 125.7, 78.3, 75.6, 75.3, 39.4, 38.4, 33.9, 21.5, 17.8; IR (neat) 3307, 3034, 2926, 
2855, 1605, 1495, 1451, 1354, 1123, 1091, 1036, 970, 744 cm-1; HRMS (ESI) calcd for 
C16H22O2Na [M + Na]+ 269.1517, found 269.1509. 
 
(R)-2-phenyl-1-((2S,6R)-6-((E)-prop-1-en-1-yl)tetrahydro-2H-
pyran-2-yl)ethanol (3-21) 
The general rearrangement procedure was followed with 3-18 (29.5 mg, 0.120 mmol), Re2O7 
(2.9 mg, 0.006 mmol), and CH2Cl2 (12.0 mL). The reaction was stirred at 20 °C for 36 hrs (5% 
more catalyst added at 12 h and 24 h respectively) and then quenched with five drops of 
pyridine. After evaporation of the solvent, the crude mixture was purified by flash 
chromatography (10%-20% ethyl acetate in hexanes) to give the product (27.4 mg, 93%, dr = 
10:11). 1H NMR (400 MHz, CDCl3) δ 7.30-7.37 (m, 2H), 7.23-7.30 (m, 3H), 5.72 (ddt, J = 0.8, 
6.4, 15.6, 1H), 5.55 (ddt, J = 1.6, 6.0, 15.6, 1H), 3.96 (h, J = 4.0, 1H), 3.84 (dd, J = 6.2, 10.2, 
1H), 3.34 (ddd, J = 1.8, 4.2, 10.6, 1H), 2.88 (dd, J = 5.0, 13.8, 1H), 2.81 (dd, J = 8.2, 13.8, 1H), 
2.01-2.04 (m, 1H), 1.92-1.98 (m, 1H), 1.73 (d, J = 6.4, 3H), 1.72 (br, 1H), 1.58-1.67 (m, 1H), 
1.41-1.58 (m, 2H), 1.36 (m, 1H); 13C NMR (100 MHz, CDCl3) 138.5, 132.4, 129.4, 128.5, 126.5, 
126.3, 79.4, 78.5, 74.6, 38.7, 31.9, 24.9, 23.0, 17.9; IR (neat) 3360, 3029, 2960, 2928, 2912, 
2839, 1677, 1495, 1453, 1379, 1293, 1196, 1078, 1037, 748 cm-1; HRMS (ESI) calcd for 
C16H22O2Na [M + Na]+ 269.1517, found 269.1535.        
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(R)-2-phenyl-1-((2S,6S)-6-((E)-prop-1-en-1-yl)tetrahydro-2H-
pyran-2-yl)ethanol (3-22) 
1H NMR (400 MHz, CDCl3) δ 7.31-7.38 (m, 2H), 7.23-7.31 (m, 3H), 5.64-5.75 (m, 2H), 4.40-
4.46 (m, 1H), 3.87-3.93 (m, 1H), 3.64 (ddd, J = 2.2, 5.2, 9.0, 1H), 3.95 (dd, J = 3.6, 14.0, 1H), 
2.72 (dd, J = 9.0, 14.0, 1H), 1.92 (br, 1H), 1.78-1.86 (m, 1H), 1.76 (d, J = 4.8, 3H), 1.68-1.74 (m, 
3H), 1.56-1.67 (m, 2H); 13C NMR (100 MHz, CDCl3) 138.7, 130.6, 129.5, 128.5, 127.9, 126.4, 
73.9, 73.2, 72.8, 39.0, 29.2, 25.5, 18.4, 18.0; IR (neat) 3434, 3026, 2934, 2859, 1668, 1603, 
1494, 1452, 1202, 1077, 1035, 966, 890, 748 cm-1; HRMS (ESI) calcd for C16H22O2Na [M + 
Na]+ 269.1517, found 269.1496. 
 
The absolute configuration of the secondary alcohols in structures 3-19 to 3-22 were determined 
by Mosher ester analysis.71 Typically, 5-6 mg of each alcohol was divided into two parts, these 
two parts were treated with R and S Mosher acid  respectively: 2-3 mg alcohol, 5 equiv Mosher 
acid (R or S), 5.5 equiv DCC, 5.5 equiv DMAP in 1ml DCM.  The reactions were stirred at 20 
°C and monitored by TLC, when the starting alcohol was completely consumed, filter the 
reaction mixture through a short column of silica gel to remove the insoluble salts, then flush the 
column with DCM until all ester products are eluted. After the removal of the solvents under 
reduced pressure, 1H NMR and 19F NMR were taken to determine the confituration and 
enantiopurity of  the conrresponding alcohols.  
 
Structures 3-19 and 3-20, 3-21 and 3-22 were difficult to differentiate by 1H NMR , 14C NMR, 
COSY and NOESY. But it became easier to differentiate them once they are oxidized to the 
corresponding ketones since they have very different chemical shifts and splitting patterns for 
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those benzylic hydrogens.  The ketone products were obained by submitting the corresponding 
alcohols to the PCC oxidation conditions: typically, 2-7 mg of alcohol was treated with 5-10 
equiv PCC and celite in DCM until complete consumption of the alcohol, then the reaction 
mixture was filtered through a short column of silica gel to give the pure ketones. (yield: 92%-
97%) The sturctures 3-20 and 3-21 were also confirmed by X-ray crystallography. 
 
(2R,7R)-2-benzyl-7-((E)-prop-1-en-1-yl)oxepan-3-one 
1H NMR (400 MHz, CDCl3) δ 7.20-7.32 (m, 5H), 5.40-5.56 (m, 
2H), 4.03 (dd, J = 4.0, 8.4, 1H), 3.66 (d, J = 9.4, 1H), 3.06 (dd, J = 3.6, 14.0, 1H), 2.89 (dd, J = 
9.0, 14.0, 1H), 2.69 (dt, J = 2.4, 12.4, 1H), 2.32 (dd, J = 6.4, 12.0, 1H), 1.90-1.99 (m, 1H), 1.80-
1.88 (m, 1H), 1.64 (d, J = 6.0, 3H), 1.58-1.69 (m, 1H), 1.41-1.54 (m, 1H); 13C NMR (100 MHz, 
CDCl3) 216.3, 137.6, 131.8, 129.6, 128.1, 126.4, 125.7, 87.1, 83.2, 41.6, 39.2, 36.2, 23.3, 17.4; 
IR (neat) 3061, 3029, 2931,2859, 1711, 1603, 1495, 1452, 1434, 1319, 1173, 1107, 966, 735 cm-
1; HRMS (ESI) calcd for C16H20O2Na [M + Na]+ 267.1361, found 267.1350. 
 
(2R,7S)-2-benzyl-7-((E)-prop-1-en-1-yl)oxepan-3-one 
1H NMR (400 MHz, C6D6) δ 7.19-7.23 (m, 2H), 7.12-7.15 (m, 2H), 
7.04-7.09 (m, 1H), 5.11-5.27 (m, 2H), 4.08 (dd, J = 3.6, 8.8, 1H), 3.91 (m, 1H), 3.23 (dd, J = 3.6, 
14.4, 1H),  2.79 (dd, J = 8.8, 14.4, 1H), 2.46-2.54 (m, 1H), 2.27-2.36 (m, 1H), 1.41 (d, J = 5.6, 
3H), 1.32-1.37 (m, 3H), 1.22-1.32 (m, 1H); 13C NMR (100 MHz, C6D6) 212.9, 138.5, 130.9, 
129.8, 127.6, 126.5, 126.1, 81.3, 76.4, 40.2, 37.0, 33.1, 21.3, 17.4; IR (neat) 3061, 3028, 2933, 
2863, 1711, 1604, 1459, 1452, 1324, 1180, 1093, 968, 785 cm-1; HRMS (ESI) calcd for 
C16H20O2Na [M + Na]+ 267.1361, found 267.1379. 
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2-phenyl-1-((2S,6R)-6-((E)-prop-1-en-1-yl)tetrahydro-2H-pyran-2-
yl)ethanone (3-31cis) 
1H NMR (400 MHz, C6D6) δ 7.22-7.28 (m, 2H), 7.12-7.17 (m, 2H), 7.03-7.09 (m, 1H), 5.65 (ddq, 
J = 0.8, 6.4, 15.2, 1H), 5.53 (ddq, J = 1.6, 5.6, 15.2, 1H), 3.92 (d, J = 15.2, 1H), 3.84 (d, J = 15.2, 
1H), (3.61 (dd, J = 2.4, 11.2, 1H), 3.51 (ddt, J =1.2, 5.6, 10.2, 1H), 1.70-1.76 (m, 1H), 1.60 (dt, J 
= 1.2, 6.4, 3H), 1.43-1.49 (m, 1H), 1.25-1.30 (m, 1H), 1.02-1.21 (m, 3H); 13C NMR (100 MHz, 
C6D6) 206.7, 134.7, 132.5, 130.0, 128.3, 126.5, 125.5, 82.0, 78.0, 44.7, 31.4, 27.5, 22.9, 17.6; IR 
(neat) 3061, 3029, 2936, 2855, 1722, 1601, 1495, 1452, 1299, 1199, 1095, 1034, 965, 742, 702 
cm-1; HRMS (ESI) calcd for C16H20O2Na [M + Na]+ 267.1361, found 267.1406. 
 
2-phenyl-1-((2S,6S)-6-((E)-prop-1-en-1-yl)tetrahydro-2H-pyran-2-
yl)ethanone (3-31trans) 
1H NMR (400 MHz, CDCl3) δ 7.30-7.35 (m, 2H), 7.22-7.28 (m, 3H), 
5.72 (ddt, J = 1.2, 6.4, 15.2, 1H), 5.56 (ddt, J = 1.6, 5.6, 15.2, 1H), 4.30 (t, J = 5.0, 1H), 4.11 (t, J 
= 5.6, 1H), 3.95 (d, J = 15.2, 1H), 3.85 (d, J = 15.2, 1H), 1.83-1.91 (m, 1H), 1.74 (dt, J = 1.2, 6.4, 
3H), 1.64-1.72 (m, 3H), 1.44-1.62 (m, 2H); 13C NMR (100 MHz, CDCl3) 209.6, 134.2, 131.0, 
128.5, 128.0, 126.8, 77.3, 74.4, 45.3, 30.2, 25.2, 19.3, 17.9; IR (neat) 3029, 2936, 2854, 1717, 
1601, 1495, 1453, 1260, 1202, 1084, 1028, 965, 797 cm-1; HRMS (ESI) calcd for C16H20O2Na 
[M + Na]+ 267.1361, found 267.1359. 
 
Isomerization of 3-31cis and 3-31trans: to of a mixture of 3-31cis and 3-31trans (14.9 mg, 
0.061 mmol, dr = 5:4) in 5 ml DCM was added Re2O7 (1.5 mg, 0.003 mmol), reaction was 
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stirred at 20 °C for 4 h before quenched  with 5 drops of pyridine (measured by pipet). After 
evaporation of the solvent, the crude mixture was purified by flash chromatography (5%-10% 
ethyl acetate in hexanes) to give the product (11.5 mg, 73%, dr = 11.5:1). 
 
Synthesis of 3-32cis and 3-32trans: at 0 °C, to a mixture of 3-21 and 3-22 (27.4 mg, 0.111 
mmol, dr = 1:1) in 3ml THF was added 60% NaH dispersed in mineral oil (8.9 mg, 0.222 mmol) 
followed by addtion of MeI (31.6 mg, 0.222 mmol), then stirred at 20 °C for 6h and quenched 
with saturated NH4Cl solution (10 ml). Then the mixture was extracted by ether (3*20 ml), the 
organic layer was combined and concentrated under reduced pressure. The crude mixture was 
purified by flash chromatography (5%-10% ethyl acetate in hexanes) to give the product (25.6 
mg, 88%, dr = 1:1). 
 
Isomerization of 3-32cis and 3-32trans: to of a mixture of 3-32cis and 3-32trans (12.4 mg, 
0.048 mmol, dr = 1:1) in 2 ml DCM was added Re2O7 (1.2 mg, 0.0023 mmol), reaction was 
stirred at 20 °C for 5 h before quenched with 5 drops of pyridine. After evaporation of the 
solvent, the crude mixture was purified by flash chromatography (5%-10% ethyl acetate in 
hexanes) to give the product (11.2 mg, 90%, dr > 30:1). 
 
(2S,6R)-2-((R)-1-methoxy-2-phenylethyl)-6-((E)-prop-1-en-1-yl) 
tetrahydro-2H-pyran (3-32cis) 
1H NMR (400 MHz, CDCl3) δ 7.20-7.35 (m, 5H), 5.73 (dt, J = 6.4, 15.6, 1H), 5.56 (dd, J = 4.4, 
15.6, 1H), 3.74 (dd, J = 5.6, 10.4, 1H), 3.41 (q, J = 6.0, 1H), 3.36 (s, 3H), 3.23 (ddd, J = 1.8, 5.8, 
11.0, 1H), 2.95 (dd, J = 4.4, 14.0, 1H), 2.85 (dd, J = 6.8, 14.0, 1H), 1.86-1.94 (m, 1H), 1.76-1.82 
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(m, 1H), 1.74 (d, J = 6.4, 3H), 1.59-1.66 (m, 1H), 1.44-1.56 (m, 1H), 1.28-1.41 (m, 2H); 13C 
NMR (100 MHz, CDCl3) 139.0, 132.7, 129.7, 128.1, 126.0, 125.9, 84.8, 78.7, 78.2, 58.8, 36.7, 
31.9, 26.7, 23.3, 17.9; IR (neat) 3061, 3027, 2932, 2855, 1603, 1495, 1453, 1352, 1301, 1196, 
1103, 1037, 964, 749 cm-1; HRMS (ESI) calcd for C17H24O2Na [M + Na]+ 283.1674, found 
283.1684. 
 
(2S,6S)-2-((R)-1-methoxy-2-phenylethyl)-6-((E)-prop-1-en-1-yl) 
tetrahydro-2H-pyran (3-32trans) 
1H NMR (400 MHz, CDCl3) δ 7.24-7.33 (m, 4H), 7.18-7.24 (m, 1H), 5.55-5.69 (m, 2H), 3.58 
(ddd, J = 2.4, 6.0, 9.6, 1H), 3.41 (ddd, J = 4.0, 6.8, 7.2, 1H), 3.27 (s, 3H), 3.98 (dd, J = 3.6, 14.0, 
1H), 3.75 (dd, J = 7.2, 14.0, 1H), 1.62-1.82 (m, 4H), 1.71 (d, J = 5.2, 3H), 1.46-1.60 (m, 2H); 13C 
NMR (100 MHz, CDCl3) 139.3, 130.9, 129.7, 128.1, 127.6, 125.9, 83.8, 72.9, 71.9, 58.7, 36.8, 
29.5, 26.5, 18.8, 18.0; IR (neat) 3061, 3027, 2932, 2824, 1603, 1494, 1453, 1378, 1352, 1200, 
1105, 1036, 966, 887, 749 cm-1; HRMS (ESI) calcd for C17H24O2Na [M + Na]+ 283.1674, found 
283.1678. 
 
H
Ph
O OH
OH
Reaction conditions:
a) BuLi, THF, TMSCl, -78 ºC to rt, then 1.0N HCl, 91%; b) Cp2ZrCl2, AlMe3, (CH2Cl)2, then I2, THF;
c) MeOH, NaOMe, 65 ºC, 39% for two steps; d) TBSCl, imidazole, DMAP, CH2Cl2, 95%; e) Ni(PPh3)2Cl2,
Et2O, Benzylmagnesium bromide, rt, quantitive; f) TBAF, THF, rt, quantitive; g) TsCl, pyridine, DCM,
0 ºC, 94%; h) NaCN, DMSO, 90 ºC, 93%; i) DIBAL-H, DCM, -78 ºC to 0 ºC, 97%; j) Vinylmagnesium bromide,
THF, 83%; k) MCPBA, DCM, NaHCO3, 0 ºC, 87%.
H
Ph
OH
a-f g-k
 
Scheme B3 Synthesis of substrate 3-28 
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6-(3-benzyl-2-methyloxiran-2-yl)hex-1-en-3-ol (3-28) 
1H NMR (300 MHz, CD2Cl2) δ 7.28-7.35 (m, 2H), 7.19-7.28 (m, 3H), 
5.88 (ddd, J = 6.0, 10.2, 17.1, 1H), 5.24-5.26 (m, 0.5H), 5.18-5.20 (m, 
0.5H), 5.10-5.12 (m, 0.5H), 5.07-5.09 (m, 0.5H), 4.05-4.15 (m, 1H), 2.90-2.96 (m, 1H), 2.77-
2.88 (m, 2H), 1.78 (br, 1H), 1.50-1.70 (m, 6H), 1.28 (s, 3H); 13C NMR (75 MHz, CD2Cl2) 155.8, 
154.9, 131.2, 131.1, 130.5, 130.3, 99.8, 99.7, 63.3, 63.2, 32.6, 31.3, 31.1, 27.54, 27.1; IR (neat) 
3428, 3063, 3028, 2920, 2864, 1643, 1604, 1494, 1453, 1428, 1380, 1129, 1074, 1029, 993, 920, 
737 cm-1; HRMS (ESI) calcd for C16H22O2Na [M + Na]+ 269.1517, found 269.1541. 
 
 rac-(R)-1-((2R,6S)-2-methyl-6-vinyltetrahydro-2H-pyran-2-yl)-2-
phenylethan-1-ol (3-29) 
The general rearrangement procedure was followed with 3-28, the resulting products are non-
separable mixturex of two isomers, the ratio of which are shown in scheme 3.5 under different 
conditions. The following is the result for entry 7, in which the genera procudure was followed 
with 3-28 (21.3 mg, 0.0865 mmol), Re2O7, DCM (8.5 ml),  the reaction was conducted at -78 ºC 
for 10 hours, followed by quenching with 5 drops of pyridine. After removal of solvent under 
reduced pressure, flash chromatography (5%-10% ethyl acetate in hexanes) give 12.4 mg 3-29 
(58%, dr = 5.6 :1), 7.7 mg (36%) starting material was recoverd, 1H and 13C NMR of this 
recoverd material showed that only one isomer is left. The reaction was stirred at 20 °C for 12 
hrs. 1H NMR (400 MHz, CD2Cl2) δ 7.23-7.30 (m, 4H), 7.16-7.21 (m, 1H), 5.82 (ddd, J = 5.2, 
10.4, 17.2, 1H), 5.17 (dt, J = 1.6, 17.2, 1H), 5.04 (dt, J = 1.6, 10.4, 0.15H), 5.02 (dt, J = 1.6, 10.4, 
0.75H), 4.28 (dd, J = 2,8, 9.6, 0.15H), 4.09 (ddddd, J = 0.8, 1.2, 1.6, 4.0, 11.6, 1H), 3.58 (dt, J = 
2.8, 10.4, 0.85H), 2.76-2.83 (m, 1H), 2.50-2.65 (m, 2H), 1.71-1.79 (m, 2H), 1.62-1.70 (m, 1H), 
H
Ph
O OH
O
Ph
OH
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1.45-1.51 (m, 2H), 1.27-1.32 (m, 0.15H), 1.24 (s, 3H), 1.14-1.24 (m, 0.85H); 13C NMR (100 
MHz, CD2Cl2) 140.2, 129.3, 128.1, 125.9, 113.5, 80.5, 76.2, 71.0, 37.0, 31.7, 31.0, 19.3, 14.8; IR 
(neat) 3428, 3063, 3028, 2920, 2864, 1643, 1604, 1494, 1453, 1428, 1380, 1320, 1129, 1074, 
1029, 993, 920, 737 cm-1; HRMS (ESI) calcd for C16H22O2Na [M + Na]+ 269.1517, found 
269.1533. 
 
 
Scheme B4 Synthesis of substrate 3-33 
 
(E)-methyl 4-(3-(6-hydroxyhept-4-en-1-yl)oxiran-2-yl) 
butanoate (3-33) 
1H NMR (400 MHz, CDCl3) δ 5.58 (dt, J = 6.4, 15.2, 1H), 5.49 (dd, J = 6.4, 15.2, 1H), 4.22 (p, J 
= 6.0, 1H), 3.64 (s, 3H), 2.62-2.67 (m, 2H), 2.34 (dt, J = 1.4, 7.2, 2H), 2.01-2.08 (m, 2H), 1.82 
(br, 1H), 1.68-1.80 (m, 2H), 1.42-1.62 (m, 6H), 1.22 (d, J = 6.4, 3H); 13C NMR (100 MHz, 
CDCl3) 173.7, 134.8, 130.0, 68.7, 58.4, 58.2, 51.6, 33.6, 31.8, 31.40, 31.37, 25.5, 23.4, 21.5; IR 
(neat) 3433, 2928, 2860, 1737, 1438, 1367, 1248, 1169, 1117, 1061, 970, 893 cm-1; HRMS (ESI) 
calcd for C14H24O4Na [M + Na]+ 279.1572, found 279.1552. 
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(2R,2'S,6'R)-6'-((E)-prop-1-en-1-yl)hexahydro-2H,2'H-[2,2'-
bipyran]-6(3H)-one (3-34) 
The general rearrangement procedure was followed with 3-33 (32.0 
mg, 0.125 mmol), Re2O7 (3.0 mg, 0.006 mmol), and CH2Cl2 (12.5 mL). The reaction was stirred 
at 20 °C for 12 hrs. The solvent was then removed under reduced pressure and the reaction 
mixture was kept at high vaccum for 1hr, after which the reaction mixture was redispersed in 
CH2Cl2 (12.5 mL) and 5% more catalyst was added. The reaction mixture was stirred at 20 °C 
for another 12 hrs before quenched with 5 drops of pyridine. After the removal of solvent under 
reduced pressure, the crude mixture was purified by flash chromatography (20%-30% ethyl 
acetate in hexanes) to give the product (23.0 mg, purity: 87%, 71% with respect to the desired 
product). 1H NMR (400 MHz, CDCl3) δ 5.66 (ddq,  J = 0.8, 6.4, 15.2, 1H), 5.46 (ddq, J = 1.2, 
6.0, 15.2, 1H), 4.17 (ddd, J = 3.6, 6.4, 10.4, 1H), 3.79 (dd, J = 6.0, 10.4, 1H), 3.42 (ddd, J = 2.0, 
6.0, 11.2, 1H), 2.52-2.62 (m, 1H), 2.41-2.51 (m, 1H), 2.06-2.14 (m, 1H), 1.75-1.98 (m, 4H), 1.68 
(d, J = 6.4, 3H), 1.57-1.72 (m, 2H), 1.46-1.56 (m, 1H), 1.20-1.37 (m, 2H); 13C NMR (100 MHz, 
CDCl3) 171.5, 132.2, 126.4, 82.5, 78.8, 78.3, 31.6, 29.8, 27.2, 24.0, 22.9, 18.1, 17.9; IR (neat) 
2935, 2855, 1738, 1440, 1346, 1240, 1203, 1169, 1089, 1049, 965, 933 cm-1; HRMS (ESI) calcd 
for C13H21O3 [M + H]+ 225.1491, found 225.1481. 
 
OBn
OBnOOHOH
a-d
Reaction Conditions:
1) PCC, celite, rt; b) BnOH, PTSA•H2O, DCM, Na2SO4, rt, 67% for two steps; c) MCPBA, NaHCO3,
DCM, 0 ºC, 57%; d) (Z)-hex-3-ene-2,5-diol, Hoveyda-Grubbs 2nd, DCM, rt, 73%.
(From Scheme B4)
 
Scheme B5 Synthesis of substrate 3-35 
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(E)-7-(3-(4,4-bis(benzyloxy)butyl)oxiran-2-yl)hept-3-en-
2-ol (3-35) 
1H NMR (400 MHz, CDCl3) δ 7.34-7.40 (m,8H), 7.28-7.34 (m, 2H), 5.63 (dt, J = 6.4, 15.2, 1H), 
5.54 (dd, J = 6.4, 15.2, 1H), 4.76 (t, J = 6.0, 1H), 4.68 (dd, J = 0.8, 12.0, 2H), 4.58 (d, J = 12.0, 
2H), 4.26 (p, J = 6.4, 1H), 2.62-2.70 (m, 2H), 2.03-2.13 (m, 2H), 1.76-1.86 (m, 2H), 1.64 (br, 
1H), 1.45-1.62 (m, 8H), 1.26 (d, J = 6.4, 3H); 13C NMR (100 MHz, CDCl3) 138.2, 134.8, 130.2, 
128.5, 127.8, 127.7, 101.9, 68.8, 67.33, 67.28, 58.6, 33.1, 31.9, 31.8, 31.5, 25.6, 23.5, 21.4; IR 
(neat) 3444, 3030, 2929, 2863, 1605, 1496, 1454, 1366, 1307, 1207, 1123, 1046, 970, 737 cm-1; 
HRMS (ESI) calcd for C27H36O4Na [M + Na]+ 447.2511, found 447.2531. 
 
(2R,2'S,6R,6'R)-6-(benzyloxy)-6'-((E)-prop-1-en-1-yl)octahydro-
2H,2'H-2,2'-bipyran (3-36a) 
The general rearrangement procedure was followed with 3-35 (25.0 
mg, 0.059 mmol), 10% Re2O7 on SiO2 (14.3 mg, 0.003 mmol), and CH2Cl2 (12.0 mL). The 
reaction was stirred at -25 °C for 8 hrs (when all starting materials was consumed) and then 20 
°C for another 10 hrs before quenched with five drops of pyridine. After evaporation of the 
solvent, the crude mixture was purified by flash chromatography (2%-5% ethyl acetate in 
hexanes) to give the product (11.5 mg, 62%, dr = 5:2). 1H NMR (400 MHz, C6D6) δ 7.35-7.39 
(m, 2H), 7.16-7.21 (m, 2H), 7. 07-7.13 (m, 1H), 5.69 (ddq, J = 0.8, 6.4, 15.2, 1H), 5.59 (ddq, J = 
1.2, 5.2, 15.2, 1H), 4.88 (d, J = 2.8, 1H), 4.80 (d, J = 12.0, 1H), 4.39 (d, J = 12.0, 1H), 3.91 (ddd, 
J = 2.0, 6.8, 10.8, 1H), 3.74 (dd, J = 5.2, 9.6, 1H), 3.33 (ddd, J = 2.0, 6.8, 10.4, 1H), 2.00-2.07 
(m, 1H), 1.88-1.99 (m, 2H), 1.61-1.75 (m, 2H), 1.58 (dt, J = 1.2, 6.4, 3H), 1.27-1.54 (m, 7H); 13C 
NMR (100 MHz, C6D6) 138.8, 133.3, 128.2, 127.9, 127.3, 124.6, 96.2, 80.3, 77.9, 71.8, 68.8, 
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32.2, 30.0, 27.9, 27.8, 23.3, 18.0, 17.6; IR (neat) 3029, 2932, 2854, 1496, 1453, 1440, 1360, 
1302, 1195, 1126, 1079, 1036, 964, 734 cm-1; HRMS (ESI) calcd for C20H28O3Na [M + Na]+ 
339.1936, found 339.1923. 
 
(2R,2'S,6S,6'R)-6-(benzyloxy)-6'-((E)-prop-1-en-1-yl) octahydro 
-2H,2'H-2,2'-bipyran (3-36b) 
1H NMR (400 MHz, C6D6) δ 7.36-7.40 (m, 2H), 7.17-7.21 (m, 2H), 7.08-7.12 (m, 1H), 5.55-5.70 
(m, 2H), 4.95 (d, J = 12.0, 1H), 4.55 (d, J = 12.0, 1H), 4.33 (dd, J = 2.0, 9.2, 1H), 3.72 (dd, J = 
4.8, 10.0, 1H), 3.38 (ddd, J = 2.0, 7.2, 10.4, 1H), 5.25 (ddd, J = 2.0, 7.2,10.4, 1H), 1.96-2.02 (m, 
1H), 1.88-1.94 (m, 1H), 1.64-1.76 (m, 2H), 1.58 (d, J = 6.0, 3H), 1.50-1.61 (m, 2H), 1.41-1.49 
(m, 1H), 1.14-1.40 (m, 5H); 13C NMR (100 MHz, C6D6) 138.7, 133.2, 128.2, 127.6, 127.3, 
124.8, 101.3, 80.2, 78.9, 77.9, 69.4, 32.3, 31.5, 28.2, 27.8, 23.2, 21.8, 17.6; IR (neat) 3030, 2933, 
2854, 1496, 1453, 1439, 1360, 1305, 1261, 1199, 1123, 1086, 1024, 964, 732 cm-1; HRMS (ESI) 
calcd for C20H28O3Na [M + Na]+ 339.1936, found 339.1945. 
 
OOHOH
a-d
Reaction Conditions:
1) PCC, celite, rt; b) 60% NaH on Mineral oil, Diethyl (20oxopropyl)Phosphonate, THF, 0 C,78%
 for two steps; c) MCPBA, NaHCO3,DCM, 0 ºC,66%; d) (Z)-hex-3-ene-2,5-diol, Hoveyda-Grubbs 2nd,
DCM, RT,56%.
(From Scheme B4)
O
 
Scheme B6 Synthesis of substrate 3-37 
 
(E)-7-(3-((E)-6-hydroxyhept-4-en-1-yl)oxiran-2-
yl)hept-3-en-2-one (3-37) 
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1H NMR (400 MHz, CDCl3) δ 6.78 (dt, J = 6.8, 16.0, 1H), 6.08 (d, J = 16.0, 1H), 5.62 (dt, J = 
6.4, 15.2, 1H), 5.52 (dd, J = 6.4, 15.2, 1H), 5.26 (p, J = 6.4, 1H), 2.64-2.69 (m, 2H), 2.28 (q, J = 
6.8, 2H), 2.24 (s, 3H), 2.03-2.10 (m, 2H), 1.57-1.70 (m, 4H), 1.45-1.57 (m, 5H), 1.25 (d, J = 6.4, 
3H); 13C NMR (100 MHz, CDCl3) 198.7, 147.6, 134.8, 131.6, 130.1, 68.8, 58.5, 58.3, 32.1, 31.8, 
31.5, 31.4, 27.0, 25.5, 24.6, 23.5; IR (neat) 3446, 2969, 2930, 2859, 1673, 1626, 1454, 1363, 
1255, 1145, 1062, 974, 894 cm-1; HRMS (ESI) calcd for C16H26O3Na [M + Na]+ 289.1780, 
found 289.1795. 
 
1-((2R,2'S,6S,6'R)-6'-((E)-prop-1-en-1-yl)octahydro-2H,2'H-
[2,2'-bipyran]-6-yl)propan-2-one (3-38) 
The general rearrangement procedure was followed with 3-37 (22.0 mg, 0.083 mmol), Re2O7 
(2.0 mg, 0.004 mmol), and CH2Cl2 (8.3 mL). The reaction was stirred at 20 °C for 3.5 days and 
then quenched with five drops of pyridine. Me2(Bn)SiH (5 µl) was added as an internal standard 
and crude NMR was used to determine the yield of 59% (dr >20:1). 1H NMR (400 MHz, CDCl3) 
δ 5.66 (ddq, J = 0.8, 6.4, 15.2, 1H), 5.49 (ddq, J = 1.6, 6.0, 15.2, 1H), 3.72-3.81 (m, 2H), 3.15-
3.25 (m, 2H), 2.64 (dd, J = 8.2, 15.0, 1H), 2.42 (dd, J = 4.6, 15.0, 1H), 2.18 (s, 3H), 1.76-1.95 (m, 
2H), 1.68 (d, J = 6.4, 3H), 1.55-1.64 (m, 2H), 1.42-1.55 (m, 2H), 1.11-1.34 (m, 4H); 13C NMR 
(100 MHz, CDCl3) 207.9, 132.6, 126.2, 80.8, 80.3, 78.1, 74.7, 50.5, 31.9, 31.7, 30.8, 28.0, 27.9, 
23.1, 23.0, 17.9; IR (neat) 2928, 2846, 1707, 1439, 1405, 1379, 1360, 1319, 1305, 1194, 1170, 
1091, 1042, 963 cm-1; HRMS (ESI) calcd for C16H26O3 [M]+ 289.1780, found 289.1766. 
 
1-((2R,2'S,6S,6'S)-6'-((E)-prop-1-en-1-yl)octahydro-2H,2'H-
[2,2'-bipyran]-6-yl)propan-2-one 
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Minor product obtained when quenched before isomerization is complete: the general 
rearrangement procedure was followed with 3-37 (23.0 mg, 0.086 mmol), Re2O7 (2.1 mg, 0.004 
mmol), and CH2Cl2 (8.6 mL). The reaction was stirred at 20 °C for 12hrs and then quenched 
with five drops of pyridine. Me2(Bn)SiH (5 µl) was added as an internal standard and crude 
NMR was used to determine the yield of 67% (dr = 3:1). 1H NMR (400 MHz, CDCl3) δ 5.65 
(ddq, J = 0.8, 6.4, 15.2, 1H), 5.53 (ddq, J = 1.6, 5.2, 15.2, 1H), 4.18-4.25 (m, 1H), 3.78 (dddd, J 
= 2.4, 4.8, 8.4, 10.4, 1H), 3.54 (dt, J = 3.2, 7.6, 1H), 3.39 (ddd, J = 1.6, 7.6, 11.2, 1H), 2.67 (dd, J 
= 8.4, 15.2, 1H), 2.42 (dd, J = 4.4, 15.2, 1H), 2.18 (s, 3H), 1.80-1.91 (m, 2H), 1.71 (d, J = 6.4, 
3H), 1.41-1.69 (m, 8H), 1.13-1.30 (m, 2H); 13C NMR (100 MHz, CDCl3) 207.7, 131.4, 127.3, 
78.6, 74.8, 73.7, 72.5, 50.3, 31.6, 30.9, 29.8, 27.6, 26.6, 23.1, 18.6, 17.9; IR (neat) 2932, 2857, 
1716, 1440, 1357, 1262, 1198, 1090, 1044 965, 889 cm-1; HRMS (ESI) calcd for C16H26O3 [M]+ 
289.1780, found 289.1776. 
 
 
Scheme B7 Synthesis of substrate 3-30 
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(E)-7-(3-((E)-6-hydroxyhept-4-en-1-yl)-2-
methyloxiran-2-yl)hept-3-en-2-one (3-39) 
1H NMR (300 MHz, CDCl3) δ 6.75 (dt, J = 6.9, 15.9, 1H), 6.04 (dt, J = 1.5, 15.9, 1H), 5.46-5.65 
(m, 2H), 4.23 (p, J = 6.3, 1H), 2.64-2.70 (m, 1H), 2.16-2.26 (m, 2H), 2.21 (s, 3H), 2.01-2.10 (m, 
2H), 1.87 (br, 1H), 1.41-1.65 (m, 8H), 1.22 (d, J = 6.3, 3H), 1.21 (s, 3H); 13C NMR (75 MHz, 
CDCl3) 198.7, 147.6, 134.9, 131.5, 130.0, 68.7, 63.3, 60.5, 60.4, 38.1, 32.3, 31.8, 28.1, 26.9, 
26.0, 23.7, 23.5, 16.5; IR (neat) 3447, 2928, 2861, 1673, 1626, 1457, 1363, 1255, 1145, 1063, 
974, 865 cm-1; HRMS (ESI) calcd for C17H27O3 [M-H]+ 279.1960, found 279.1962. 
 
1-((2R,2'S,6S,6'R)-2-methyl-6'-((E)-prop-1-en-1-yl)octahydro-
2H,2'H-[2,2'-bipyran]-6-yl)propan-2-one (3-40) 
The general rearrangement procedure was followed with 3-39 
(44.5 mg, 0.159 mmol), Re2O7 (3.8 mg, 0.008 mmol), and CH2Cl2 (8.6 mL). The reaction was 
stirred at 20 °C for 20hrs and then quenched with five drops of pyridine. Me2(Bn)SiH (5 µl) was 
added as an internal standard and crude NMR was used to determine the yield of 85% (3-40:3-41 
= 3:2) 1H NMR (400 MHz, CD2Cl2) δ 5.61 (ddq, J = 1.2, 6.4, 15.2, 1H), 5.44 (ddq, J = 1.6, 5.2, 
15.2, 1H), 3.97 (dddd, J = 2.4,4.4, 8.4, 11.2, 1H), 3.72 (dd, J = 5.6, 11.2, 1H), 3.04 (dd, J = 1.6, 
11.2, 1H), 2.45 (dd, J = 8.4, 14.8, 1H), 2.34 (dd, J = 4.4, 14.8, 1H), 2.10 (s, 3H), 1.78-1.85 (m, 
1H), 1.60-1.71 (m, 3H), 1.65 (d, J = 6.4, 3H), 1.50-1.60 (m, 3H), 1.40-1.49 (m, 1H), 1.05-1.29 
(m, 4H), 1.12 (s, 3H); 13C NMR (100 MHz, CD2Cl2) 207.5, 133.1, 125.0, 85.6, 78.3, 75.2, 67.1, 
50.9, 33.0, 32.3, 31.8, 30.3, 24.1, 23.5, 19.2, 17.5, 14.9; IR (neat) 2932, 2854, 1716, 1439, 1369, 
1281, 1206, 1187, 1102, 1050, 963 cm-1; HRMS (ESI) calcd for C17H27O3 [M-H]+ 279.1960, 
found 279.1962. 
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1-((2R,2'S,6R,6'R)-2-methyl-6'-((E)-prop-1-en-1-yl)octahydro 
-2H,2'H-[2,2'-bipyran]-6-yl)propan-2-one (3-41) 
1H NMR (400 MHz, CD2Cl2) δ 5.61 (ddq, J = 1.2, 6.4, 15.2, 1H), 5.44 (ddq, J = 1.6, 5.2, 15.2, 
1H), 3.90 (dddd, J = 2.0,4.4, 7.6, 12.0, 1H), 3.79 (dd, J = 1.6, 11.2, 1H), 3.73 (dd, J = 5.6, 11.2, 
1H), 2.53 (dd, J = 8.0, 15.2, 1H), 2.29 (dd, J = 4.4, 15.6, 1H), 2.10 (s, 3H), 1.96-2.03 (m, 1H), 
1.84-1.91 (m, 1H), 1.45-1.73 (m, 5H), 1.65 (dt, J = 1,2, 6.4, 3H), 1.16-1.28 (m, 5H), 1.01 (s, 3H); 
13C NMR (100 MHz, CD2Cl2) 207.4, 135.1, 125.0, 78.5, 75.3, 74.9, 67.2, 50.7, 32.2, 31.7, 31.2, 
31.1, 23.7, 23.6, 23.3, 18.9, 17.5; IR (neat) 2933, 2857, 1718, 1441, 1359, 1206, 1075, 1046, 
965, 837 cm-1; HRMS (ESI) calcd for C17H29O3 [M+H]+ 281.2117, found 281.2124. 
 
HO Ph
OH
R
a-c
Reaction Conditions:
a) PCC, celite, DCM, 20 ºC; b) Pent-4-en-1-ylmagnesium bromide, Et2O, 0 ºC, 70% for two steps; c) PCC
celite, DCM, 20 ºC, 93%; d) MCPBA, NaHCO3, DCM, 0 ºC, 52%; e) But-2-ene-1,4-diol (R = H) or (Z)-hex-3-
ene-2,5-diol (R = CH3), Hoveyda-Grubbs 2nd, DCM, 20 ºC, 59% (R = H, dr = 9 :1) or 75% (R = CH3)
(From Scheme B1)
O
Ph
O
O
Ph
d-e
 
Scheme B8 Synthesis of substrates 3-42 (R = H) and 3-44 (R = CH3) 
 
(E)-1-(3-benzyloxiran-2-yl)-10-hydroxydec-8-en-4-
one (3-42) 
1H NMR (400 MHz, CDCl3) δ 7.29-7.35 (m, 2H), 7.22-7.27 (m, 3H), 5.59-5.69 (m, 2H), 4.08 (d, 
J = 2.0, 2H), 2.88-2.96 (m, 2H), 2.75-2.83 (m, 2H), 2.41 (d, J = 7.2, 2H), 2.37 (d, J = 7.2, 2H), 
2.01-2.11 (m, 2H), 1.92 (br, 1H), 1.56-1.77 (m, 5H), 1.49 (p, J = 7.2, 1H); 13C NMR (100 MHz, 
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CDCl3) 210.6, 137.3, 131.8, 130.0, 128.9, 128.6, 126.6, 63.5, 58.6, 58.4, 42.0, 41.9, 38.4, 31.6, 
31.2, 23.0, 20.2; IR (neat) 3443, 3027, 2934, 2863, 1709, 1604, 1494, 1453, 1410, 1089, 1001, 
972, 744 cm-1; HRMS (ESI) calcd for C19H27O3 [M + H]+ 303.1960, found 303.1942. 
 
(R)-2-phenyl-1-((2S,6S,8S)-8-vinyl-1,7-dioxaspiro[5.5]undecan-2-yl) 
ethanol (3-43) 
The general rearrangement procedure was followed with 3-42 (33.9 mg, 
0.112 mmol), Re2O7 (2.7 mg, 0.006 mmol), and CH2Cl2 (11.2 mL). The reaction was stirred at 
20 °C for 20 hrs and then quenched with five drops of pyridine. After evaporation of the solvent, 
the crude mixture was purified by flash chromatography (10%-15% ethyl acetate in hexanes) to 
give the product (31.5 mg, 93%). 1H NMR (400 MHz, CDCl3) δ 7.23-7.37 (m, 5H), 5.85 (ddd, J 
= 5.6, 10.4, 17.2, 1H), 5.20 (dt, J = 1.6, 17.2, 1H), 5.09 (dt, J = 1.6, 10.4, 1H), 4.04 (ddddd, J = 
0.8, 1.2, 2.6, 5.6, 11.2, 1H), 3.86 (p, J = 4.4, 1H), 3.00 (dd, J = 4.0, 14.0, 1H), 2.68 (dd, J = 9.2, 
14.0, 1H), 1.86-2.04 (m, 3H), 1.74-1.82 (m, 1H), 1.57-1.73 (m, 5H), 1.41-1.51 (m, 2H), 1.27-
1.41 (m, 2H); 13C NMR (100 MHz, CDCl3) 139.4, 138.9 129.3, 128.5, 126.4, 114.5, 96.6, 75.1, 
71.7, 70.0, 39.3, 35.5, 35.0, 30.6, 24.9, 18.7, 18.2; IR (neat) 3470, 3062,2938, 2868, 1646, 1603, 
1495, 1453, 1438, 1373, 1279, 1222, 1142, 1059, 980, 915, 747 cm-1; HRMS (ESI) calcd for 
C19H27O3 [M + H]+ 303.1960, found 303.1979. 
 
(E)-1-(3-benzyloxiran-2-yl)-10-hydroxyundec-8-en-4-
one (3-44) 
1H NMR (400 MHz, CDCl3) δ 7.28-7.33 (m, 2H), 7.20-7.26 (m, 3H), 5.48-5.61 (m, 2H), 4.24 (p, 
J = 6.4, 1H), 2.87-2.93 (m, 2H), 2.73-2.82 (m, 2H), 2.39 (t, J = 7.6, 2H), 2.35 (t, J = 7.6, 2H), 
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2.06 (br, 1H), 2.00 (q, J = 6.8, 2H), 1.54-1.74 (m, 5H), 1.48 (p, J = 7.2, 1H), 1.24 (d, J = 6.4, 
3H); 13C NMR (100 MHz, CDCl3) 210.5, 137.3, 135.2, 129.6, 128.9, 128.6, 126.6, 68.6, 58.6, 
58.4, 42.0, 41.9, 38.4, 31.5, 31.2, 23.5, 23.1, 20.2; IR (neat) 3450, 3061, 2968, 2930, 1709, 1604, 
1494, 1452, 1409, 1370, 1138, 1063, 970, 743 cm-1; HRMS (ESI) calcd for C20H29O3 [M + H]+ 
317.2117, found 317.2095. 
 
(R)-2-phenyl-1-((2S,6S,8S)-8-((E)-prop-1-en-1-yl)-1,7-dioxaspiro 
[5.5]undecan-2-yl)ethanol (3-45) 
The general rearrangement procedure was followed with 3-44 (12.0 mg, 
0.038 mmol), O3ReOSiPh3 (1.0 mg, 0.002 mmol), and CH2Cl2 (3.8 mL). The reaction was 
initiated at -78 °C followed by warming to -30 °C, stir at  -30 °C (90 min) until complete 
consumption of starting compound, then the reaction mixture was warmed up to 0 °C and strred 
at 0 °C for 4 hrs. The final isomerization was monitored closely by TLC, the reaction was 
quenched immediately with five drops of pyridine when the mixture of isomers change to one 
major with tiny amount of minor product (Longer reaction time increase the ration between 
major and minor products with the price of reduced yield). After evaporation of the solvent, the 
crude mixture was purified by flash chromatography (10%-15% ethyl acetate in hexanes) to give 
the product (8.5 mg, 71%). 1H NMR (400 MHz, CDCl3) δ 7.21-7.35 (m, 5H), 5.55 (ddq, J = 0.8, 
6.4, 15.6, 1H), 5.46 (ddq, J = 1.2, 6.4, 15.6, 1H), 3.94 (dd, J = 6.0, 11.6, 1H), 3.85 (p, J = 4.4, 
1H), 3.58 (ddd, J = 2.4, 4.8, 11.6, 1H), 2.98 (dd, J =  4.4, 13.6, 1H), 2.68 (dd, J = 9.2, 13.6, 1H), 
1.97 (br, 1H), 1.88 (tq, J = 4.0, 12.8, 2H), 1.72-1.80 (m, 1H), 1.69 (d, J = 6.4, 3H), 1.54-1.66 (m, 
5H), 1.35-1.48 (m, 3H), 1.25-1.34 (m, 1H); 13C NMR (100 MHz, CDCl3) 138.8, 132.3, 129.3, 
128.5, 126.9, 126.3, 96.6, 75.1, 71.5, 70.0, 39.3, 35.5, 35.0,30.8, 24.8, 18.8, 18.3, 17.9; IR (neat) 
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3464, 3060, 2937, 2868, 1603, 1495, 1453, 1439, 1377, 1279, 1221, 1203, 1142, 1042, 979, 746 
cm-1; HRMS (ESI) calcd for C20H29O3 [M + H]+ 317.2117, found 317.2141. 
 
HO
O O
O
Cl O
OMe
Reaction Cconditions:
a) Pent-4-en-1-ylmagnesium bromide, Et2O, 0 ºC, 74%; B) DIBAL-H, CH2Cl2, -78 ºC, 88%;
c) DMSO, (COCl)2, Et3N, CH2Cl2; d) Diethyl (2-oxopropyl)phosphonate, NaH, THF, 79%
for two steps; e) (Z)-2-Butene-1,4-diol, Grubbs-Hoveyda 2nd generation matathesis catalyst,
CH2Cl2, 68%.
a-e
 
Scheme B9 Synthesis of substrate 3-53 
 
 (3E, 12E)-14-Hydroxytetradeca-3, 12-diene-2, 8-
dione (3-53) 
1H NMR (400 MHz, CDCl3) δ 6.74 (dt, J = 6.8, 16.0 Hz, 1H), 6.06 (dt, J = 1.6, 16.0 Hz, 1H), 
5.44-5.68 (m, 2H), 4.04-4.17 (m, 2H), 2.36-2.45 (m, 4H), 2.18-2.26 (m, 2H), 2.23 (s, 3H), 1.99-
2.09 (m, 2H), 1.75 (p, J = 7.6 Hz, 2H), 1.66 (p, J = 7.6 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 
210.1, 198.7, 147.3, 131.8, 130.0, 63.5, 42.1, 41.7, 31.8, 31.5, 26.9, 23.0, 21.9; IR (neat) 3445, 
3000, 2935, 1709, 1672, 1626, 1413, 1363, 1256, 1186, 1090, 974 cm-1; HRMS (EI) calcd for 
C14H22O3 [M]+ 238.1569, found 238.1595. 
 
1-(2-vinyl-3,4,5,6,7,8-hexahydro-2H-chromen-5-yl)propan-2-one (3-58) 
The general rearrangement procedure was followed with 3-53 (25.0 mg, 0.105 
mmol), Re2O7 (2.5 mg, 0.005 mmol), and CH2Cl2 (2.5 mL). The reaction was 
stirred at 20 °C 2h and then quenched with five drops of pyridine. After 
evaporation of the solvent, the crude mixture was purified by flash chromatography (5%-10% 
HO
O O
O
O
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ethyl acetate in hexanes) to give the product (12.9 mg, 56%). 1H NMR (400 MHz, CDCl3) δ 
5.84-5.96 (m, 1H), 5.29 (dt, J = 1.6, 17.2, 0.55H), 5.26 (dt, J = 1.6, 17.2, 0.45H), 5.13-5.19 (m, 
1H), 4.29-4.34 (m, 0.45H), 4.17-4.23 (m, 0.55H), 2.65 (dd, J = 4.0, 15.6, 0.55H), 2.51-2.61 (m, 
1.45H), 2.26-2.40 (m, 1H), 2.16 (d, J = 6.4, 3H), 2.08-2.12 (m, 2.45H), 1.85-1.98 (m, 2H), 1.50-
1.80 (m, 5H), 1.35-1.45 (m, 0.55). 13C NMR (100 MHz, CDCl3) 209.2, 209.1, 147.8, 147.3, 
138.2, 137.9, 115.7, 115.5, 106.2, 105.6, 75.4, 75.0, 48.1, 47.5, 34.7, 33.2, 30.63, 30.56, 28.9, 
28.3, 27.9, 27.63, 27.55, 23.4, 22.2, 20.4, 19.0; IR (neat) 2929, 2860, 1713, 1682, 1446, 1408, 
1360, 1241, 1167, 1080, 991, 925 cm-1; HRMS (ESI) calcd for C14H21O2 [M+H]+ 221.1536, 
found 221.1530. 
MeO P
O
MeO OTES
O
Cl O
OMe O
O
TESO
O
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a-d
e-g
h-i
Reaction conditions:
a) O3, Na2CO3, DCM, MeOH,-78 ºC, then Et3N, Ac2O, DCM, 0 ºC, 81%; b) Vinylmagnesium bromide, THF, -78 ºC
to rt, 49%; c) TESCl, DMAP, imidazole, DCM, rt, 89%; d) dimethyl methylphosphonate, nBuLi, THF, -78 ºC to rt,
62%; e) Pent-4-en-1-ylmagnesium bromide, Et2O, 0 ºC, 74%; f) DIBAL-H, -78 ºC, DCM, 88%; g) DMSO, (COCl)2, 
Et3N, DCM, -78 ºC to rt; h) NaH, THF, 0 ºC, 65% for two steps; i) Grubbs-Hoveyda 2nd generation matathesis 
catalyst, toluene, 110 ºC.  
Scheme B10 Synthesis of substrate 3-59 
 
Macrocycle (3-59) 
1H NMR (400 MHz, CDCl3) δ 6.70 (dt, J = 7.6, 15.6, 1H), 6.13 (dt, 
J = 1.2, 15.6, 1H), 5.28-5.43 (m, 2H), 4.98-4.04 (m, 1H), 2.48 (t, J 
= 6.8, 2H), 2.25-2.36 (m, 6H), 2.08-2.20 (m, 1H), 1.92-2.02 (m, 
1H), 1.78-1.85 (m, 2H), 1.59-1.72 (m, 4H), 1.39-1.59 (m, 2H), 1.22-1.34 (m, 4H), 1.12-1.22 (m, 
TESO
O
O
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2H), 0.93 (t, J = 8.0, 9H), 0.57 (q, J = 8.0, 6H); 13C NMR (100 MHz, CDCl3) δ 210.2, 201.8, 
146.8, 135.1, 131.8, 129.8, 73.5, 41.7, 40.9, 40.2, 38.3, 31.3, 31.2, 29.7, 29.5, 26.3, 25.1, 22.6, 
21.3, 6.8, 4.9. 
 
Macrocycle (3-60) 
The general rearrangement procedure was followed with 3-60 (10.0 mg, 
0.024 mmol), Re2O7 (1.2 mg, 0.002 mmol), and CH2Cl2 (6.0 mL). The 
reaction was stirred at 20 °C 3h and then quenched with five drops of pyridine. After evaporation 
of the solvent, the crude mixture was purified by flash chromatography (5%-10% ethyl acetate in 
hexanes) to give the product (2.8 mg, 41%). 1H NMR (400 MHz, CDCl3) δ 5.43-5.52 (m, 1H), 
5.33-5.37 (m, 1H), 4.65-4.70 (m, 1H), 2.73 (dd, J = 3.2, 15.2, 1H), 2.27-2.47 (m, 4H), 1.95-2.23 
(m, 5H), 1.85-1.95 (m, 1H), 1.77-1.84 (m, 1H), 1.66-1.77 (m, 3H), 1.50-1.65 (m, 4H), 1.21-1.59 
(m, 5H), 1.12-1.21 (m, 2H). 13C NMR (100 MHz, CDCl3) 211.0, 146.3, 130.6, 130.5, 105.0, 
72.0, 46.3, 42.8, 36.1, 31.2, 29.1, 27.7, 27.2, 26.6, 25.8, 25.6, 21.6, 21.4, 20.6; IR (neat) 2926, 
2855, 1709, 1676, 1444, 1409, 1375, 1244, 1170, 1139, 1085, 1012, 967 cm-1; HRMS (ESI) 
calcd for C19H29O2 [M+H]+ 289.2168, found 289.2220. 
 
HO Ph
a-c
Reaction Conditions:
a) PCC, celite, DCM, 20 ºC; b) But-3-en-1-ylmagnesium bromide, Et2O, 0 ºC, 77% for two steps; c) PCC
celite, DCM, 20 ºC, 86%; d) MCPBA, NaHCO3, DCM, 0 ºC, 49%; e) But-2-ene-1,4-diol, Hoveyda-Grubbs 
2nd, DCM, 20 ºC,71% (dr = 9 :1).
(From Scheme B1)
O
Ph
O
O
Ph
d-e
HO
 
Scheme B11 Synthesis of substrate 3-63 
O
O
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(E)-1-(3-benzyloxiran-2-yl)-9-hydroxynon-7-en-4-one 
(3-63) 
1H NMR (400 MHz, CD2Cl2) δ 7.27-7.33 (m, 2H), 7.19-7.26 (m, 3H), 5.57-5.68 (m, 2H), 4.01 
(br, 2H), 2.76-2.89 (m, 3H), 2.73 (t, J = 5.6, 1H), 2.43 (t, J = 7.2, 2H), 2.39 (t, J = 7.2, 2H), 2.22-
2.30 (m, 2H), 1.60-1.73 (m, 3H), 1.41-1.59 (m, 2H); 13C NMR (100 MHz, CD2Cl2) 209.9, 138.1, 
131.1, 130.5, 129.3, 128.8, 126.9, 63.6, 58.8, 58.6, 42.4, 42.3, 38.8, 31.6, 26.6, 20.5; IR (neat) 
3433,3027, 2929, 2862, 1710, 1494, 1453, 1410, 1373, 1089, 1007, 972, 745 cm-1; HRMS (ESI) 
calcd for C18H25O3 [M + H]+ 289.1804, found 289.1829. 
 
(R)-2-phenyl-1-((2S,5R,7S)-2-vinyl-1,6-dioxaspiro[4.5]decan-7-yl) 
ethanol (3-64) 
The general rearrangement procedure was followed with 3-63 (29.0 mg, 
0.101 mmol), Re2O7 (2.4 mg, 0.005 mmol), and CH2Cl2 (10.0 mL). The reaction was stirred at 
20 °C for 3 hrs and then quenched with five drops of pyridine. After evaporation of the solvent, 
the crude mixture was purified by flash chromatography (10%-15% ethyl acetate in hexanes) to 
give the product (27.5 mg, 95%, 32:33 = 50:49). 1H NMR (400 MHz, C6D6) δ 7.19-7.23 (m, 2H), 
7.13-7.19 (m, 2H), 7.05-7.10 (m, 1H), 5.82 (ddd, J = 6.4, 10.4, 16.8, 1H), 5.22 (dt, J = 1.6, 16.8, 
1H), 4.98 (dt, J = 1.6, 10.4, 1H), 4.49 (q, J = 6.4, 1H), 3.85 (ddd, J = 2.4, 5.2, 11.6, 1H), 3.75-
3.83 (m, 1H), 2.83 (dd, J = 3.6, 14.0, 1H), 2.66 (dd, J = 9.2, 14.0, 1H), 1.87-2.19 (m, 2H), 1.77-
1.87 (m, 1H), 1.59-1.67 (m, 3H), 1.47-1.59 (m, 3H), 1.31-1.47 (m, 2H); 13C NMR (100 MHz, 
C6D6) 135.4, 129.5, 128.3, 127.6, 126.1, 114.0, 106.4, 78.7, 74.9, 73.3, 39.3, 37.5, 33.6, 30.3, 
25.0, 19.8; IR (neat) 3463, 3027, 2945, 2872, 1644, 1603, 1495, 1454, 1439, 1370, 1271, 1222, 
 129 
1071,1036, 988, 874, 748 cm-1; HRMS (ESI) calcd for C18H25O3 [M + H]+ 289.1804, found 
289.1828. 
 
(R)-2-phenyl-1-((2R,5R,7S)-2-vinyl-1,6-dioxaspiro[4.5]decan-7-yl) 
ethanol (3-65) 
1H NMR (300 MHz, C6D6) δ 7.12-7.23 (m, 4H), 7.04-7.11 (m, 1H), 5.91 
(ddd, J = 7.2, 10.2, 17.4, 1H), 5.10 (ddd, J = 1.2, 1.8, 17.2, 1H), 4.95 (ddd, J = 0.9, 1.8, 10.4, 1H), 
4.35 (q, J = 7.2, 1H), 3.96 (ddd, J = 2.4, 5.1, 11.4, 1H), 3.74-3.83 (m, 1H), 2.88 (dd, J = 3.9, 13.8, 
1H), 2.69 (dd, J = 9.3, 13.8, 1H), 1.78-2.05 (m, 3H), 1.56-1.76 (m, 4H), 1.30-1.55 (m, 5H); 13C 
NMR (100 MHz, C6D6) 141.1, 139.4, 129.4, 128.3, 126.0, 114.4, 106.2, 81.6, 75.1, 73.0, 39.5, 
38.9, 33.6, 30.6, 25.1, 19.8; IR (neat) 3463, 3026, 2943, 2870, 1643, 1603, 1495, 1454, 1370, 
1296, 1220, 1034, 988, 875, 747 cm-1; HRMS (ESI) calcd for for C18H25O3 [M + H]+ 289.1804, 
found 289.1832. 
 
The relative stereochemistry was determined by a combination of 1H NMR, 13C NMR, COSY, 
NOESY. While both 3-65 and 3-65 showed similar 1H NMR, 13C NMR and COSY spectra, only 
structure 3-64 showed a NOESY coupling of the two ethereal hydrogens as indicated because of 
their spacial proximity. 
 
The two stereoisomers were resubmitted to the following isomerization conditions: ~20mM 
solution,  5% Re2O7, stirred at 20 °C for 18 hrs (no obvious change after 12hrs) then quenched 
with 5 drops of pyridine. After After evaporation of the solvent, the crude mixture was purified 
by flash chromatography (10%-15% ethyl acetate in hexanes) to give the product (yield for each 
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isomerization: ~90%-95%, dr = 11:9). Isomerization of 3-64 gave additional 19% of 3-65 while 
isomerization of 3-64 gave additional 22% of 3-65. Thus after one recycling of isomerization: a 
total yield of 69% could be obtained for 3-64 and a total yield of 63% could be obtained for 3-65. 
A second recycling gave a total yield of 78% for 3-64 and a total yield of 75% for 3-65. 
 
HO Ph
a-d
Reaction Conditions:
a) PCC, celite, DCM, 20 ºC; b)Allylmagnesium bromide, Et2O, 0 ºC, 69% for two steps; c) TBSCl, DMAP,
imidazole, DCM, 20 ºC; d) 9-BBM, THF, then 3.0 M NaOH and 30% H2O2, 0 ºC, 72%; e) Py•SO3, DMSO,
Et3N, DCM, 0-20 ºC,; f) Pent-4-en-1-ylmagnesium bromide, Et2O, 0 ºC; g) TBAF, THF, 20 ºC, 76% for 
three steps; h) PCC, celite, DCM, 20 ºC, 84%; i) MCPBA, NaHCO3, DCM, 0 ºC, 49%; i) But-2-ene-1,4-diol, 
Hoveyda-Grubbs 2nd, DCM, 20 ºC, 81% (dr = 9 :1).
(From Scheme B1)
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Scheme B12 Synthesis of substrate 3-66 
 
(E)-1-(3-benzyloxiran-2-yl)-13-hydroxytrid- 
ec-11-ene-4,7-dione (3-66) 
1H NMR (400 MHz, CDCl3) δ 7.27-7.33 (m, 2H), 7.20-7.26 (m, 3H), 5.57-5.68 (m, 2H), 4.07 (d, 
J = 3.6, 2H), 2.87-2.93 (m, 2H), 2.72-2.81 (m, 2H), 2.59-2.68 (m, 4H), 2.43-2.49 (m, 4H), 2.02-
2.09 (m, 2H), 1.83 (br, 1H), 1.62-1.75 (m, 4H), 1.47-1.63 (m, 2H); 13C NMR (100 MHz, CDCl3) 
209.3, 209.2, 137.4, 131.9, 130.1, 128.9, 128.6, 126.6, 63.6, 58.6, 58.4, 42.0, 41.9, 38.5, 36.1, 
36.0, 31.6, 31.1, 22.9, 20.2; IR (neat) 3463, 3026, 2940, 2869, 1711, 1603, 1495, 1454, 1438, 
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1365, 1236, 1164, 1076, 1028, 970, 752 cm-1; HRMS (ESI) calcd for C22H30O4Na [M + Na]+ 
381.2042, found 381.2014. 
 
Spirotricycles 3-67 and 3-68 
The general rearrangement procedure was followed with 3-66 (32.0 mg, 
0.089 mmol), 10% Re2O7 supported on SiO2 (21.6 mg, 0.0045 mmol), and 
CH2Cl2 (8.9 mL). The reaction was stirred at 20 °C for 2.5 hrs and then 
quenched with five drops of pyridine. After evaporation of the solvent, the 
crude mixture was purified by flash chromatography (10%-15% ethyl 
acetate in hexanes) to give the product (26.2 mg, 82%, 3-67:3-68 = 4:5).  
 
Faster eluting major isomer 3-68: 1H NMR (400 MHz, C6D6) δ 7.12-7.21 (m, 4H), 7.05-7.11 (m, 
1H), 5.90 (ddd, J = 5.2, 10.4, 17.2, 1H), 5.27 (dt, J = 1.6, 17.2, 1H), 5.01 (dt, J = 1.6, 10.4, 1H), 
4.42 (ddddd, J = 2.0, 2.8, 3.6, 5.2, 11.2, 1H), 3.85 (ddd, J = 2.0, 5.2, 11.6, 1H), 3.77 (h, J = 4.4, 
1H), 2.87 (dd, J = 4.0, 14.0, 1H), 2.72 (dd, J = 8.4, 14.0, 1H), 1.80-2.06 (m, 6H), 1.45-1.71(m, 
9H), 1.20-1.42 (m, 2H); 13C NMR (100 MHz, C6D6) 140.1, 139.2, 129.5, 128.3, 126.1, 113.2, 
107.1, 106.8, 74.9, 73.3, 71.3, 39.4, 36.7, 36.6, 35.0, 34.7, 31.0, 25.1, 20.3, 20.0; IR (neat) 3466, 
3062, 2942, 2867, 1646, 1603, 1495, 1453, 1438, 1366, 1265, 1232, 1123, 1073, 1034, 969, 877, 
747 cm-1; HRMS (ESI) calcd for C22H30O4Na [M + Na]+ 381.2042, found 381.2051. 
 
Slower eluting minor isomer 3-67: 1H NMR (300 MHz, C6D6) δ 7.23-7.29 (m, 2H), 7.16-7.20 (m, 
2H), 7.05-7.11 (m, 1H), 5.91 (ddd, J = 5.2, 10.8, 17.2, 1H), 5.32 (dt, J = 1.6, 17.2, 1H), 5.02 (dt, 
J = 1.6, 10.4, 1H), 4.40 (ddddd, J = 1.2, 1.6, 2.8, 5.2, 11.6, 1H), 3.94 (ddd, J = 2.0, 5.2, 11.6, 1H), 
O OO
HO Ph
O O
O
HO Ph
3-67
3-68
H H
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3.84 (h, J = 4.4, 1H), 3.03 (dd, J = 3.6, 14.0, 1H), 2.77 (dd, J = 9.6, 14.0, 1H), 2.22-2.29 (m, 1H), 
2.12-2.19 (m, 1H), 1.84-1.98 (m, 2H), 1.78 (d, J = 4.0, 1H), 1.66-1.73 (m, 1H), 1.34-1.62 (m, 
10H), 1.20-1.31 (m, 1H); 13C NMR (100 MHz, C6D6) ; IR (neat) 140.0, 139.8, 129.5, 128.3, 
126.0, 113.3, 107.3, 107.2, 75.0, 74.8, 72.3, 39.7, 37.5, 37.4, 34.8, 30.9, 25.4, 20.1, 19.9 cm-1; 
HRMS (ESI) calcd for for C22H30O4Na [M + Na]+ 381.2042, found 381.2043. 
 
The relative stereochemistry was determined by a combination of 1H NMR, 13C NMR, COSY, 
NOESY. While both 3-67 and 3-68 showed similar 1H NMR, 13C NMR and COSY spectra, only 
structure 3-67 showed a NOESY coupling of the two ethereal hydrogens as indicated because of 
their spacial proximity. 
 
The two stereoisomers were resubmitted to the following isomerization conditions: ~10mM 
solution,  5% Re2O7, stirred at 20 °C for 12 hrs then quenched with 5 drops of pyridine. After 
After evaporation of the solvent, the crude mixture was purified by flash chromatography (10%-
20% ethyl acetate in hexanes) to give the product (yield for each isomerization: ~80%, dr = 5:4). 
Isomerization of 3-68 gave additional 15% of 3-67 while isomerization of 3-67 gave additional 
16% of 3-68. Thus after one recycling of isomerization: a total yield of 50% could be obtained 
for 3-67 and a total yield of 62% could be obtained for 3-68.  
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Reaction Conditions:
a) Cl2Pd(dppf)2, Et2O, 20 ºC, 79%; b) Py•SO3, DMSO, Et3N, DCM, 0-20 ºC, 86%; c) Pent-4-en-1-ylmagnesium
bromide, Et2O, 0 ºC, 85%; d) TBAF, THF, 20 ºC, 69%; e) PCC, celite, DCM, 20 ºC, 66%; f) 60% NaH dispersed
in mineral oil, diethyl (2-oxopropyl)phosphonate, THF, 0 ºC, 87%; g) MCPBA, NaHCO3, DCM, 0 ºC, 70%; h)
But-2-ene-1,4-diol, Hoveyda-Grubbs 2nd generation alkene metathesis catalyst, DCM, 20 ºC, 69% ( dr = 1:1).
OH
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O
O
HO OH
O
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Scheme B13 Synthesis of substrate 3-69 
 
(E)-10-hydroxy-1-(3-((E)-6-oxohept-4-en-1-yl) 
oxiran-2-yl)dec-8-en-4-one (3-69) 
1H NMR (400 MHz, CD2Cl2) δ 6.76 (dt, J = 6.8, 16.0, 
1H), 6.03 (dt, J = 1.6, 16.0, 1H), 5.56-5.67 (m, 2H), 4.02 (br, 2H), 2.60-2.65 (m, 2H), 2.43 (t, J = 
7.2, 2H), 2.38 (t, J = 7.2, 2H), 2.26 (dq, J = 1.6, 7.2, 2H), 2.19 (s, 3H), 1.99-2.07 (m, 2H), 1.39-
1.70 (m, 11H); 13C NMR (100 MHz, CD2Cl2) 210.1, 198.2, 147.5, 131.6, 131.5, 130.1, 63.3, 
58.1, 57.9, 42.1, 41.8, 32.1, 31.53, 31.46, 31.4, 26.6, 24.6, 23.1, 20.2; IR (neat) 3451, 2934, 
2862, 11708, 1672, 1626, 1431, 1364, 1256, 1089, 976, 893 cm-1; HRMS (ESI) calcd for 
C19H30O4Na [M + Na]+ 345.2042, found 345.2071. 
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1-((2S,6R)-6-((2S,6S,8S)-8-vinyl-1,7-
dioxaspiro[5.5]undecan-2-yl) tetrahydro-2H-pyran-2-
yl)propan-2-one (3-70) 
The general rearrangement procedure was followed with 3-69 (25.2 mg, 0.078 mmol), Re2O7 
(1.9 mg, 0.004 mmol), and CH2Cl2 (7.8 mL). The reaction was stirred at 20 °C for 8 hrs and then 
quenched with five drops of pyridine. After evaporation of the solvent, the crude mixture was 
purified by flash chromatography (10%-15% ethyl acetate in hexanes) to give the product (21.2 
mg, 84%). 1H NMR (400 MHz, CDCl3) δ 5.84 (ddd, J = 5.2, 10.4, 17.2, 1H), 5.23 (dt, J = 1.6, 
17.2, 1H), 5.07 (dt, J = 1.6, 10.4, 1H), 4.04 (ddddd, J = 1.2, 1.6, 2.8, 5.2, 11.6, 1H), 3.77 (dddd, J 
= 1.2, 4.4, 8.8, 10.4, 1H), 3.42 (ddd, J = 2.0, 8.0, 10.4, 1H), 3.18 (ddd, J = 2.0, 8.0, 10.4, 1H), 
2.64 (dd, J = 8.8, 14.8, 1H), 2.41 (dd, J = 4.4, 14.8, 1H), 2.18 (s, 3H), 1.95-2.03 (m, 1H), 1.78-
1.94 (m, 4H), 1.49-1.69 (m, 7H), 1.33-1.44 (m, 2H), 1.21-1.32 (m, 2H), 1.05-1.21 (m, 2H); 13C 
NMR (100 MHz, CDCl3) 207.8, 139.5, 114.3, 96.1, 80.9, 74.8, 71.8, 69.7, 50.4, 35.6, 35.2, 31.7, 
30.9, 30.7, 28.3, 27.8, 23.0, 18.8, 18.3; IR (neat) 3078, 2936, 2861, 1716, 1646, 1438, 1371, 
1279, 1224, 1202, 1134, 1089, 1040, 981, 914, 861 cm-1; HRMS (ESI) calcd for C19H30O4Na [M 
+ Na]+ 345.2042, found 345.2007. 
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APPENDIX C 
HETEROCYCLE SYNTHESIS BASED ON ALLYLIC ALCOHOL TRANSPOSITION 
USING TRACELESS TRAPPING GROUPS 
General Information 1H NMR and 13C NMR spectra were taken on a Bruker Avance 300 
spectrometer at 300 MHz and 75 MHz respectively, a Bruker Avance 400 spectrometer at 400 
MHz and 100 MHz, a Bruker Avance 500 spectrometer at 500 MHz and 125 MHz if specified. 
The chemical shifts are given in parts per million (ppm) on the delta (δ) scale. The solvent peak 
was used as a reference value, for 1H NMR: CDCl3 = 7.27 ppm, CD2Cl2 = 5.31 ppm, C6D6 = 
7.16 ppm,  for 13C NMR: CDCl3 = 77.2, CD2Cl2 = 53.52, C6D6 = 128.37 . Data are reported as 
follows: m=multiplet, s = singlet; d = doublet; t = triplet; q = quartet; p = pentet; dd = doublet of 
doublets; dt = doublet of triplets; br = broad. High resolution and low-resolution mass spectra 
were collected on a VG 7070 spectrometer. Infrared (IR) spectra were taken on a Mattson 
Cygnus 100 spectrometer. Samples for IR were prepared as thin films on a NaCl plates by 
dissolving the corresponding compounds in CH2Cl2 followed by evaporation of the CH2Cl2. 
Methylene chloride was distilled under N2 from CaH2. Analytical TLC was performed on E. 
Merck pre-coated (25 mm) silica gel 60F-254 plates. Visualization was done under UV (254 
nm). Flash chromatography was done using ICN SiliTech 32-63 60 Å silica gel. Reagent grade 
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ethyl acetate, diethyl ether, pentane and hexanes (commercial mixture) were purchased from EM 
Science and used as is for chromatography. All reactions were performed in oven or flame-dried 
glassware under a positive pressure of N2 with magnetic stirring unless otherwise noted. Product 
volatility dictated yield determination by NMR in many cases. NMR-based yield determinations 
were conducted in accord with a validated protocol that was previously reported.53 Primary data 
for these analyses are included with the spectra. When possible products were purified and 
characterized following yield determination.  
 
General procedure for Re2O7- catalyzed cyclization  
To a solution (~20 mM) of corresponding substrate and Et3SiH or nucleophile (2 equiv) in 
CH2Cl2 (DCM) or CH2ClCH2Cl (DCE) was added Re2O7 (0.03 equiv). The reaction mixture was 
stirred at rt (unless otherwise noted) and monitored by TLC until complete consumption of the 
starting material, after which the reaction was quenched by adding a few drops of pyridine or 
triethylamine. The solvent was removed under vacuum and the crude product was purified by 
flash chromatography or preparative TLC to give the product.  
 
O
R
O
H
a-d
Reagents and conditions
a) 150 °C, quantitative. b) BnOH, p-TsOH, Na2SO4, 64%. c) (Z)-2-Butene-1,4-diol or
(Z)-hex-3-ene-2,5-diol, Grubbs-Hoveyda 2nd generation metathesis catalyst, CH2Cl2.
d) CF3CO2H, CH2Cl2, H2O, 30% ( R = H) or 57% (R = Me) (two steps).
S1: R = H
S2: R = Me
OH
 
Scheme C1 Synthesis of substrates S1 and S2 
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 (E)-6-Hydroxyhex-4-enal (S1) 
1H NMR (400 MHz, CDCl3) δ 9.74 (t, J = 1.2 Hz, 1H), 5.51-5.73 (m, 2H), 
4.06 (d, J = 3.2 Hz, 2H), 2.53 (dt, J = 1.2, 6.8 Hz, 2H), 2.32-2.40 (m, 2H); 13C NMR (100 MHz, 
CDCl3) δ 202.1, 130.4, 130.2, 63.2, 43.0, 24.6; IR (neat) 3371, 2924, 2856, 2730, 1721, 1671, 
1443, 1411, 1362, 1245, 1179, 1110, 1026, 971 cm-1; LRMS calcd for C6H8O [M-H2O]+ 96, 
found 96. Note: HRMS was not possible for this compound due to its low molecular weight. GC 
evidence for purity is included in the spectra section. 
 
2-Vinyltetrahydrofuran (4-5) 
The general reductive cyclization procedure was followed with S1 (22 mg, 0.19 mmol), Et3SiH 
(44 mg, 0.38 mmol), Re2O7 (2.7 mg, 0.0057 mmol), and DCM (9.4 mL). The reaction was stirred 
at rt for 48 h, then was quenched with 5 drops of pyridine. After evaporation of the solvent under 
slightly reduced presssure, 5 µl of benzyldimethylsilane was added into the crude as an internal 
standard. The mixture was dissolved in CDCl3 and 1H NMR showed a yield of 85%. 1H NMR 
data for this compound matched those from a prior study.85 
 
 (E)-6-Hydroxyhept-4-enal (S2) 
1H NMR (300 MHz, CD2Cl2) δ 9.72 (t, J = 1.5 Hz, 1H), 5.49-5.66 (m, 2H), 
4.20 (p, J = 6.3 Hz, 1H), 2.46-2.53 (m, 2H), 2.28-2.36 (m, 2H), 1.91 (br, 1H), 1.19 (d, J = 6.3 
Hz, 3H); 13C NMR (75 MHz, CD2Cl2) δ 202.29, 136.0, 128.4, 68.7, 43.5, 25.0, 23.6; IR (neat) 
3393, 2970, 2925, 2850, 2725, 1725, 1443, 1409, 1389, 1369, 1313, 1186, 1141, 1107, 1057, 969, 
871 cm-1; LRMS calcd for C7H10O [M-H2O]+ 110, found 110. Note: HRMS was not possible for 
HO
O
H
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this compound due to its low molecular weight. GC evidence for purity is included in the spectra 
section. 
 
(E)-2-(Prop-1-en-1-yl)tetrahydrofuran (4-6) 
The general rearrangement cyclization procedure was followed with S2 (28 mg, 0.22 
mmol), Et3SiH (51 mg, 0.44 mmol), Re2O7 (3.2 mg, 0.0057 mmol), and DCM (11 mL). The 
reaction was stirred at rt for 48 h, then was quenched with 5 drops of pyridine. After evaporation 
of the solvent under slightly reduced presssure, 5 µl of benzyldimethylsilane was added into the 
crude as an internal standard. The mixture was dissolved in CDCl3 and 1H NMR showed a yield 
of 90%. 1H NMR data matched those from a previously prepared sample.86 
 
HO
S3
HO
OH
a-e
Reagents and conditions
a) PCC, Celite, CH2Cl2. b) Methyl acrylate, Grubbs-Hoveyda 2nd generation metathesis
catalyst, CH2Cl2, reflux, 72% (two steps). c) (MeO)3CH, PPTs, MeOH, 50 °C, 88%. 
d) DIBAL-H, CH2Cl2, –78 °C. e) HOAc, H2O (1:1), rt, 91% (two steps).  
Scheme C2 Synthesis of substrate S3 
 
 (E)-7-Hydroxyhept-5-enal (S3) 
1H NMR (300 MHz, CDCl3) δ 9.71-9.76 (m, 1H), 5.50-5.72 (m, 2H), 3.90-
4.20 (m, 2H), 2.43 (t, J = 7.2 Hz, 2H), 2.00-2.13 (m, 2H), 1.93 (br, 1H), 1.70  (p, J = 7.2 Hz, 2H); 
13C NMR (75 MHz, CDCl3) δ 202.6, 131.4, 130.3, 63.4, 43.1, 31.4, 21.4; IR (neat) 3399, 2996, 
2935, 2862, 2726, 1721, 1676, 1456, 1438, 1364, 1208, 1169, 1112, 972, 840 cm-1; LRMS calcd 
HO
HO
O
 139 
for C7H10O [M-H2O]+ 110, found 110. Note: HRMS was not possible for this compound due to 
its low molecular weight. GC evidence for purity is included in the spectra section. 
 
2-Vinyltetrahydro-2H-pyran (4-7) 
The general rearrangement cyclization procedure was followed with S3 (23 mg, 0.18 
mmol), Et3SiH (42 mg, 0.36 mmol), Re2O7 (2.6 mg, 0.0054 mmol), and DCM (9.0 mL). The 
reaction was stirred at rt for 96 h, then was quenched with 5 drops of pyridine. After evaporation 
of the solvent under slightly reduced presssure, 5 µl of benzyldimethylsilane was added into the 
crude as an internal standard. The mixture was dissolved in CDCl3 and 1H NMR showed a yield 
of 70%. 1H NMR data for this compound matched those from a from a prior study.2 
 
OH
HO
OH
a-b
Reagents and conditions
a) PCC, Celite, CH2Cl2; b) (Z)-hex-3-ene-2,5-diol, Grubbs-Hoveyda 2nd generation 
metathesis catalyst, CH2Cl2, rt, 43% for two steps.  
Scheme C3 Synthesis of substrate 4-34 
 
 (E)-7-Hydroxyoct-5-enal (25) 
1H NMR (400 MHz, CDCl3) δ 9.72 (t, J = 1.6, 1H), 5.42-5.59 (m, 2H), 4.20 
(t, J = 6.4 Hz, 1H), 2.41 (dt, J = 1.6, 7.2 Hz, 2H), 2.05 (br, 1H), 2.03 (q, J = 6.4 Hz, 2H), 1.69 (p, 
J = 7.2 Hz, 2H), 1.21 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 202.7, 135.5, 129.2, 
68.6, 43.1, 31.3, 23.4, 21.4; IR (neat) 3408, 2971, 2930, 2870, 2722, 1722, 1670, 1454, 1392, 
HO
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1368, 1142, 1105, 1060, 971, 864 cm-1; HRMS (EI) calcd for C8H14O2 [M]+ 142.0994, found 
141.1006. 
 
 (E)-2-(Prop-1-en-1-yl)tetrahydro-2H-pyran (4-8) 
The general reductive cyclization procedure was followed with 25 (21 mg, 0.15 mmol), 
Et3SiH (34 mg, 0.29 mmol), Re2O7 (2.1 mg, 0.0044 mmol), and DCM (7.4 mL). The reaction 
was stirred at rt for 36 h, then was quenched with 5 drops of pyridine. After evaporation of the 
solvent under slightly reduced presssure, 5 µl of benzyldimethylsilane was added into the crude 
as an internal standard. The mixture was dissolved in CDCl3 and 1H NMR showed a yield of 
87%. The 1H NMR was compared to the literature for the same compound. 1H NMR data for 
this compound matched those from a prior study.3 
 
O
H
OR
OH
a-b
S4: R = H
S5: R = Me
Reagents and conditions
a) But-3-en-1-ylmagnesium bromide, Et2O, 0 °C, 66%. b) PCC, Celite, CH2Cl2, 94%. c) (Z)-
2-Butene-1,4-diol or (Z)-hex-3-ene-2,5-diol, Grubbs-Hoveyda 2nd generation metathesis 
catalyst, CH2Cl2, rt, 51% (R = H), 65% (R = Me).  
Scheme C4 Synthesis of substrates S4 and S5 
 
(E)-8-Hydroxy-1-phenyloct-6-en-3-one (S4) 
1H NMR (400 MHz, CDCl3) δ 7.27-7.34 (m, 2H), 7.17-7.25 (m, 3H), 5.61-
5.72 (m, 2H), 4.09 (d, J = 3.6, 2H), 2.93 (t, J = 7.6, 2H), 2.76 (t, J = 7.6, 2H), 2.52 (t, J = 7.2, 
2H), 2.35 (p, J = 6.8, 2H, 1.59 (br, 1H). 13C NMR (100 MHz, CDCl3) δ 209.3, 141.0, 131.0, 
O
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130.0, 128.5, 128.3, 126.1, 63.5, 42.3, 42.2, 29.7, 26.2. IR (neat) 3406, 3061, 3027, 2924, 1710, 
1603, 1495, 1453, 1407, 1371, 1091, 1003, 972, 750, 700 cm-1; HRMS (ESI) calcd for C14H17O 
[M-OH]+ 201.1279, found 201.1286. 
 
2-Phenethyl-5vinyltetrahydrofuran (4-9) 
The general reductive cyclization procedure was followed with S4 (26 mg, 
0.12 mmol), Et3SiH (28 mg, 0.24 mmol), Re2O7 (1.7 mg, 0.0036 mmol), and DCM (6 mL). The 
reaction was stirred at rt for 20 h, then was quenched with 5 drops of pyridine. After evaporation 
of the solvent, the crude material was purified by flash chromatography (1-5% ethyl acetate in 
hexanes) to give the product (21 mg, 86%, dr = 57:43). 1H NMR (400 MHz, CDCl3) δ 7.26-7.32 
(m, 2H), 7.17-7.25 (m, 3H), 5.82-5.95 (m, 1H), 5.22-5.32 (m, 1H), 5.08-5.14 (m, 1H), 4.42-4.48 
(m, 0.43H), 4.29-4.36 (m, 0.57H), 4.01-4.08 (m, 0.43H), 3.89-3.97 (m, 0.57H), 2.75-2.84 (m, 
1H), 2.64-2.74 (m, 1H), 1.89-2.17 (m, 3H), 1.75-1.86 (m, 1H), 1.65-1.74 (m, 1H), 1.53-1.65 (m, 
1H); 13C NMR (100 MHz, CDCl3) δ 142.2, 139.7, 139.6, 128.4, 128.3, 125.7, 115.2, 114.9, 80.1, 
79.6, 79.1, 78.6, 37.81, 37.76, 32.58, 32.54, 32.0, 31.8, 31.1; IR (neat) 3083, 3062, 3026, 2932, 
2862, 1603, 1495, 1454, 1426, 1107, 1051, 989, 921, 746, 699 cm-1; HRMS (ESI) calcd for 
C14H19O [M+H]+ 203.1436, found 203.1420. 
 
 (E)-8-Hydroxy-1-phenylnon-6-en-3-one (S5) 
1H NMR (400 MHz, CDCl3) δ 7.28-7.33 (m, 2H), 7.18-7.24 (m, 
3H), 5.50-5.66 (m, 2H), 4.26 (p, J = 6.4 Hz, 1H), 2.93 (t, J = 7.2 Hz, 2H), 2.76 (d, J = 7.2 Hz, 
2H), 2.50 (d, J = 7.2 Hz, 2H), 2.31 (t, J = 7.2 Hz, 2H), 1.80 (br, 1H), 1.26 (t, J = 6.4 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 209.3, 141.0, 135.2, 128.8, 128.5, 128.3, 126.1, 68.6, 44.3, 42.3, 
O
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29.7, 26.1, 23.4; IR (neat) 3405, 3027, 2968, 2925, 1710, 1603, 1495, 1453, 1407, 1369, 1063, 
970, 749, 700 cm-1; HRMS (ESI) calcd for C15H21O2 [M+H]+ 233.1542, found 233.1527. 
 
 (E)-2-Phenethyl-5-(prop-1-en-1-yl)tetrahydrofuran (4-10) 
The general reductive cyclization procedure was followed with S5 (45 mg, 0.19 mmol), 
Et3SiH (45 mg, 0.38 mmol), Re2O7 (2.8 mg, 0.0058 mmol), and DCM (9.6 mL). The reaction 
was stirred at 0 °C for 24 h, then was quenched with 5 drops of pyridine. After evaporation of the 
solvent, 5 µl of benzyldimethylsilane was added into the crude as an internal standard, then the 
mixture was dissolved in CDCl3 and 1H NMR showed a yield of 57% (dr = 1:1). 1H NMR (400 
MHz, CDCl3) δ 7.26-7.32 (m, 2H), 7.16-7.25 (m, 3H), 5.65-5.77 (m, 1H), 5.46-5.55 (m, 1H), 
4.37 (q, J = 7.2 Hz, 0.5H), 4.24 (q, J = 7.2 Hz, 0.5H), 4.03 (p, J = 6.8 Hz, 0.5H), 3.88 (p, J = 6.8 
Hz, 0.5H), 2.74-2.83 (m, 1H), 2.62-2.72 (m, 1H), 2.04-2.11 (m, 1H), 1.87-2.03 (m, 2H), 1.74-
1.85 (m, 1H), 1.71 (d, J = 6.4 Hz, 3H), 1.53-1.68 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 142.3, 
142.27, 132.5, 132.4, 128.4, 128.3, 127.7, 127.4, 125.7, 80.2, 79.5, 78.8, 78.5, 37.9, 37.8, 32.9, 
32.59, 32.56, 32.3, 32.0, 31.3, 17.75, 17.71; IR (neat) 3061, 3026, 2934, 2859, 1603, 1495, 1453, 
1377, 1047, 1000, 964, 927, 746, 699 cm-1; HRMS (ESI) calcd for C15H21O [M+H]+ 217.1592, 
found 217.1604. 
a-d
S6: R = H
S7: R = Me
Reagents and conditions
a)  PCC, Celite, CH2Cl2. b)(3-Phenylpropyl)magnesium bromide, Et2O, 0 °C, 60% (two steps). c) PCC, 
Celite, CH2Cl2, 97%. c) (Z)-2-Butene-1,4-diol or (Z)-hex-3-ene-2,5-diol, Grubbs-Hoveyda 2nd generation 
metathesis catalyst, CH2Cl2, rt, 66% (R = H), 77% (R = Me).
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Scheme C5 Synthesis of substrates S6 and S7 
O
 143 
 (E)-10-Hydroxy-1-phenyldec-8-en-4-one (S6) 
1H NMR (400 MHz, CDCl3) δ 7.28-7.33 (m, 2H), 7.17-7.24 (m, 3H), 
5.60-5.70 (m, 2H), 4.04-4.18 (m, 2H), 2.63 (t, J = 7.6 Hz, 2H), 2.42 (t, J = 7.6 Hz, 2H), 2.40 (t, J 
= 7.6 Hz, 2H), 2.12 (br, 1H), 2.02-2.09 (m, 2H), 1.92 (p, J = 7.2 Hz, 2H), 1.67 (p, J = 7.2 Hz, 
2H); 13C NMR (100 MHz, CDCl3) δ 211.0, 141.6, 131.8, 129.9, 128.5, 128.4, 126.0, 63.5, 42.00, 
41.98, 35.1, 31.6, 25.2, 23.1; IR (neat) 3405, 3061, 3025, 2934, 2861, 1709, 1603, 1496, 1453, 
1408, 1372, 1091, 999, 971, 748, 700 cm-1; HRMS (EI) calcd for C16H22O2 [M]+ 246.1620, 
found 246.1622. 
 
Cis-2-(3-phenylpropyl)-6-vinyltetrahydro-2H-pyran (4-11) 
The general reductive cyclization procedure was followed with S6 
(30 mg, 0.12 mmol), Et3SiH (29 mg, 0.25 mmol), Re2O7 (1.8 mg, 0.0037 mmol), and DCM (6.2 
mL). The reaction was stirred at rt for 15 h then was quenched with 5 drops of pyridine. After 
evaporation of the solvent, the crude residue was purified by flash chromatography (1-5% ethyl 
acetate in hexanes) to give the product (26 mg, 86%). 1H NMR (400 MHz, CDCl3) δ 7.26-7.31 
(m, 2H), 7.16-7.22 (m, 3H), 5.88 (ddd, J = 4.2, 10.4, 17.2 Hz, 1H), 5.25 (dt, J = 1.6, 17.2 Hz, 
1H), 5.09 (dt, J = 1.6, 10.4 Hz, 1H), 3.82 (ddddd, J = 0.8, 1.6, 2.4, 5.2, 10.8 Hz, 1H), 3.36 (dddd, 
J = 2.4, 5.2, 8.8, 9.2 Hz, 1H), 2.64 (t, J = 7.2 Hz, 2H), 1.76-1.91 (m, 2H), 1.45-1.75 (m, 6H), 
1.15-1.36 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 142.7, 139.7, 128.5, 128.3, 114.4, 78.3, 77.7, 
36.2, 36.0, 31.5, 31.3, 27.5, 23.6; IR (neat) 3083, 3062, 3025, 2934, 2857, 1603, 1495, 1453, 
1439, 1409, 1367, 1310, 1201, 1130, 1091, 1048, 988, 917, 748, 698 cm-1; HRMS (ESI) calcd 
for C16H23O [M+H]+ 231.1749, found 231.1748. 
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 (E)-10-Hydroxy-1-phenylundec-8-en-4-one (S7) 
1H NMR (400 MHz, CDCl3) δ 7.28-7.34 (m, 2H), 7.18-7.24 (m, 
3H), 5.45-5.65 (m, 2H), 4.28 (p, J = 6.4 Hz, 1H), 2.64 (t, J = 7.2 Hz, 2H), 2.43 (t, J = 7.2 Hz, 
2H), 2.40 (t, J = 7.2 Hz, 2H), 2.04 (q, J = 6.8 Hz, 2H), 1.93 (p, J = 7.6 Hz, 2H), 1.68 (p, J = 7.6 
Hz, 2H), 1.63 (br, 1H), 1.27 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 210.8, 141.6, 
135.1, 129.8, 128.5, 128.4, 126.0, 68.8, 42.01, 41.98, 35.1, 31.5, 25.2, 23.5, 23.1; IR (neat) 3405, 
3026, 2930, 1709, 1603, 1496, 1453, 1408, 1370, 1063, 970, 937, 748, 700 cm-1; HRMS (EI) 
calcd for C17H23O2 [M-H]+ 259.1698, found 259.1697. 
 
Cis-2-(3-Phenylpropyl)-6-((E)-prop-1-en-1-yl)tetrahydro-2H-pyran 
(4-12) 
The general reductive cyclization procedure was followed with S7 (45 mg, 0.17 mmol), Et3SiH 
(40 mg, 0.34 mmol), Re2O7 (2.5 mg, 0.0052 mmol), and DCM (8.6 mL). The reaction was stirred 
at 0 °C for 30 h, then was quenched with 5 drops of pyridine. After evaporation of the solvent, 5 
µl of benzyldimethylsilane was added into the crude mixture as an internal standard, then the 
mixture was dissolved in CDCl3 and 1H NMR was taken to determine a 62% yield. 1H NMR 
(400 MHz, CDCl3) δ 7.25-7.30 (m, 2H), 7.15-7.21 (m, 3H), 5.68 (ddq, J = 1.2, 6.4, 15.2 Hz, 1H), 
5.52 (ddq, J = 1.6, 6.0, 15.2 Hz, 1H), 3.75 (dd, J = 6.4, 10.8 Hz, 1H), 3.34 (dddd, J = 1.6, 5.2, 5.6, 
12.4 Hz, 1H), 2.63 (t, J = 7.2 Hz, 2H), 1.73-1.88 (m, 2H), 1.70 (d, J = 6.4 Hz, 3H), 1.58-1.72 (m, 
3H), 1.42-1.53 (m, 3H), 1.13-1.36 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 142.7, 132.8, 128.5, 
128.2, 126.3, 125.6, 78.2, 77.7, 36.3, 36.1, 31.7, 31.2, 27.6, 23.6, 17.9; IR (neat) 3061, 3025, 
2933, 2856, 1603, 1459, 1453, 1439, 1377, 1325, 1198, 1078, 1034, 964, 934, 747, 698 cm-1; 
HRMS (ESI) calcd for C17H25O [M+H]+ 245.1905, found 245.1911. 
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Reaction Cconditions:
a) Pent-4-en-1-ylmagnesium bromide, Et2O, 0 ºC, 74%; B)  (Z)-2-Butene-1,4-diol, Grubbs-
Hoveyda 2nd generation matathesis catalyst,CH2Cl2, 54%.
O
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Scheme C6 Synthesis of substrate 4-13 
 
Methyl (E)-11-hydroxy-5-oxonudec-9-enoate (4-13) 
1H NMR (300 MHz, CDCl3) δ 5.41-5.87 (m, 2H), 4.05-4.18 (m, 
2H), 3.67 (s, 3H), 2.46 (t, J = 7.2 Hz, 2H), 2.41 (t, J = 7.2 Hz, 2H), 2.34 (t, J = 7.2 Hz, 2H), 1.98-
2.12 (m, 2H), 1.89 (p, J = 7.2 Hz, 2H), 1.67 (p, J = 7.2 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 
210.1, 173.7, 132.0, 130.0, 63.6, 51.6, 41.9, 41.6, 33.0, 31.5, 23.0, 18.9; IR (neat) 3447, 2949, 
2868, 1735, 1711, 1438, 1414, 1375, 1315, 1254, 1202, 1172, 1092, 1004, 972 cm-1; HRMS 
(ESI) calcd for C12H21O4 [M+H]+ 229.1440, found 229.1446. 
 
Methyl 4-(Cis-6-vinyltetrahydro-2H-pyran-2-yl) butanoate (4-14) 
The general reductive cyclization procedure was followed with 4-13 (26 
mg, 0.12 mmol), Et3SiH (27 mg, 0.23 mmol), Re2O7 (1.7 mg, 0.0034 mmol), and DCM (5.7 mL). 
The reaction was stirred at rt for 30 h, then was quenched with 5 drops of pyridine. After 
evaporation of the solvent, 5 µl of benzyldimethylsilane was added into the crude mixture as an 
internal standard, then the mixture was dissolved in CDCl3. 1H NMR was taken to show a yield 
of 81%. 1H NMR (400 MHz, CDCl3) δ 5.86 (ddd, J = 5.2, 10.8, 17.2 Hz, 1H), 5.22 (dt, J = 1.6, 
17.2 Hz, 1H), 5.07 (dt, J = 1.6, 10.8 Hz, 1H), 3.80 (ddddd, J = 1.2, 1.2, 2.4, 4.8, 10.4 Hz, 1H), 
3.66 (s, 3H), 3.34 (dddd, J = 2.0, 5.2, 7.2, 11.2 Hz, 1H), 2.27-2.40 (m, 2H), 1.67-1.90 (m, 3H), 
O
O
OMe
HO
OH H
O
OMe
 146 
1.42-1.65 (m, 5H), 1.15-1.34 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 174.2, 139.6, 114.3, 78.2, 
77.3, 51.5, 35.8, 34.1, 31.4, 31.2, 23.5, 21.1; IR (neat) 2935, 2844, 1740, 1455, 1437, 1365, 1310, 
1247, 1199, 1172, 1091, 1045, 1021, 989, 917 cm-1; HRMS (ESI) calcd for C12H21O3 [M+H]+ 
213.1491, found 213.1508. 
 
HO OH
Reaction Cconditions:
a) NaH, THF, then TBSCl, 0 ºC, 56%; b) Py•SO3, DMSO, Et3N, CH2Cl2, 88%; c)  Pent-4-en-1-ylmagnesium
bromide, Et2O, 0 ºC, 70%; d) Py•SO3, DMSO, Et3N, CH2Cl2, 79%; e)Bu4NF, THF, 100%; f) CBr4, Ph3P, 
CH2Cl2, 0 ºC, 80%; g) (Z)-2-Butene-1,4-diol, Grubbs-Hoveyda 2nd generation matathesis catalyst,CH2Cl2, 
55%.
O
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Scheme C7 Synthesis of substrate 4-15 
 
 (E)-1-Bromo-11-hydroxyundec-9-en-5-one (4-15) 
1H NMR (300 MHz, CDCl3) δ 5.29-5.93 (m, 2H), 4.07-4.16 (m, 
2H), 3.39 (t, J = 6.6 Hz, 2H), 2.41 (q, J = 6.6 Hz, 4H), 1.99-2.12 (m, 2H), 1.84 (p, J = 6.6, 2H), 
1.60-1.76 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 210.3, 131.9, 129.9, 63.5, 41.9, 417, 33.3, 
32.1, 31.5, 23.0, 22.3; IR (neat) 3405, 2936, 2867, 1710, 1438, 1409, 1373, 1254, 1237, 1089, 
999, 971, 740, 645 cm-1; HRMS (ESI) calcd for C11H18BrO [M-OH]+ 245.0541, found 245.0539. 
 
Cis-2-(4-Bromobutyl)-6-vinyltetrahydro-2H-pyran (4-16) 
The general reductive cyclization procedure was followed with 4-15 
(47 mg, 0.18 mmol), Et3SiH (42 mg, 0.35 mmol), Re2O7 (2.6 mg, 0.0054 mmol), and DCM (8.9 
mL). The reaction was stirred at rt for 24 h, then was quenched with 5 drops of pyridine. After 
O Br
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evaporation of the solvent, the crude mixture was purified by flash chromatography (1-5% ethyl 
acetate in hexanes) to give the product (41 mg, 92%). 1H NMR (400 MHz, CDCl3) δ 5.86 (ddd, J 
= 5.2, 10.4, 17.2 Hz, 1H), 5.23 (dt, J = 1.6, 17.2 Hz, 1H), 5.08 (dt, J = 1.6, 10.4 Hz, 1H), 3.80 
(ddddd J = 1.0, 1.6, 2.6, 5.2, 10.8 Hz, 1H), 3.41 (t, J = 7.2 Hz, 2H), 3.33 (dddd, J = 1.6, 4.4, 4.8, 
12.0 Hz, 1H), 1.82-1.91 (m, 3H), 1.40-1.67 (m, 7H), 1.14-1.34 (m, 2H); 13C NMR (100 MHz, 
CDCl3) δ 139.6, 114.3, 78.2, 77.5, 35.6, 33.9, 32.9, 31.4, 31.3, 24.3, 23.6. IR (neat) 3011, 2935, 
2859, 1646, 1455, 1438, 1409, 1367, 1310, 1254, 1239, 1205, 1127, 1078, 1046, 988, 919, 737, 
648 cm-1; HRMS (ESI) calcd for C11H18BrO [M-H]+ 245.0541, found 245.0540. 
 
HO
Reaction Cconditions:
a) PCC, Celite, CH2Cl2; b) Methyl acrylate, Grubbs-Hoveyda 2nd generation metathesis catalyst, CH2Cl2,
reflux, 72% for two steps; c) (MeO)3CH, PPTS, MeOH, 50 ºC, 88%; d)DIBAL-H, CH2Cl2, -78 ºC; e) HOAC,
H2O (1:1), 91% for two steps; f) TBSCl, imidazole, CH2Cl2, 58%; g) Pent-4-en-1-ylmagnesium bromide,
Et2O, 0 ºC, 80%; h) Py•SO3, DMSO, Et3N, CH2Cl2, i) Bu4NF, THF, 85% for two steps.
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 (E)-12-Hydroxydodeca-1,10-dien-6-one (4-17) 
1H NMR (300 MHz, CDCl3) δ 7.67-7.81 (m, 1H), 5.55-5.67 (m, 2H), 
4.90-5.03 (m, 2H), 3.99-4.10 (m, 2H), 2.38 (t, J = 7.5 Hz, 4H), 2.02 (q, J = 6.6 Hz, 4H), 1.95 (br, 
1H), 1.64 (p, J = 7.5 Hz, 4H); 13C NMR (100 MHz, CDCl3) δ 211.1, 138.0, 131.9, 129.9, 115.2, 
63.5, 42.0, 41.9, 33.1, 31.6, 23.1, 22.8; IR (neat) 3405, 3076, 2934, 2865, 1710, 1640, 1439, 
1411, 1372, 1089, 999, 971, 913 cm-1; HRMS (ESI) calcd for C12H19O [M-OH]+ 179.1436, 
found 179.1427. 
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Cis-2-(pent-4-en-1-yl)-6-vinyltetrahydro-2H-pyran (4-18) 
The gneral reductive cyclization procedure was followed with 4-17 
(38 mg, 0.19 mmol), Et3SiH (45 mg, 0.38 mmol), Re2O7 (2.8 mg, 0.0058 mmol), and DCM (9.6 
mL). The reaction was stirred at rt for 20 h, then was quenched with 5 drops of pyridine. After 
evaporation of the solvent, 5 µl of benzyldimethylsilane was added into the crude residue as an 
internal standard. The mixture was dissolved in CDCl3 and 1H NMR showed a yield of 90 %. 1H 
NMR (400 MHz, C6D6) δ 5.82 (ddd, J = 5.2, 10.4, 17.2 Hz, 1H), 5.80 (ddt, J = 6.8, 10.0, 17.2 Hz, 
1H), 5.22 (d, J = 17.2 Hz, 1H), 5.07 (d, J = 10.4 Hz, 1H), 4.99 (dd, J = 1.2, 17.2 Hz, 1H), 4.93 (d, 
J = 10.0 Hz, 1H), 3.80 (dd, J = 4.0, 10.4 Hz, 1H), 3.32 (p, J = 5.2 Hz, 1H), 2.05 (p, J = 6.8 Hz, 
2H), 1.80-1.89 (m, 1H), 1.37-1.65 (m, 7H), 1.13-1.34 (m, 2H); 13C NMR (100 MHz, C6D6) δ 
139.7, 139.0, 114.4, 114.3, 78.2, 77.7, 36.0, 33.9, 31.5, 31.3, 24.9, 23.6; IR (neat) 3077, 2934, 
2858, 1641, 1456, 1439, 1410, 1367, 1310, 1199, 1079, 1048, 988, 910 cm-1; HRMS (EI) calcd 
for C12H19O [M-H]+ 179.1436, found 179.1445. 
 
rac-(2R,6R,8S)-2-vinyl-1-oxaspiro(5,5)undecan-8-ol (4-19) 
The gneral reductive cyclization procedure was followed with 4-17 (36.6 mg, 
0.187 mmol), no Et3SiH, Re2O7 (2. mg, 0.0056 mmol), and DCM (9.3 mL). 
The reaction was stirred at rt for 10 h, then was quenched with 5 drops of pyridine. After 
evaporation of the solvent, the crude residue was purified by flash chromatography (10-30% 
ethyl acetate in hexanes) to give 4-19 (slow eluting, 26.3 mg, 71.9%) and 4-20 (fast eluting, 7.9 
mg, 21.6%). 1H NMR (400 MHz, CDCl3) δ 5.82 (ddd, J = 5.2, 10.8, 17.6 Hz, 1H), 5.21 (dt, J = 
1.6, 17.6, 1H), 5.05 (dt, J = 1.6, 10.8, 1H), 4.05 (ddddd, J = 0.8, 1.2, 1.6, 4.8, 11.6, 1H), 3.76 (tt, 
OH H
O
OH
 149 
J = 4.0, 11.2, 1H), 2.69 (dddd, J = 2.0, 2.4, 4.4, 13.2, 1H), 1.94-2.02 (m, 1H), 1.69-1.86 (m, 3H), 
1.61-1.69 (m, 2H), 1.54-1.61 (m, 2H), 1.24-1.46 (m, 2H), 1.13-1.31 (m, 3H), 0.89 (dd, J = 11.2, 
13.2, 1H); 13C NMR (100 MHz, C6D6) δ 140.2, 114.0, 74.1, 70.1, 67.0, 39.1, 38.4, 36.1, 36.0, 
31.5, 19.5, 19.2; IR (neat) 3338, 2935, 2866, 1645, 1450, 1365, 1312, 1248, 1200, 1152, 1113, 
1041, 1015, 990, 919, 855, 809 cm-1; HRMS (EI) calcd for C12H21O2 [M+H]+ 197.1542, found 
197.1565. 
 
 rac-(2R,6R,8R)-2-vinyl-1-oxaspiro(5,5)undecan-8-ol (4-20) 
1H NMR (400 MHz, CDCl3) δ 5.81 (ddd, J = 4.6, 10.4, 17.2, 1H), 5.27 (dt, J = 
1.6, 17.2, 1H), 5.09 (dt, J = 1.6, 10.4, 1H), 4.23 (dd, J = 5.6, 11.2, 1H), 3.92-3.40 (m, 1H), 3.54 
(d, J = 10.0, 1H), 2.45-2.53 (m, 1H), 1.93-2.05 (m, 1H), 1.60-1.82 (m, 5H), 1.37-1.55 (m, 4H), 
1.20-1.35 (m, 4H); 13C NMR (400 MHz, CDCl3) δ 139.3, 115.0, 74.2, 71.6, 67.7, 39.9, 36.4, 
34.1, 33.3, 31.5, 19.0, 15.9; IR (neat) 3430, 2936, 2864, 1724, 1645, 1554, 1450, 1408, 1361, 
1294, 1205, 1120, 1102, 1066, 1023, 986, 920, 803 cm-1; HRMS (ESI) calcd for C12H21O2 
[M+H]+ 197.1542, found 197.1514. 
 
O
Reaction Cconditions:
a) Pent-4-en-1-ylmagnesium bromide, Et2O, 0 ºC, 89%; b) PCC, Celite, CH2Cl2, rt, 98%;
c) (Z)-2-Butene-1,4-diol,Grubbs-Hoveyda 2nd generation metathesis catalyst, CH2Cl2, 67%.
O
HO
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Scheme C9 Synthesis of substrate 4-21 
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 (E)-7-Hydroxy-1-phenylhept-5-en-1-one (4-21) 
1H NMR (400 MHz, CDCl3) δ 7.92-7.97 (m, 2H), 7.51-7.58 (m, 1H), 
7.42-7.48 (m, 2H), 4.07-4.18 (m, 2H), 2.97 (t, J = 6.8 Hz, 2H), 2.11-2.20 (m, 2H), 1.84 (p, J = 
6.8 Hz, 2H), 1.78 (br, 1H); 13C NMR (100 MHz, CDCl3) δ 200.3, 137.0, 133.0, 132.0, 130.0, 
128.6, 128.0, 63.6, 37.8, 31.7, 23.6; IR (neat) 3399, 3060, 2934, 2865, 1681, 1597, 1580, 1448, 
1408, 1368, 1227, 1200, 1181, 1158, 1087, 972, 740, 691 cm-1; HRMS (ESI) calcd for C13H17O2 
[M+H]+ 205.1224, found 205.1218. 
 
 Cis-2-phenyl-6-vinyltetrahydro-2H-pyran (4-22) 
The general reductive cyclization procedure was followed with 4-21 (38 
mg, 0.18 mmol), Et3SiH (43 mg, 0.37 mmol), Re2O7 (2.7 mg, 0.0055 mmol), and DCM (9.2 mL). 
The reaction was stirred at rt for 24 h, then was quenched with 5 drops of pyridine. After 
evaporation of the solvent, the crude residue was purified by flash chromatography (1-5% ethyl 
acetate in hexanes) to give the product (32 mg, 92%). 1H NMR (400 MHz, CDCl3) δ 7.38-7.44 
(m, 2H), 7.31-7.38 (m, 2H), 7.24-7.30 (m, 1H), 5.98 (ddd, J = 1.6, 10.8, 17.6 Hz, 1H), 5.33 (dt, J 
= 1.6, 17.6 Hz, 1H), 5.13 (dt, J = 1.6, 10.8 Hz, 1H), 4.46 (dd, J = 2.4, 11.2 Hz, 1H), 4.06 (ddddd 
J = 0.8, 1.6, 2.4, 5.2, 11.2 Hz, 1H), 1.96-2.04 (m, 1H), 1.83-1.90 (m, 1H), 1.69-1.82 (m, 2H), 
1.39-1.60 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 143.4, 139.5, 128.2, 127.2, 125.9, 114.4, 79.8, 
78.7, 33.7, 31.3, 24.0; IR (neat) 3064, 3029, 2936, 2855, 1645, 1604, 1495, 1452, 1438, 1410, 
1374, 1352, 1300, 1256, 1210, 1131, 1078, 1048, 988, 917, 951, 698 cm-1; HRMS (ESI) calcd 
for C13H15O [M-H]+ 187.1123, found 187.1126. 
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Reaction Cconditions:
a) PCC, Celite, CH2Cl2, rt; b) Ethyl diazoacetate, SnCl2, CH2Cl2, 79% for two steps;
c) (Z)-2-Butene-1,4-diol,Grubbs-Hoveyda 2nd generation metathesis catalyst, CH2Cl2, 31%.
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Scheme C10 Synthesis of substrate 4-23 
 
 Ethyl (E)-9-hydroxy-3-oxonon-7-enoate (4-23) 
1H NMR (300 MHz, CDCl3) δ 5.40-5.80 (m, 2H), 4.17 (q, J = 7.2, Hz 
2H), 4.06 (d, J = 3.6 Hz, 2H), 3.41 (s, 2H), 2.53 (t, J = 7.2 Hz, 2H), 2.00-2.12 (m, 2H), 1.85 (br, 
1H), 1.69 (p, J = 7.2 Hz, 2H), 1.26 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 202.6, 
167.3, 131.6, 130.2, 63.4, 61.4, 49.4, 42.1, 31.4, 22.7, 14.1; IR (neat) 3421, 2983, 2936, 1741, 
1714, 1646, 1445, 1411, 1368, 1315, 1258, 1180, 1091, 1028, 972 cm-1; HRMS (ESI) calcd for 
C11H17O3 [M-OH]+ 197.1178, found 197.1182. 
 
Ethyl 2-(Cis-6-vinyltetrahydro-2H-pyran-2-yl) acetate (4-24) 
The general reductive cyclization procedure was followed with 4-23 (34 
mg, 0.16 mmol), Et3SiH (37 mg, 0.31 mmol), Re2O7 (2.3 mg, 0.0047 mmol), and DCE (7.9 mL). 
The reaction was stirred at 55 °C for 20 h, then was quenched with 5 drops of pyridine. After 
evaporation of the solvent, 5 µl of benzyldimethylsilane was added to the crude residue as an 
internal standard. The mixture was dissolved in CDCl3 and 1H NMR was used to determine a 
yield of 85%. 1H NMR (400 MHz, C6D6) δ 5.82 (ddd, J = 5.2, 10.8, 17.2 Hz, 1H), 5.25 (dt, J = 
1.6, 17.2 Hz, 1H), 4.98 (dt, J = 1.6, 10.8 Hz, 1H), 3.96 (q, J = 6.8 Hz, 2H), 3.83 (dddd, J = 2.0, 
5.6, 7.6, 10.8 Hz, 1H), 3.68 (ddddd, J = 1.2, 1.6, 2.8, 5.2, 10.8 Hz, 1H), 2.59 (dd, J = 7.2, 14.8 
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Hz, 1H), 2.26 (dd, J = 5.6, 14.8 Hz, 1H), 1.47-1.54 (m, 1H), 1.34-1.41 (m, 1H), 1.28-1.34 (m, 
1H), 1.18-1.28 (m, 1H), 1.10-1.18 (m, 1H), 0.99-1.09 (m, 1H), 0.95 (t, J = 6.8 Hz, 3H); 13C 
NMR (100 MHz, C6D6) δ 170.4, 139.6, 113.3, 77.8, 74.1, 59.8, 41.7, 31.2, 30.8, 23.2, 13.9; IR 
(neat) 2982, 2936, 2860, 1738, 1647, 1440, 1411, 1370, 1336, 1295, 1248, 1191, 1150, 1134, 
1075, 1042, 989, 921, 875 cm-1; HRMS (ESI) calcd for C11H18O3 [M]+ 198.1256, found 
198.1251. 
 
Reaction Cconditions:
a) DIBAL-H, hexanes, rt, then I2, THF, -78 ºC; b) Pent-e-en-1-ylmagnesium bromide, (dppf)2PdCl2, 
Et2O, 52% for two steps; c) PCC, Celite, CH2Cl2, 84%; d) (3-Phenylpropyl)magnesium bromide, Et2O,
0 ºC; e) PCC, Celite, Ch2Cl2, 98%; f) MCPBA, NaHCO3, Ch2Cl2, 0 ºC, 73%; g) (Z)-2-Butene-1,4-
diol,Grubbs-Hoveyda 2nd generation metathesis catalyst, CH2Cl2, 61%.
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Scheme C11 Synthesis of substrate 4-25 
 
(E)-1-(3-(6-Hydroxyhept-4-en-1-yl)oxiran-2-yl)-7-phenylheptan-4-
one (4-25) 
1H NMR (400 MHz, CDCl3) δ 7.25-7.32 (m, 2H), 7.15-7.22 (m, 3H), 5.50-5.66 (m, 2H), 4.26 (p, 
J = 6.4 Hz, 1H), 2.60-2.68 (m, 4H), 2.39-2.48 (m, 4H), 2.03-2.12 (m, 2H), 1.92 (p, J = 7.2 Hz, 
2H), 1.87 (br, 1H), 1.71 (p, J = 7.2, 2H), 1.40-1.64 (m, 6H), 1.26 (d, J = 6.4, 3H); 13C NMR (100 
MHz, CDCl3) δ 210.4, 141.6, 134.9, 130.0, 128.5, 128.4, 126.0, 68.7, 58.4, 58.3, 42.2, 41.9, 
35.1, 31.8, 31.43, 31.41, 25.5, 25.2, 23.5, 20.3; IR (neat) 3446, 3025, 2930, 2859, 1710, 1602, 
1496, 1453, 1409, 1370, , 1145, 1064, 892, 747, 700 cm-1; HRMS (ESI) calcd for C22H32O3Na 
[M+Na]+ 367.2249, found 367.2239. 
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rac-(2R, 2ʹ′S, 6R, 6ʹ′R)-6-(3-Phenylpropyl)- 6ʹ′-((E)-prop-1-en-1-
yl)octahydro-2H, 2ʹ′H-2, 2ʹ′-bipyran (4-26) 
The general reductive cyclization procedure was followed with 4-25 (61 mg, 0.18 mmol), Et3SiH 
(41 mg, 0.35 mmol), Re2O7 (2.6 mg, 0.0053 mmol), and DCM (8.8 mL). The reaction was stirred 
at rt for 36 h, then was quenched with 5 drops of pyridine. After evaporation of the solvent, the 
crude residue was purified by preparative TLC (5% ethyl acetate in hexanes) to give the product 
(39 mg, 68%). 1H NMR (400 MHz, C6D6) δ 7.15-7.21 (m, 2H), 7.05-7.15 (m, 3H), 5.54-5.70 (m, 
2H), 3.72 (dd, J = 4.8, 10.0 Hz, 1H), 3.23-3.36 (m, 2H), 3.13 (dddd, J = 2.4, 4.4, 8.0, 10.8 Hz, 
1H), 2.52 (t, J = 7.6 Hz, 2H), 1.98-2.10 (m, 2H), 1.77-1.88 (m, 1H), 1.48-1.72 (m, 4H), 1.56 (d, J 
= 6.4 Hz, 3H), 1.23-1.46 (m, 7H), 1.05-1.15 (m, 1H); 13C NMR (100 MHz, C6D6) δ 142.7, 133.4, 
128.4, 128.3, 125.6, 124.6, 80.9, 80.6, 77.9, 77.5, 36.2, 36.0, 32.3, 31.9, 28.5, 28.3, 27.7, 23.4, 
23.3, 17.5; IR (neat) 3061, 3025, 2932, 2854, 1603, 1459, 1453, 1439, 1463, 1303, 1249, 1197, 
1093, 1043, 964, 940, 747, 698 cm-1; HRMS (ESI) calcd for C22H32O2 [M]+ 328.2402, found 
328.2407. 
 
(E)-2-(Dec-1-yn-1-yl)-5-(4-phenylbut-1-en-1-yl) tetrahydro-
furan (4-29) 
The general cyclization procedure was followed with 4-27 (same as 2-10, 27 mg, 0.12 mmol), 
potassium dec-1-yn-1-yltrifluoroborate (59 mg, 0.24 mmol), Re2O7 (1.8 mg, 0.0036 mmol), and 
DCM (6 mL). The reaction was stirred at rt for 12 h and another portion of Re2O7 (1.8 mg, 
0.0036 mmol) added. The reaction was stirred at rt for another 12 h, then was quenched with 5 
drops of pyridine. After evaporation of the solvent, the crude residue was purified by flash 
O OH H
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chromatography (1-5% ethyl acetate in hexanes) to give the product (33 mg, 81%, dr = 46:54). 
1H NMR (400 MHz, CDCl3) δ 7.26-7.31 (m, 2H), 7.16-7.22 (m, 3H), 5.75 (dt, J = 6.4, 15.2 Hz, 
1H), 5.59 (ddt, J = 1.2, 7.2, 15.2 Hz, 0.46H), 5.48 (ddt, J = 1.2, 7.2, 15.2 Hz, 0.54H), 4.69 (tt, J = 
2.0, 6.4 Hz, 0.54H), 4.56 (tt, J = 2.0, 6.4 Hz, 0.46H), 4.49 (q, J = 7.6 Hz, 0.54H), 4.27 (q, J = 7.6 
Hz, 0.46H), 2.63-2.76 (m, 2H), 2.30-2.40 (m, 2H), 2.18-2.24 (m, 2H), 2.09-2.18 (1H), 1.90-2.08 
(m, 1.54H), 1.74-1.82 (0.46), 1.57-1.65 (m, 1H), 1.45-1.56 (m, 2H), 1.35-1.43 (m, 2H), 1.31-1.34 
(m, 8H), 0.86-0.92 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 141.9, 141.8, 132.2, 132.0, 131.5, 
130.8, 128.5, 128.4, 128.3, 125.8, 85.34, 85.31, 80.7, 80.2, 79.4, 68.6, 68.4, 35.55, 35.53, 34.09, 
34.08, 33.9, 33.8, 32.06, 32.02, 31.9, 29.2, 29.1,2, 29.10, 28.90, 28.88, 28.66, 22.7, 18.4, 18.81, 
14.1; IR (neat) 3061, 3026, 2927, 2855, 1603, 1495, 1454, 1335, 1190, 1157, 1034, 967, 746, 
698 cm-1; HRMS (ESI) calcd for C24H35O [M+H]+ 339.2688, found 339.2702. 
 
(E)-2-Allyl-5-(4-phenylbut-1-en-1-yl)tetrahydrofuran (4-31) 
The general cyclization procedure was followed with 4-27 (27 mg, 0.12 
mmol), allyltrimethylsilane (57 mg, 0.50 mmol), Re2O7 (1.8 mg, 0.0037 mmol), and DCM (6.2 
mL). The reaction was initiated at 0 °C, then warmed up slowly to rt and  stirred at rt for a total 
of 16 h, after which the reaction was quenched with 5 drops of pyridine. After evaporation of the 
solvent, the crude residue was purified by flash chromatography (1-5% ethyl acetate in hexanes) 
to give the product (26 mg, 86%, dr = 53:47). 1H NMR (400 MHz, CDCl3) δ 7.29-7.34 (m, 2H), 
7.19-7.24 (m, 3H), 5.80-5.92 (m, 1H), 5.70-5.80 (m, 1H), 5.48-5.57 (m, 1H), 5.06-5.16 (m, 2H), 
4.40 (q, J = 6.8 Hz, 0.47H), 4.27 (q, J = 6.8 Hz, 0.53H), 4.09 (p, J = 6.4 Hz, 0.47H), 3.96 (p, J = 
6.4 Hz, 0.53H), 2.65-2.80 (m, 2H), 2.33-2.48 (m, 3H), 2.22-2.32 (m, 1H), 1.94-2.12 (m, 2H), 
1.56-1.70 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 141.9, 135.04, 134.99, 131.71, 131.66, 131.4, 
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128.46, 128.44, 128.3, 125.8, 116.85, 116.81, 80.2, 79.7, 78.8, 78.4, 40.45, 40.42, 35.6, 34.1, 
32.8, 32.0, 31.6, 30.6; IR (neat) 3063, 3026, 2929, 2855, 1641, 1603, 1495, 1453, 1362, 1052, 
994, 966, 913, 746, 698 cm-1; HRMS (ESI) calcd for C17H22O [M]+ 242.1671, found 242.1704. 
 
Ethyl-(E)-2-(5-(4-phenylbut-1-en-1yl)tetrahydrofuran-2-yl) 
acetate (4-33) 
The general cyclization procedure was followed with 4-27 (29 mg, 0.13 mmol), tert-butyl-((1-
ethoxyvinyl)oxy)dimethylsilane (131 mg, 0.655 mmol), Re2O7 (1.8 mg, 0.0036 mmol), and 
DCM (6 mL). The reaction was initiated at 0 °C, then was warmed up slowly to rt and stirred for 
a total of 24 h, after which the reaction was quenched with 5 drops of pyridine. After evaporation 
of the solvent, the crude residue was purified by flash chromatography (2-10% ethyl acetate in 
hexanes) to give the product (17 mg, 46%, dr = 3:2). 1H NMR (400 MHz, CDCl3) δ 7.25-7.32 (m, 
2H), 7.15-7.22 (m, 3H), 5.67-5.78 (m, 1H), 5.45-5.54 (m, 1H), 5.25-5.46 (m, 2H), 4.16 (q, J = 
7.2 Hz, 2H), 2.62-2.78 (m, 3H), 2.43-2.51 (m, 1H), 2.30-2.42 (m, 2H), 1.98-2.20 (m, 2H), 1.58-
1.70 (m, 2H), 1.27 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.2, 141.9, 131.8, 131.5, 
131.3, 128.4, 128.3, 125.8, 80.3, 79.7, 75.5, 75.2, 60.4, 41.1, 41.0, 35.5, 34.1, 32.7, 32.0, 31.9, 
31.1, 14.2; IR (neat) 3085, 3061, 3026, 2977, 2934, 1734, 1672, 1603, 1496, 1453, 1369, 1338, 
1299, 1253, 1187, 1095, 1052, 968, 747, 700 cm-1; HRMS (ESI) calcd for C18H23O3 [M-H]+ 
287.1647, found 287.1655. 
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 (E)-2-(Hex-5-yn-1-yloxy)-6-(prop-1-en-1-yl)tetrahydro-2H-pyran 
(4-36) 
The general cyclization procedure was followed with 4-341 (19 mg, 0.13 mmol), 5-hexyn-1-ol 
(26 mg, 0.27 mmol), Re2O7 (1.9 mg, 0.0040 mmol), and DCM (6.7 mL). The reaction was stirred 
at rt for 30 min, then was quenched with 5 drops of pyridine. After evaporation of the solvent, 
the crude residue was purified by flash chromatography (1-5% ethyl acetate in hexanes) to give 
the product (26 mg, 87%, dr = 65:35). 1H NMR (400 MHz, CDCl3) δ 5.69 (ddq, J = 0.8, 6.4, 17.2 
Hz, 1H), 5.53 (ddq, J = 1.6, 6.8, 17.2 Hz, 0.35H), 5.47 (ddq, J = 1.6, 6.8, 17.2 Hz, 0.65H), 4.81-
4.85 (m, 0.65H), 4.41 (dd, J = 2.4, 9.6 Hz, 0.35H), 4.13 (dd, J = 7.2, 10.4 Hz, 0.65H), 3.92 (dt, J 
= 6.8, 9.6 Hz, 0.35H), 3.84 (dd, J = 6.0, 10.4 Hz, 0.35H), 3.69 (dt, J = 6.4, 9.6 Hz, 0.65H), 3.46 
(dt, J = 6.4, 9.6 Hz, 0.35H), 3.41 (dt, J = 6.4, 9.6 Hz, 0.65H), 1.19-2.26 (m, 2H), 1.95 (t, J = 2.4 
Hz, 0.65H), 1.93 (t, J = 2.4 Hz, 0.35H), 1.80-1.92 (m, 1H), 1.50-1.78 (m, 11H), 1.22-1.50 (m, 
2H); 13C NMR (100 MHz, CDCl3) δ 132.4, 131.8, 127.1, 126.3, 102.1, 97.3, 84.4, 76.4, 69.5, 
68.36, 68.32, 68.0, 66.3, 31.4, 31.1, 31.0, 29.6, 28.8, 25.5, 25.2, 22.1, 18.3, 18.2, 18.0, 17.81, 
17.78; IR (neat) 3306, 2939, 2866, 1455, 1438, 1373, 1329, 1262, 1144, 1121, 1069, 1044, 1022, 
988. 966, 929, 888, 629 cm-1; HRMS (ESI) calcd for C14H23O2 [M+H]+ 223.1698, found 
223.1687. 
 
 (E)-2-(prop-1-en-1-yl)-6-(propylthio)tetrahydro-2H-pyran (4-38) 
The general cyclization procedure was followed with 4-34 (20.2 mg, 
0.142 mmol), propanethiol (21.6 mg, 0.284 mmol), 3*Re2O7 (2.1 mg, 0.0042 mmol), and DCM 
(7.1 mL). The reaction was stirred at rt for 2h (2.1 mg, 0.0042 mmol R2O7 was added three times 
at time 0, 40 min, 80min), then was quenched with 5 drops of pyridine. After evaporation of the 
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solvent, the crude residue was purified by flash chromatography (1-5% ethyl acetate in hexanes) 
to give the product (20.0 mg, 70%, dr = 53:47). 1H NMR (400 MHz, CDCl3) δ 5.63-5.75 (m, 1H), 
5.45-5.56 (m, 1H), 5.34 (d, J = 4.8, 0.53H), 4.48-4.56 (m, 1H), 3.81(dd, J = 6.0, 10.4, 0.43H), 
2.46-2.75 (m, 2H), 1.50-2.00 (m, 11H), 1.28-1.53 (m, 1H), 0.99 (t, J = 7.2, 3H); 13C NMR (100 
MHz, CDCl3) δ 132.14, 132.06, 127.3, 126.6, 82.5, 81.8, 79.1, 69.1, 32.6, 32.4, 31.54, 31.48, 
31.0, 30.3, 24.2, 23.4, 23.2, 19.4, 17.9, 17.8, 13.6; IR (neat) 2936, 2857, 1453, 1438, 1376, 1338, 
1293, 1261, 1236, 1191, 1071, 1020, 964, 933, 909 cm-1; HRMS (ESI) calcd for C11H21OS 
[M+H]+ 201.1313, found 201.1329. 
 
trans-2-allyl-6((E)-prop-1-en-1-yl)tetrahydro-2H-pyran (4-40) 
The general cyclization procedure was followed with 4-34 (28.4 mg, 
0.20 mmol), Et3SiH (92 mg, 0.80 mmol), HCat 2-1 ([3,5-(CF3)2C6H3NH]2SO2, 10.4 mg, 0.02 
mmol), Re2O7 (2.9 mg, 0.006 mmol), and DCM (10 mL). The reaction was stirred at 0 °C for 20 
h, then was quenched with 5 drops of pyridine. After evaporation of the solvent under slightly 
reduced presssure, 5 µl of benzyldimethylsilane was added into the crude as an internal standard. 
The mixture was dissolved in CDCl3 and 1H NMR showed a yield of 83%. 1H NMR (400 MHz, 
CDCl3) δ 5.83 (ddt, J = 6.8, 10.0, 17.2, 1H), 5.56-5.71 (m, 2H), 5.02-5.11 (m, 2H), 4.28 (m, 1H), 
3.79 (dq, J = 2.8, 7.2, 1H), 2.39 (tp, J = 1.2, 7.2, 1H), 2.01 (tp, J = 1.2, 7.2, 1H), 1.61-1.75 (m, 
7H), 1.49-1.57 (m, 1H), 1.30-1.40 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 135.4, 131.5, 127.3, 
116.4, 72.1, 70.7, 38.9, 29.8, 29.7, 18.6, 17.9; IR (neat) 2935, 2856, 1688, 1641, 1441, 1375, 
1278, 1200, 1178, 1139, 1035, 965, 912, 861, 838 cm-1; HRMS (ESI) calcd for C11H19O [M+H]+ 
167.1436, found 167.1455. 
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Reagents and Cconditions:
a) Pent-4-en-1-ylmagnesium bromide, Et2O, 0 ºC, 74%; B) DIBAL-H, CH2Cl2, -78 ºC, 88%;
c) DMSO, (COCl)2, Et3N, CH2Cl2; d) Diethyl (2-oxopropyl)phosphonate, NaH, THF, 79%
for two steps; e) (Z)-2-Butene-1,4-diol, Grubbs-Hoveyda 2nd generation matathesis catalyst,
CH2Cl2, 68%.  
Scheme C12 Synthesis of substrate 4-44 
    
 (3E, 12E)-14-Hydroxytetradeca-3, 12-diene-2, 8-dione (4-44) 
1H NMR (400 MHz, CDCl3) δ 6.74 (dt, J = 6.8, 16.0 Hz, 1H), 6.06 (dt, J = 1.6, 
16.0 Hz, 1H), 5.44-5.68 (m, 2H), 4.04-4.17 (m, 2H), 2.36-2.45 (m, 4H), 2.18-
2.26 (m, 2H), 2.23 (s, 3H), 1.99-2.09 (m, 2H), 1.75 (p, J = 7.6 Hz, 2H), 1.66 (p, J = 7.6 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ 210.1, 198.7, 147.3, 131.8, 130.0, 63.5, 42.1, 41.7, 31.8, 31.5, 
26.9, 23.0, 21.9; IR (neat) 3445, 3000, 2935, 1709, 1672, 1626, 1413, 1363, 1256, 1186, 1090, 
974 cm-1; HRMS (EI) calcd for C14H22O3 [M]+ 238.1569, found 238.1595. 
 
rac-1-((2R, 4aR, 5R, 8aR)-2-Vinyloctahydro-2H-chromen-5-yl)propan-2-one 
(4-45) The general reductive cyclization procedure was followed with 4-44 (20 
mg, 0.086 mmol), Et3SiH (20 mg, 0.17 mmol), Re2O7 (1.2 mg, 0.0026 mmol), 
and DCM (4.3 mL). The reaction was stirred at rt for 20 h, then was quenched 
with 5 drops of pyridine. After evaporation of the solvent, the crude residue was purified by flash 
chromatography (2% -8% ethyl acetate in hexanes) to give the products (17 mg, 92%, 4-45:4-46  
= 2:1).  
1H NMR (400 MHz, CDCl3) δ 5.86 (ddd, J = 6.0, 10.8, 17.2 Hz, 1H), 5.24 (dt, J = 1.6, 17.2 Hz, 
1H), 5.10 (dt, J = 1.6, 10.4 Hz, 1H), 3.83 (ddddd J = 1.2, 1.2, 2.4, 5.6, 11.2 Hz, 1H), 3.09 (ddd, J 
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= 4.0, 9.6, 10.8 Hz, 1H), 2.59 (dd, J = 4.0, 16.4 Hz, 1H), 2.16 (dd, J = 8.4 Hz, 16.4, 1H), 2.15 (s, 
3H), 1.90-1.96 (m, 1H), 1.85 (dq, J = 3.6, 12.8 Hz, 1H), 1.71-1.80 (m, 2H), 1.61-1.70 (m, 2H), 
1.31-1.45 (m, 3H), 1.15 (dq, J = 4.0, 12.4 Hz, 1H), 0.90-1.13 (m, 2H); 13C NMR (100 MHz, 
CDCl3) δ 208.8, 139.3, 115.0, 81.1, 78.1, 47.4, 45.6, 36.8, 32.6, 32.5, 32.1, 30.7, 27.7, 23.8; IR 
(neat) 3079, 2925, 2858, 1716, 1645, 1447, 1357, 1301, 1262, 1229, 1207, 1158, 1061, 989, 921, 
882, 866, 840 cm-1; HRMS (ESI) calcd for C14H22O2 [M]+ 222.1620, found 222.1623. 
 
 rac-1-((2R, 4aS, 5S, 8aR)-2-vinyloctahydro-2H-chromen-5-yl)propan-2-one 
(4-46) 
1H NMR (400 MHz, CDCl3) δ 5.91 (ddd, J = 6.0, 10.4, 17.2 Hz, 1H), 5.25 (dt, J 
= 1.6, 17.2 Hz, 1H), 5.09 (dt, J = 1.6, 10.4 Hz, 1H), 3.88 (ddddd J = 0.8, 1.2, 2.0, 
4.8, 9.6 Hz, 1H), 3.64 (q, J = 2.8 Hz, 1H), 2.57 (dd, J = 4.0, 15.6 Hz, 1H), 2.30-2.40 (m, 1H), 
2.15 (s, 3H), 2.12 (dd, J = 8.8, 15.6 Hz, 1H), 1.85-1.94 (m, 2H), 1.88-1.76 (m, 2H), 1.44-1.66 (m, 
2H), 1.36-1.43 (m, 3H), 1.18-1.24 (m, 1H), 0.92-1.03 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 
209.2, 139.7, 114.6, 79.1, 75.7, 48.8, 39.7, 32.8, 32.3, 30.6, 29.7, 26.6, 25.9, 20.6; IR (neat) 3079, 
2932, 2861, 1715, 1645, 1443, 1410, 1358, 1308, 1269, 1231, 1198, 1160, 1153, 1110, 1065, 
1050, 1031, 988, 919, 899, 838 cm-1; HRMS (ESI) calcd for C14H23O2 [M]+ 223.1698, found 
223.1706. 
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Reaction Cconditions:
a) O3, CH2Cl2, -78 ºC, then Me2S, rt, 56%; b) (3-Phenylpropyl)magnesium bromide, Et2O, 0 ºC, 73%; 
c) PCC, Celite, CH2Cl2, 98%; d) (Z)-2-Butene-1,4-diol or (Z)-hex-3-ene-2,5-diol, Grubbs-Hoveyda 2nd
metathesis catalyst, CH2Cl2, 41% (R = H), or 67% (R = CH3).
a-d
HO R
O
 
Scheme C13 Synthesis of substrates 4-58 (R = H) and 4-61 (R = CH3) 
 
 (R, E)-10-Hydroxy-7-methyl-1-phenyldec-8-en-4-one (4-58) 
1H NMR (400 MHz, CDCl3) δ 7.27-7.33 (m, 2H), 7.16-7.24 (m, 
3H), 5.60 (dt, J = 5.6, 15.2 Hz, 1H), 5.50 (dd, J = 7.6, 15.2 Hz, 1H), 4.09 (d, J = 6.0 Hz, 2H), 
2.63 (t, J = 7.6 Hz, 2H), 2.42 (t, J = 7.6 Hz, 2H), 2.37 (t, J = 7.6 Hz, 2H), 2.12 (heptet, J = 7.2 
Hz, 1H), 2.09 (br, 1H), 1.92 (p, J = 7.2 Hz, 2H), 1.48-1.67 (m, 2H), 1.02 (d, J = 6.8 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 211.2, 141.6, 137.5, 128.5, 128.4, 128.3, 126.0, 63.5, 42.0, 40.6, 
36.1, 35.1, 30.4, 25.2, 20.5; IR (neat) 3411, 3061, 3026, 2928, 2867, 1710, 1603, 1496, 1454, 
1409, 1374, 1263, 1214, 1094, 1007, 973, 748, 700 cm-1; HRMS (ESI) calcd for C17H24O2 [M]+ 
260.1776, found 260.1772. 
 
 (2S, 3R, 6R)-3-Methyl-6-(3-phenylpropyl)-2-vinyltetrahydro-2H-
pyran (4-59)  
The general reductive cyclization procedure was followed with 4-58 (44 mg, 0.17 mmol), 
Ph3SiH (88 mg, 0.34 mmol), Re2O7 (2.5 mg, 0.0048 mmol), and DCM (8.4 mL). The reaction 
was stirred at rt for 15 h, then was quenched with 5 drops of pyridine. After evaporation of the 
solvent, the crude residue was purified by flash chromatography (1-5% ethyl acetate in hexanes) 
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to give the product (34 mg, 82%, 4-59:4-60 = 9:1).  1H NMR (400 MHz, C6D6) δ 7.13-7.19 (m, 
2H), 7.04-7.10 (m, 2H), 5.89 (ddd, J = 6.8, 10.4, 17.2 Hz, 1H), 5.28 (ddd, J = 1.2, 2.0, 17.2 Hz, 
1H), 5.08 (ddd, J = 1.2, 2.0, 10.4 Hz, 1H), 3.27 (dd, 6.8, 9.6 Hz, 1H), 3.13 (dddd, J = 2.4, 4.8, 
7.2, 10.8 Hz, 1H), 2.51 (t, J = 7.6 Hz, 2H), 1.78-1.90 (m, 1H), 1.54-1.70 (m, 3H), 1.13-1.44 (m, 
4H), 0.97 (dq, J = 4.0, 12.0 Hz, 1H), 0.71 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, C6D6) δ 
142.6, 138.5, 128.4, 128.2, 125.6, 115.5, 84.9, 76.9, 36.1, 35.3, 32.7, 32.0, 27.7, 17.5; IR (neat) 
3082, 3062, 3025, 2927, 2847, 1645, 1603, 1495, 1455, 1408, 1376, 1303, 1227, 1152, 1097, 
1075, 1017, 989, 922, 748, 698 cm-1; HRMS (ESI) calcd for C17H25O [M+H]+ 245.1905, found 
245.1906. 
 
 (2R, 3R, 6S)-3-methyl-6-(3-phenylpropyl)-2-vinyltetrahydro-2H-
pyran (4-60)  
1H NMR (400 MHz, CDCl3) δ 7.25-7.31 (m, 2H), 7.15-7.22 (m, 3H), 5.80 (ddd, J = 4.8, 10.8, 
17.2 Hz, 1H), 5.23 (dt, J = 1.6, 17.2 Hz, 1H), 5.11 (dt, J = 1.6, 10.8 Hz, 1H), 3.95-3.40 (m, 1H), 
3.31-3.39 (m, 1H), 2.64 (t, J = 7.2 Hz, 2H), 1.59-1.87 (m, 6H), 1.32-1.55 (m, 3H), 0.92 (d, J = 
7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 142.7, 138.8, 128.5, 128.2, 125.6, 114.1, 80.5, 78.2, 
36.13, 36.05, 31.8, 30.8, 27.5, 26.1, 11.9; IR (neat) 3084, 3062, 3025, 2931, 2854, 1645, 1603, 
1495, 1453, 1409, 1379, 1326, 1206, 1107, 1077, 1037, 990, 919, 747, 698 cm-1; HRMS (EI) 
calcd for C17H24O [M]+ 244.1827, found 244.1822. 
 
(7R, E)-10-Hydroxy-7-methyl-1-phenylundec-8en-4-one (4-61) 
1H NMR (400 MHz, CDCl3) δ 7.27-7.33 (m, 2H), 7.17-7.24 (m, 
3H), 5.41-5.53 (m, 2H), 4.27 (p, J = 6.4 Hz, 1H), 2.64 (t, J = 7.6 Hz, 2H), 2.422 (t, J = 7.2 Hz, 
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1H), 2.418 (t, J = 7.2 Hz, 1H), 2.37 (t, J = 7.6 Hz, 1H), 2.36 (t, J = 7.6 Hz, 1H), 2.05-2.14 (m, 
1H), 1.92 (p, J = 7.2 Hz, 2H), 1.79 (br, 1H), 1.58-1.67 (m, 1H), 1.48-1.58 (m, 1H), 1.27 (d, J = 
6.4 Hz, 3H), 1.01 (d, J = 6.8 Hz, 1.5H), 1.00 (d, J = 6.8 Hz, 1.5H); 13C NMR (100 MHz, CDCl3) 
δ 211.0, 210.9, 141.6, 135.5, 135.4, 133.5, 128.5, 128.4, 126.0, 68.69, 68.67, 42.0, 40.63, 40.60, 
36.01, 35.98, 35.1, 30.4, 25.2, 23.61, 23.57, 20.56, 20.54; IR (neat) 3411, 3061, 3026, 2963, 
2927, 2868, 1710, 1603, 1496, 1453, 1408, 1371, 1293, 1062, 972, 945, 748, 700 cm-1; HRMS 
(ESI) calcd for C18H25O [M-OH]+ 257.1905, found 257.1883. 
 
(2R, 3R, 6R)-3-Methyl-6-(2-phenylpropyl)-2((E)-prop-1-en-1-
yl)tetrahydro-2H-pyran (4-62) 
The general reductive cyclization procedure was followed with 4-61 (41 mg, 0.15 mmol), Et3SiH 
(35 mg, 0.30 mmol), Re2O7 (2.2 mg, 0.0045 mmol), and DCM (7.5 mL). The reaction was stirred 
at 0 °C for 22 h, then was warmed to rt and stirred for another 2 h. The reaction was quenched 
with 5 drops of pyridine. After evaporation of the solvent, 5 µl of benzyldimethylsilane was 
added into the crude as an internal standard. The mixture was dissolved in C6D6  and 1H NMR 
showed a yield of 77% (dr = 11:1). 1H NMR (400 MHz, C6D6) δ 7.13-7.19 (m, 2H), 7.04-7.10 
(m, 3H), 5.67 (ddq, J = 0.4, 6.4, 15.2 Hz, 1H), 5.57 (ddq, J = 1.2, 6.8, 15.2 Hz, 1H), 3.30 (dd, J = 
7.2, 9.6 Hz, 1H), 3.17 (dddd, J = 2.4, 4.8, 7.2, 10.8 Hz, 1H), 2.53 (t, J = 7.2 Hz, 2H), 1.80-1.93 
(m, 1H), 1.59-1.72 (m, 3H), 1.57 (d, J = 6.4 Hz, 3H), 1.17-1.42 (m, 4H), 1.02 (dq, J = 4.4, 12.8 
Hz, 1H), 0.75 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, C6D6) δ 142.6, 132.1, 128.5, 128.2, 
127.0, 125.6, 85.8, 77.0, 36.2, 36.1, 35.5, 32.8, 32.1, 27.7, 17.8, 17.5; IR (neat) 3061, 3026, 2927, 
2847, 1603, 1496, 1453, 1376, 1325, 1151, 1079, 1031, 1014, 964, 747, 698 cm-1; HRMS (ESI) 
calcd for C18H27O [M+H]+ 259.2062, found 259.2069. 
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Reaction Cconditions:
a) NaH, THF, then TBSCl, 0 ºC, 51%; b) Py•SO3, Et3N, CH2Cl2, 84%; c) Triethyl phosphonateacetate,
NaH, THF, 0 ºC, 98%; d) DIBAL-H, CH2Cl2, - 78 ºC, 98%; e) TBDPSCl, imidazole, CH2Cl2; f) HCl 
(1.0M), THF, H2O (1:1); 85% for two steps; g) Py•SO3, DMSO, Et3N, CH2Cl2, 60%; j) Bu4NF, THF, 
94%.  
Scheme C14 Synthesis of substrate 4-63 
 
 (E)-10-hydroxy-6-methyl-1-phenyldec-8-en-4-one (4-63) 
1H NMR (400 MHz, CDCl3) δ 7.24-7.30 (m, 2H), 7.13-7.21 (m, 
3H), 5.55-5.66 (m, 2H), 4.06 (d, J = 3.2 Hz, 2H), 2.60 (t, J = 7.6 Hz, 2H), 2.33-2.40 (m, 3H), 
2.13-2.20 (m, 1H), 2.08 (h, J = 6.8 Hz, 1H), 1.93-2.03 (m, 2H), 1.88 (p, J = 7.2 Hz, 2H), 1.76 
(br, 1H), 0.88 (d, J = 6.4 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 210.71, 141.6, 131.1, 130.5, 
128.5, 128.4, 126.0, 63.5, 49.4, 42.6, 39.5, 35.1, 29.1, 25.2, 19.9; IR (neat) 3403, 3061, 3025, 
2927, 2870, 1708, 1602, 1495, 1454, 1407, 1372, 1212, 1085, 1005, 972, 748, 700 cm-1; HRMS 
(ESI) calcd for C17H23O [M-OH]+ 243.1749, found 243.1748. 
 
rac-(2R, 4S, 6R)-4-Methyl-2-(3-phenylpropyl)-6-vinyltetrahydro-2H-
pyran (4-64) 
The general rearrangement cyclization procedure was followed with 4-63 (40 mg, 0.15 mmol), 
Et3SiH (36 mg, 0.31 mmol), Re2O7 (2.2 mg, 0.0046 mmol), and DCM (7.6 mL). The reaction 
was stirred at rt for 20 h, then was quenched with 5 drops of pyridine. After evaporation of the 
solvent, the crude mixture was purified by flash chromatography (1-5% ethyl acetate in hexanes) 
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to give the product (35 mg, 88%, dr > 30:1). 1H NMR (400 MHz, CDCl3) δ 7.25-7.31 (m, 2H), 
7.15-7.21 (m, 3H), 5.88 (m, ddd, J = 5.6, 10.4, 17.2 Hz, 1H), 5.25 (dt, J = 1.6, 17.2 Hz, 1H), 5.09 
(dt, J = 1.6, 10.4 Hz, 1H), 3.81 (ddddd, J = 1.2, 2.0, 3.2, 5.2, 11.2 Hz, 1H), 3.56 (dddd, J = 1.6, 
5.2, 8.8, 9.2 Hz, 1H), 2.64 (t, J = 7.6 Hz, 2H), 1.75-1.87 (m, 1H), 1.58-1.75 (m, 5H), 1.44-1.55 
(m, 1H), 0.95 (d, J = 6.4 Hz, 3H), 0.82-1.00 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 142.7, 
139.6, 128.5, 128.3, 125.6, 114.4, 77.9, 77.2, 40.06, 40.0, 36.03, 36.02, 30.23, 27.6, 22.3; IR 
(neat) 3083, 3062, 3025, 2947, 2924, 2862, 2836, 1647, 1603, 1495, 1454, 1409, 1370, 1310, 
1181, 1133, 1092, 1081, 1029, 988, 919, 748, 698 cm-1; HRMS (ESI) calcd for C17H25O [M+H]+ 
245.1905, found 245.1928. 
 
Reaction Cconditions:
a) O3, CH2Cl2, -78 ºC, then Me2S, rt, 56%; b) (MeO)3CH, TsOH, MeOH, 50 ºC, 58%; c) Methyl acrylate,
Grubbs-Hoveyda 2nd generation metathesis catalyst, CH2Cl2, reflux, 72%; d) DIBAL-H, CH2Cl2, -78 ºC,
94%; e) Py•SO3, DMSO, Et3N, CH2Cl2, 89%; f) (3-Phenylpropyl)magnesium bromide, Et2O, 0 ºC, 92%; 
g) HOAc, H2O (1:1), 92%.
a-g H
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Scheme C15 Synthesis of substrate 4-65 
 
 (4R, E)-7-Hydroxy-4-methyl-10-phenyldec-5-enal (4-65) 
1H NMR (300 MHz, CDCl3) δ 9.62-9.68 (m, 1H), 7.15-7.23 (m, 
2H), 7.05-7.14 (m, 3H), 5.30-5.42 (m, 2H), 3.98 (p, J = 5.1 Hz, 1H), 2.56 (t, J = 7.2 Hz, 2H), 
2.32 (q, J = 6.6 Hz, 2H), 1.98-2.14 (m, 1H), 1.40-1.70 (m, 7H), 0.94 (d, J = 6.6 Hz, 1.5H), 0.93 
(d, J = 6.6 Hz, 1.5H); 13C NMR (75 MHz, CDCl3) δ 202.7, 202.5, 142.3, 136.3, 136.2, 132.6, 
128.4, 128.3, 125.8, 72.7, 41.9, 36.9, 36.1, 35.8, 28.7, 27.3, 20.54, 20.49; IR (neat) 3412, 3025, 
O H
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2928, 2861, 1721, 1603, 1495, 1453, 1374, 1081, 1017, 973, 749. 699 cm-1; HRMS (ESI) calcd 
for C17H24O2Na [M+Na]+ 283.1674, found 283.1681. 
 
 (2R, 3R)-3-Methyl-2-((E)-5-phenylpent-1-en-1-yl)tetrahydro-2H-pyran (4-
66)  
The general reductive cyclization procedure was followed with 4-65 (42 mg, 
0.16 mmol), Et3SiH (37 mg, 0.32 mmol), Re2O7 (2.3 mg, 0.0048 mmol), and DCM (8.0 mL). 
The reaction was stirred at rt for 24 h, then was quenched with 5 drops of pyridine. After 
evaporation of the solvent, the crude residue was purified by flash chromatography (1-5% ethyl 
acetate in hexanes) to give the product (32 mg, 83%, dr = 3:1).  
4-66: 1H NMR (400 MHz, CDCl3) δ 7.26-7.32 (m, 2H), 7.16-7.22 (m, 3H), 5.73 (dt, J = 6.8, 15.2 
Hz, 1H), 5.45 (ddt, J = 1.2, 8.0, 15.2 Hz, 1H), 4.01 (ddt, J = 1.6, 4.4, 11.2 Hz, 1H), 3.43 (ddd, J = 
2.4, 11.2, 12.4 Hz, 1H), 3.31 (dd, J = 8.0, 9.2 Hz, 1H), 2.64 (t, J = 8.0 Hz, 2H), 2.05-2.16 (m, 
2H), 1.80-1.88 (m, 1H), 1.63-1.79 (m, 3H), 1.51-1.59 (m, 1H), 1.35-1.47 (m, 1H), 1.19 (dq, J = 
4.0, 12.8 Hz, 1H), 0.80 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 142.5, 133.8, 130.4, 
128.5, 128.3, 125.7, 85.2, 68.1, 35.7, 35.4, 32.4, 31.9, 30.9, 26.6, 18.2; IR (neat) 3025, 2927, 
2846, 1603, 1495, 1455, 1373, 1222, 1152, 1095, 1071, 1034, 986, 967, 745, 698 cm-1; HRMS 
(EI) calcd for C17H23O [M-H]+ 243.1749, found 243.1743. 
 
 (2S, 3R)-3-methyl-2-((E)-5-phenylpent-1-en-1-yl)tetrahydro-2H-pyran 
(minor) 
Minor product: 1H NMR (400 MHz, C6D6) δ 7.13-7.20 (m, 2H), 7.03-7.10 (m, 2H), 5.77 (ddt, J 
= 1.6, 6.8, 15.2 Hz, 1H), 5.49 (ddt, J = 1.6, 5.2, 15.2 Hz, 1H), 3.87-3.94 (m, 2H), 3.31 (dt, J = 2.8, 
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11.2 Hz, 1H), 2.49 (t, J = 8.0 Hz, 2H), 1.99 (q, J = 7.2 Hz, 2H), 1.55-1.71 (m, 4H), 1.39-1.54 (m, 
2H), 0.97-1.05 (m, 1H), 0.99 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, C6D6) δ 142.4, 130.5, 
130.2, 128.4, 128.3, 125.7, 79.9, 67.6, 35.3, 32.7, 32.0, 31.2, 30.3, 21.4, 12.6; IR (neat) 3061, 
3026, 2932, 2855, 1603, 1495, 1453, 1378, 1354, 1269, 1215, 1202, 1143, 1118, 1092, 1074, 
1054, 1030, 1011, 965, 745, 698 cm-1; HRMS (EI) calcd for C17H23O [M-H]+ 243.1749, found 
243.1755. 
 
O H
HO OH
a-j
Reaction Cconditions:
a) NaH, THF, then TBSCl, 0 ºC, 51%; b) Py•SO3, Et3N, CH2Cl2, 84%; c) Triethyl phosphonateacetate,
NaH, THF, 0 ºC, 98%; d) HF•Pyridine, THF, 99%; e) PCC, Celite, CH2Cl2; f) p-TsOH, BnOH, Na2SO4, 
THF, 50% for two steps; g) DIBAL-H, CH2Cl2, -78 ºC, 97%; h) Py•SO3, DMSO, Et3N, Ch2C2, 64%; i) 
(3-Phenylpropyl)magnesium bromide, Et2O, 0 ºC, 87%; j) CF3CO2H, THF, H2O, 82%.
OH
 
Scheme C16 Synthesis of substrate 4-67 
 
 (E)-7-hydroxy-3-methyl-10-phenyldec-5-enal (4-67) 
1H NMR (400 MHz, CDCl3) δ 9.73-9.77 (m, 1H), 7.25-7.31 (m, 
2H), 7.15-7.21 (m, 3H), 5.54-5.63 (m, 1H), 5.45-5.53 (m, 1H), 4.09 (q, J = 6.0 Hz, 1H), 2.65 (t, J 
= 7.2 Hz, 3H), 2.39-2.46 (m, 1H), 2.11-2.28 (m, 2H), 1.97-2.10 (m, 2H), 1.48-1.78 (m, 5H), 0.98 
(d, J = 6.4 Hz, 1.5H), 0.97 (d, J = 6.4 Hz, 1.5H); 13C NMR (100 MHz, CDCl3) δ 202.7, 202.6, 
142.3, 135.6, 129.1, 129.0, 128.4, 128.3, 125.872.8, 72.7, 50.4, 50.3, 39.5, 39.4, 36.9, 35.8, 
28.18, 28.17, 27.3, 19.96, 19.93; IR (neat) 3420, 3084, 3061, 3025, 2929, 2860, 2720, 1722, 
O H
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1602, 1496, 1454, 1379, 1251, 1097, 1081, 1013, 972, 749, 699 cm-1; HRMS (ESI) calcd for 
C17H23O2 [M+Na]+ 259.1698, found 259.1692. 
 
 rac-(2R, 4S)-4-Methyl-2-((E)-5-phenylpent-1-en-1-yl)tetrahydro-2H-pyran 
(4-68) 
The general reductive cyclization procedure was followed with 4-67 (42 mg, 
0.16 mmol), Et3SiH (38 mg, 0.32 mmol), Re2O7 (2.3 mg, 0.0048 mmol), and DCM (8.1 mL). 
The reaction was stirred at rt for 36 h, then was quenched with 5 drops of pyridine. After 
evaporation of the solvent, the crude residue was purified by flash chromatography (1-5% ethyl 
acetate in hexanes) to give the product (34 mg, 87%, dr = 4.6:1).  
4-68: 1H NMR (400 MHz, CDCl3) δ 7.26-7.33 (m, 2H), 7.17-7.23 (m, 3H), 5.72 (dt, J = 6.4, 15.6 
Hz, 1H), 5.45 (dd, J = 6.4, 15.6 Hz, 1H), 4.05 (dd, J = 3.6, 11.2 Hz, 1H), 3.77 (dd, J = 6.4, 10.8 
Hz, 1H), 3.49 (dt, J = 1.6, 12.0 Hz, 1H), 2.65 (t, J = 7.6 Hz, 2H), 2.10, (q, J = 7.2 Hz, 2H), 1.75 
(p, J = 7.6 Hz, 2H), 1.60-1.65 (m, 2H), 1.50-1.60 (m, 1H), 1.24 (dq, J = 4.0, 12.0 Hz, 1H), 1.05 
(q, J = 12.4 Hz, 1H), 0.97 (d, J = 6.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 142.5, 131.7, 
131.2, 128.5, 128.3, 125.7, 78.0, 68.0, 40.9, 35.4, 34.5, 31.9, 30.8, 30.3, 22.3; IR (neat) 3084, 
3061, 3026, 2922, 2839, 2728, 2641, 1673, 1603, 1495, 1454, 1368, 1305, 1255, 1171, 1091, 
1028, 990, 967, 911, 877, 839, 745, 698 cm-1; HRMS (EI) calcd for C17H23O [M-H]+ 243.1749, 
found 243.1745. 
 
rac-(2S, 4S)-4-methyl-2-((E)-5-phenylpent-1-en-1-yl)tetrahydro-2H-pyran 
(minor product) 
1H NMR (400 MHz, CDCl3) δ 7.25-7.31 (m, 2H), 7.15-7.21 (m, 3H), 5.68 (ddt, J 
OH
Ph
OH
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= 0.8, 6.4, 15.6 Hz, 1H), 5.54 (dd, J = 5.6, 15.6 Hz, 1H), 3.68-3.80 (m, 2H), 2.63 (t, J = 7.6 Hz, 
2H), 2.09 (q, J = 7.2 Hz, 2H), 2.00 (hexet, J = 6.0 Hz, 1H), 1.69-1.79 (m, 3H), 1.62-1.69 (m, 1H), 
1.39-1.46 (m, 1H), 1.23-1.38 (m, 1H), 1.05 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
142.4, 131.8, 131.2, 128.5, 128.3, 125.7, 72.6, 62.3, 37.9, 35.4, 32.7, 32.0, 30.8, 24.9, 19.4; IR 
(neat) 3061, 3026, 2953, 2925, 2853, 1603, 1495, 1454, 1379, 1346, 1334, 1271, 1245, 1188, 
1079, 1052, 968, 745, 698 cm-1; HRMS (ESI) calcd for C17H23O [M-H]+ 243.1749, found 
243.1753. 
 
Reaction Cconditions:
a) O3, CH2Cl2, -78 ºC, then Me2S, rt, 56%; b) Ethyl diazoacetate, SnCl2, rt, 80%; c) (Z)-2-Butene-1,4-
diol, Grubbs-Hoveyda 2nd metathesis catalyst, CH2Cl2, rt, 45%.
a-c
HO
O OEt
O
 
Scheme C17 Synthesis of substrate 4-69 
 
Ethyl-(R, E)-9-hydroxy-6-methyl-oxonon-7-enoate (4-69) 
1H NMR (300 MHz, CDCl3) δ 5.58 (dt, J = 5.4, 15.3 Hz, 1H), 
5.44 (dd, J = 7.8, 15.3 Hz, 1H), 4.17 (q, J = 7.2 Hz, 2H), 4.05 (d, J = 5.4 Hz, 2H), 3.40 (s, 2H), 
2.49 (t, J = 7.2 Hz, 2H), 2.12 (heptet, J = 6.9 Hz, 1H), 2.02 (br, 1H), 1.48-1.70 (m, 2H), 1.25 (t, J 
= 7.2 Hz, 3H), 0.98 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 202.9, 167.4, 137.3, 
128.6, 63.4, 61.4, 49.4, 40.8, 36.2, 30.0, 20.5, 14.1; IR (neat) 3413, 2960, 2930, 2871, 1741, 
1714, 1645, 1455, 1411, 1369, 1314, 1256, 1158, 1094, 1029, 974 cm-1; HRMS (ESI) calcd for 
C12H20O4 [M]+ 228.1362, found 228.1364. 
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O
O
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ethyl 2-((2S, 5R, 6S)-5-methyl-6-vinyltetrahydro-2H-Pyran-2-yl) 
acetate (4-70)  
The general rearrangement cyclization procedure was followed with 4-69 (41 mg, 0.179 mmol), 
Et3SiH (42 mg, 0.357 mmol), Re2O7 (2.6 mg, 0.0054 mmol), DCM (8.9 mL), the reaction was 
stirred at RT for 72 hrs, after which the reaction was quenched with 5 drops of pyridine. After 
evaporation of the solvent, 5 µl of benzyldimethylsilane was added into the crude as an internal 
standard, then the mixture was dissolved in CDCl3 and 1H NMR was taken to give a yield of 
92% (dr = 4.8:1). When the same reaction was performed in DCE at 50 °C for 24 hrs, a yield of 
88% (dr = 4.4 :1) was obtained. 
4-70: 1H NMR (400 MHz, CDCl3) δ 5.79 (ddd, J = 7.2, 10.4, 17.6 Hz, 1H), 5.24 (ddd, J = 1.2, 
2.0, 17.6 Hz, 1H), 5.16 (ddd, J = 1.2, 2.0, 10.4 Hz, 1H), 4.14 (q, J = 7.2 Hz, 2H), 3.79 (ddd, J = 
2.0, 6.4, 8.4, 9.2 Hz, 1H), 3.41 (dd, J = 7.2, 9.6 Hz, 1H), 2.61 (dd, J = 7.2, 15.2 Hz, 1H), 2.41 (dd, 
J = 6.4, 15.2 Hz, 1H), 1.84 (dq, J = 3.2, 12.0 Hz, 1H), 1.67-1.74 (m, 1H), 1.30-1.42 (m, 2H), 
1.25 (t, J = 7.2 Hz, 3H), 1.19-1.30 (m, 1H), 0.81 (d, J = 6.4 Hz, 3H). 13C NMR (100 MHz, 
CDCl3) δ 171.4, 137.6, 117.0, 85.3, 74.0, 60.4, 41.6, 34.8, 32.3, 31.6, 17.6, 14.2. IR (neat) 2978, 
2929, 2873, 2852, 1738, 1644, 1458, 1376, 1339, 1299, 1271, 1251, 1229, 1185, 1151, 1101, 
1071, 1033, 991, 958, 924, 854 cm-1; HRMS (ESI) calcd for C12H20O3 [M]+ 212.1412, found 
212.1408. 
 
ethyl 2-((2R, 5R, 6R)-5-methyl-6-vinyltetrahydro-2H-Pyran-2-yl) 
acetate (Minor) 
1H NMR (400 MHz, CDCl3) δ 5.75 (ddd, J = 4.8, 10.8, 17.6 Hz, 1H), 5.20 (dt, J = 2.0, 17.6 Hz, 
1H), 5.09 (dt, J = 2.0, 10.8 Hz, 1H), 4.15 (q, J = 7.2 Hz, 2H), 4.01-4.04 (m, 1H), 3.83 (dddd, J = 
O
O
H H OEt
O
O
H H OEt
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3.2, 6.0, 8.4, 9.2 Hz, 1H), 2.61 (dd, J = 7.2, 14.8 Hz, 1H), 2.43 (dd, J = 6.0, 14.8 Hz, 1H), 1.78-
1.88 (m, 1H), 1.72-1.78 (m, 1H), 1.65-1.72 (m, 1H), 1.41-1.57 (m, 2H), 1.26 (t, J = 7.2 Hz, 3H), 
0.92 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.5, 138.2, 114.2, 80.5, 74.8, 60.3, 
41.7, 31.3, 30.5, 25.7, 14.3, 11.8; IR (neat) 2974, 2933, 2857, 1740, 1645, 1453, 1411, 1379, 
1337, 1284, 1255, 1214, 1174, 1145, 1106, 1069, 1035, 992, 921, 856 cm-1; HRMS (ESI) calcd 
for C12H20O3 [M]+ 212.1412, found 212.1416. 
 
O
HO
HO OH
a-j
Reaction Cconditions:
a) NaH, THF, then TBSCl, 0 ºC, 51%; b) Py•SO3, Et3N, CH2Cl2, 84%; c) Triethyl phosphonateacetate,
NaH, THF, 0 ºC, 98%; d) DIBAL-H, CH2Cl2, -78 ºC, 98%; e) TBDPSCl, imidazole, CH2Cl2; f) HCl 
(1.0M), THF/H2O (1:1), 85% for two steps; g) Py•SO3, DMSO, Et3N, CH2Cl2, 91%; i) Bu4NF, THF, 
86%.
OEt
O
 
Scheme C18 Synthesis of substrate 4-71 
 
Ethyl (E)-9-hydroxy-5-methyl-3-oxonon-7-enoate (4-71) 
1H NMR (300 MHz, CDCl3) δ 5.52-5.68 (m, 2H), 4.17 (q, J = 7.2 Hz, 
2H), 4.06 (d, J = 3.9 Hz, 3H), 3.40 (s, 2H), 2.52 (dd, J = 6.0, 16.8 Hz, 1H), 2.31 (dd, J = 6.9, 
16.8 Hz, 1H), 2.14 (octet, J = 6.6 Hz, 1H), 1.90-2.08 (m, 3H), 1.26 (t, J = 7.2 Hz, 3H), 0.92 (d, J 
= 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 202.5, 167.4, 131.4, 130.3, 63.4, 61.4, 49.8, 49.5, 
39.5, 28.9, 20.0, 14.1; IR (neat) 3416, 2959, 2929, 2873, 1741, 1713, 1644, 1461, 1410, 1369, 
1318, 1237, 1154, 1086, 1027, 973 cm-1; HRMS (EI) calcd for C12H19O3 [M-OH]+ 211.1334, 
found 211.1332. 
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rac-Ethyl-2-((2S, 4S, 6S)-4-methyl-6-vinyltetrahydro-2H-pyran-2yl) 
acetate (4-72) 
The general reductive cyclization procedure was followed with 4-71 (40 mg, 0.17 mmol), Et3SiH 
(40 mg, 0.35 mmol), Re2O7 (2.5 mg, 0.0052 mmol), and DCE (8.6 mL). The reaction was stirred 
at 55 °C for 36 h, then was quenched with 5 drops of pyridine. After evaporation of the solvent, 
5 µl of benzyldimethylsilane was added into the crude residue as an internal standard. The 
mixture was dissolved in CDCl3 and 1H NMR showed a yield of 82% (single isomer). 1H NMR 
(400 MHz, C6D6) δ 5.84 (ddd, J = 4.8, 10.4, 17.2 Hz, 1H), 5.26 (dt, J = 1.6, 17.2 Hz, 1H), 5.00 
(dt, J = 1.6, 10.4 Hz, 1H), 3.97 (q, J = 7.2 Hz, 2H), 3.83 (dddd, J = 2.0, 6.0, 7.6, 11.2 Hz, 1H), 
3.68 (ddq, J = 1.6, 5.2, 11.2 Hz, 1H), 2.61 (dd, J = 7.2, 15.2 Hz, 1H), 2.28 (dd, J = 5.6, 15.2 Hz, 
1H), 1.35-1.41 (m, 1H), 1.23-1.35 (m, 2H), 0.96 (t, J = 7.2 Hz, 3H), 0.64-0.89 (m, 2H), 0.71 (d, J 
= 6.4 Hz, 3H); 13C NMR (100 MHz, C6D6) δ 170.5, 139.5, 113.3, 77.5, 73.7, 59.8, 41.5, 39.7, 
39.4, 29.8, 21.8, 13.9; IR (neat) 2981, 2952, 2926, 2905, 2870, 2838, 1738, 1647, 1457, 1443, 
1411, 1371, 1319, 1256, 1196, 1171, 1134, 1087, 1031, 1006, 990, 922, 861 cm-1; HRMS (ESI) 
calcd for C12H21O3 [M+H]+ 213.1491, found 213.1509. 
 
rac-(2S, 4S, 6R)-2allyl-4-methyl-6((E)-5-phenylpent-1-en-1-yl)tetra- 
hydro -2H-pyran (4-73)  
The general rearrangement cyclization procedure was followed with 4-67 
(53 mg, 0.204 mmol), allyltrimethylsilane (93 mg, 0.814 mmol), Re2O7 (3.0 mg, 0.0061 mmol), 
Hcat-1 (3,5-(CF3)2C6H3NH]2SO2, 10.6 mg, 0.0204 mmol), DCM (10.2 mL), the reaction was 
was initiated at 0 ºC and warm up slowly to rt. After a total stirring for 20 h, the reaction was 
OH OEt
O
H
OH H
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quenched with 5 drops of pyridine. After evaporation of the solvent, flash chromatography (1-
3% ethylacetate in hexanes) give mixture of four isomers in 41.1 mg yield. (71%, dr = 24:3:2:1), 
of which two major was isolated and characterized. 
Major 1 (slow eluting): 1H NMR (400 MHz, C6D6) δ 7.12-7.20 (m, 2H), 7.02-7.10 (m, 3H), 5.81 
(dddd, J = 6.4, 7.6, 14.0, 16.8, 1H), 5.70 (ddt, J = 0.8, 6.4, 15.6, 1H), 5.56 (ddt, J = 1.2, 5.2, 15.6, 
1H), 5.01-5.09(m, 2H), 4.04 (q, J = 6.8, 1H), 3.95 (dd, J = 4.4, 10.4, 1H), 2.45-2.52 (m, 1H), 
2.48 (t, J = 7.6, 2H), 2.02-2.12 (m, 1H), 1.98 (q, J = 7.2, 2H), 1.61 (p, J = 7.6, 2H), 1.49-1.58 (m, 
1H), 1.42-1.59 (m, 1H), 1.29-1.36 (m, 1H), 1.16-1.25 (m, 1H), 0.95 (q, J = 11.6, 1H), 0.78 (d, J 
= 6.4, 3H); 13C NMR (100 MHz, C6D6) δ 142.3, 136.0, 132.8, 129.5, 128.4, 128.2, 125.7, 115.8, 
72.4, 69.5, 41.0, 36.1, 35.3, 35.3, 31.8, 31.0, 24.6, 22.4; IR (neat) 3063, 3026, 2924, 2855, 1641, 
1603, 1495, 1454, 1369, 1265, 1191, 1095, 1055, 1015, 995, 967, 911, 746, 698 cm-1; HRMS 
(ESI) calcd for C20H28O [M]+ 284.2140, found 284.2166. 
 
rac-(2R, 4S, 6R)-2allyl-4-methyl-6((E)-5-phenylpent-1-en-1-yl)tetra- 
hydro -2H-pyran  
Major 2 (fast eluting): 1H NMR (400 MHz, C6D6) δ 7.14-7.20 (m, 2H), 
7.02-7.20 (m, 3H), 5.99 (dddd, J = 6.4, 7.6, 14.4, 17.2, 1H), 5.71 (ddt, J = 1.0, 6.4, 15.2, 1H), 
5.57 (ddt, J = 1.2, 5.6, 15.2, 1H), 5.03-5.12 (m, 2H), 4.04 (dd, J = 5.6, 11.6, 1H), 3.58 (dddd, J = 
2.0, 5.6, 6.4, 12.0, 1H), 2.47 (t, J = 7.6, 2H), 2.35-2.44 (m, 1H), 2.13-2.22 (m, 1H), 1.97 (q, J = 
7.2, 2H), 1.87-1.96 (m, 1H), 1.53-1.66 (m, 3H), 1.42 (ddd, J = 5.2, 12.0, 16.8, 1H), 1.28 (dq, J = 
2.0, 13.2, 1H), 1.18 (dq, J = 2.0, 13.2, 1H), 0.94 (d, J = 7.2, 3H); 13C NMR (100 MHz, C6D6) δ 
142.3, 135.5, 132.7, 129.7, 128.4, 128.2, 125.7, 116.1, 72.1, 71.1, 41.3, 37.7, 36.6, 35.3, 31.9, 
30.9, 25.7, 17.8; IR (neat) 3064, 3026, 2929, 2852, 1641, 1603, 1495, 1455, 1379, 1336, 1317, 
OH H
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1247, 1189, 1058, 993, 967, 911, 746, 698 cm-1; HRMS (ESI) calcd for C20H28O [M]+ 284.2140, 
found 284.2122. 
O
OOEt
OH
a-c
Reaction Cconditions:
a) (MeO)NHMe•HCl, Me3Al, CH2Cl2, -78 ºC to rt, 71%; b) (3-Phenylpropyl)magnesium bromide, Et2O,
0 ºC, 51%; c) (Z)-Hex-3-ene-2,5-diol, Grubbs-Hoveyda 2nd generation metathesis catalyst, CH2Cl2, 
50%.  
Scheme C19 Synthesis of substrate 4-74 
 
 (E)-9-hydroxy-6-methyl-1-phenyldec-7en-4-one (4-74) 
1H NMR (300 MHz, CDCl3) δ 7.16-7.24 (m, 2H), 7.05-7.14 (m, 3H), 
5.35-5.51 (m, 2H), 4.14 (p, J = 6.3 Hz, 1H), 2.61 (heptet, J = 6.6 Hz, 1H), 2.53 (t, J = 7.5 Hz, 
2H), 2.19-2.36 (m, 4H), 1.81 (p, J = 7.5 Hz, 2H), 1.73 (br, 1H), 1.14 (d, J = 6.3 Hz, 3H), 0.92 (d, 
J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 209.8, 141.6, 134.6, 133.0, 128.5, 128.4, 126.0, 
68.61, 68.57, 49.7, 42.6, 35.1, 31.94, 31.91, 25.1, 23.49, 23.45, 20.1; IR (neat) 3411, 3061, 3026, 
2964, 2928, 2871, 1709, 1603, 1496, 1454, 1407, 1369, 1278, 1148, 1063, 1030, 971, 937, 748, 
700 cm-1; HRMS (ESI) calcd for C17H23O [M-OH]+ 243.1749, found 243.1742. 
 
rac-(2R, 3R, 5S)-3-Methyl-5-(3-phenylpropyl)-2-((E)-prop-1-en-1-
yl)tetrahydrofuran and rac-(2R, 3R, 5R)-3-methyl-5-(3-
phenylpropyl)-2-((E)-prop-1-en-1-yl) tetrahydrofuran (4-75) 
The general reductive cyclization procedure was followed with 4-74 (39 
O
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O PhH H
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mg, 0.15 mmol), Et3SiH (35 mg, 0.30 mmol), Re2O7 (2.2 mg, 0.0045 mmol), and DCM (7.5 mL). 
The reaction was stirred at 0 °C for 10 h, then was quenched with 5 drops of pyridine. After 
evaporation of the solvent, 5 µl of benzyldimethylsilane was added into the crude mixture as an 
internal standard. Then the mixture was dissolved in CDCl3 and 1H NMR showed a yield of 75% 
(dr = 5:3:1, two major are shown). Preparative TLC with 5% ethyl acetate in hexanes gave the 
two major products as an inseparable mixture (dr = 65:35). 1H NMR (400 MHz, CDCl3) δ 7.25-
7.31 (m, 2H), 7.15-7.21 (m, 3H), 5.64-5.76 (m, 1H), 5.39-5.48 (m, 1H), 3.99-4.06 (m, 0.65H), 
3.92-3.99 (m, 0.35), 3.73 (t, J = 8.4 Hz, 0.65H), 3.65 (t, J = 8.0 Hz, 0.35H), 2.64 (t, J = 6.8 Hz, 
2H), 2.17 (p, J = 6.0 Hz, 0.65H), 1.82-1.97 (m, 1H), 1.74-1.81 (m, 1H), 1.70-1.74 (m, 3H), 1.58-
1.70 (m, 2.70H), 1.45-1.55 (m, 1H), 1.23 (dt, J = 9.6, 11.6 Hz, 0.65H), 0.95-1.00 (m, 3H); 13C 
NMR (100 MHz, CDCl3) δ 142.5, 131.3, 128.7, 128.5, 128.2, 125.7, 87.5, 86.5, 78.5, 77.8, 41.5, 
40.8, 39.7, 39.0, 36.2, 36.03, 35.96, 27.9, 27.8, 17.83, 17.80, 16.6, 15.7; IR (neat) 3061, 3026, 
2954, 2929, 2858, 1603, 1496, 1453, 1376, 1329, 1125, 1107, 1084, 1029, 1007, 964, 930, 748, 
698 cm-1; HRMS (ESI) calcd for C17H25O [M+H]+ 245.1905, found 245.1891. 
 
HO N
O
OTBDPSI
OH
O
H+ a-j
Reaction Cconditions:
a) LDA, THF, -78 ºC to rt, 92%; b) LiH2NBH3, THF, 0 ºC, 90%; c) Py•SO3, DMSO, Et3N, CH2Cl2, 81%; 
d) (EtO)2P(O)CH2CO2Et, NaH, THF, 0 ºC; e)HF•Py, THF, 80% for two steps; f) PCC, Celite, CH2Cl2, rt;
g) (MeO)3CH, PPTS, MeOH, 50 ºC, 83% for two steps; h) DIBAL-H, CH2Cl2, -78 ºC, 97%; i) Py•SO3, 
DMSO, Et3N, CH2CL2; j) (3-Phenylpropyl)magnesium bromide, Et2O, 0 ºC, 48 % for two steps.  
Scheme C20 Synthesis of substrate 4-76 
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 (3R, E)-6-Hydroxy-3-methyl-9-phenylnon-4-enal (4-76) 
1H NMR (400 MHz, CDCl3) δ 9.73 (t, J = 2.0 Hz, 1H), 7.27-7.34 (m, 
2H), 7.18-7.24 (m, 3H), 5.62 (dd, J = 6.8, 15.2 Hz, 1H), 5.50 (ddd, J = 0.8, 6.4, 15.2 Hz, 1H), 
4.09 (q, J = 6.4 Hz, 1H), 2.80 (heptet, J = 6.8 Hz, 1H), 2.66 (t, J = 6.8 Hz, 2H), 2.36-2.50 (m, 
2H), 1.85 (br, 1H), 1.50-1.78 (m, 5H), 1.11 (d, J = 6.8 Hz, 2H), 1.10 (d, J = 6.8 Hz, 1H); 13C 
NMR (100 MHz, CDCl3) δ 202.21, 202.15, 142.3, 135.10, 135.07, 132.3, 128.4, 128.3, 125.8, 
72.61, 72.58, 50.25, 50.21, 38.86, 36.83, 35.8, 31.0, 27.3, 20.37, 20.31; IR (neat) 3416, 3061, 
3025, 2929, 2861, 2723, 1722, 1602, 1495, 1453, 1406, 1374, 1261, 1081, 1010, 973, 739, 699 
cm-1; HRMS (ESI) calcd for C16H21O [M-OH]+ 229.1592, found 229.1586. 
 
(2R, 3R, 5R)-5-Allyl-3-methyl-2-((E)-5-phenylpent-1-en-1-
yl)tetrahydrofuran (4-77) 
The general cyclization procedure was followed with 4-76 (43 mg, 0.17 mmol), 
allyltrimethylsilane (79 mg, 0.69 mmol), Re2O7 (2.5 mg, 0.0052 mmol), and DCM (8.7 mL). The 
reaction was initiated at 0 °C and then warmed up slowly to rt, then was stirred at rt for a total of 
20 h. The reaction was quenched with 5 drops of pyridine. After evaporation of the solvent, the 
crude material was purified by flash chromatography (1-5% ethyl acetate in hexanes) to give the 
product (45 mg, 95%, dr = 5.0:1.7:1). The mixture of products was then redissolved in 8.5 ml 
DCM and Re2O7 (4.2 mg, 0.0087 mmol) was added. The reaction was refluxed for 36 hrs and 
then quenched with 5 drops of pyridine. After evaporation of the solvent, the crude material was 
purified by flash chromatography (1-5% ethyl acetate in hexanes) to give the product (43 mg, 
91%, dr = 8.7:1:1.3). 1H NMR (400 MHz, CDCl3) δ 7.26-7.31 (m, 2H), 7.16-7.21 (m, 3H), 5.83 
(ddt, J = 7.2, 10.0, 17.2 Hz, 1H), 5.71 (dt, J = 6.8, 15.2 Hz, 1H), 5.45 (ddt, J = 1.2, 8.0, 15.2 Hz, 
O
H
OH
OH H
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1H), 5.03-5.12 (m, 2H), 4.00-4.07 (m, 1H), 3.68 (t, J = 7.6 Hz, 1H), 2.63 (t, J = 7.6 Hz, 2H), 
2.32-2.40 (m, 1H), 2.19-2.27 (m, 1H), 2.06-2.14 (m, 2H), 1.82-1.91 (m, 2H), 1.68-1.78 (m, 2H), 
1.60-1.68 (m, 1H), 0.98 (d, J = 6.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 142.4, 135.0, 133.4, 
130.4, 128.5, 128.3, 125.7, 116.8, 87.7, 77.3, 41.0, 39.0, 38.9, 35.4, 31.8, 30.9, 16.4; IR (neat) 
3062, 3025, 2927, 2855, 1639, 1602, 1495, 1453, 1375, 1362, 1321, 1103, 1025, 995, 966, 913, 
745, 698 cm-1; HRMS (EI) calcd for C19H25O [M-H]+ 269.1905, found 269.1894. 
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